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Abstract
Glutamate Carboxypeptidase II (GCPII) is a transmembrane, zinc metallopeptidase that is
expressed in a wide range of organisms, including roundworms, mice, and humans. In humans,
GCPII is primarily expressed in the prostate, kidneys, small intestine, and central nervous
system. Within the small intestine, the expected function of GCPII is to aid in the absorption of
dietary folate from the intestinal lumen. GCPII cleaves excess glutamates from folate to yield
monoglutamated folate which is then readily transported into the enterocyte. Folate can then be
used through the one carbon metabolic cycle for the synthesis of nucleotides, conversion of
homocysteine to methionine, and serve as a precursor for methylation reactions. The human
genome contains five paralogs of GCPII (hGCPII) that share a high degree of structural
similarity to the three orthologs found in the roundworm, Caenorhabditis elegans (cGCPII).
These orthologs are known as, gcp-2.1, gcp-2.2, and gcp-2.3. Three gcp-2 insertion mutant worm
strains, the wild type (N2), RB1055 (gcp-2.1), TM6632 (gcp-2.2), and TM5414 (gcp-2.3), were
used here to study the cGCPII paralogs’ role in reproduction, growth, and development.
There were two main goals in this study: (i) the functional characterization of the roles of
the three cGCPII paralogs in folate metabolism-mediated reproduction and aging, and (ii) the
determination of the expression patterns of the cGCPII paralogs in C. elegans to further explore
its roles in C. elegans’ life stage development. Each of the C. elegans strains were fed a folatelimited E. coli OP50 bacterial diet to elucidate the differences in function of each cGCPII
paralog. The results of this study demonstrate that each of the cGCPII paralogs plays a
differential role in the biological processes of reproduction, development, and aging. The cGCPII
paralogs gcp-2.1 and gcp-2.3 played important roles in folate metabolism mediated reproduction
and aging. Additionally, an optimized, high throughput method of real-time gene expression
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analysis in C. elegans was produced and demonstrated increased expression of gcp-2.1 in wild
type C. elegans compared to the other two paralogs. Ultimately, this study supports the use of C.
elegans as a model for human GCPII and folate metabolism related mechanisms and functions.
Overall, this study contributes to the understanding of the broader biological functions of GCPII
in eukaryotic organisms.
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CHAPTER 1: INTRODUCTION
1.1 Proteases and Metalloproteases
Proteases are an immense and diverse group of enzymes. The primary function of
proteases is to cleave peptide bonds of proteins, which allows for the release of small peptides
and individual amino acids. This function allows for protein and enzyme modifications that
provide control over protein localization, activity, protein-protein interactions, creation of
biomolecules, and the generation, transduction, and amplification of signaling pathways. These
primary enzymatic functions grant proteases important direct and indirect roles in numerous
cellular processes, including replication, transcription, apoptosis, metabolism, and cell
proliferation and differentiation (1, 2). Due to the massive number of proteases identified and the
wide range of functions they serve, proteases are subdivided into groups that best describe their
mode of action. Previously, proteases were exclusively grouped by the site at which the cleavage
takes place, near either the amino or carboxy termini of the substrate, known as exopeptidases, or
in between the termini, known as endopeptidases (1, 3). Exopeptidases can be further described
by the end at which the cleavage occurs: aminopeptidase (N-terminus) or carboxypeptidase (Cterminus) (4). However, as an increasing number of proteases were discovered and more
information about the structure and function of each were determined, proteases began to be
grouped into classes. There are six classes of proteases, aspartic, cysteine, glutamic, serine,
metalloproteases, and threonine proteases. Cysteine, serine, and threonine proteases are named
after the specific amino acid in the active site that functions as the nucleophile in the proteolytic
enzyme reaction. The other three classes, aspartic, glutamic, and metalloproteases, rely on a
water molecule that is one of the active site ligands to act as the nucleophile in a reaction that
breaks the peptide bonds within a substrate (3, 5).
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Even within a single class, as metalloproteases are a diverse group of enzymes, there are
16 clans, and additional unassigned families of proteases. The class, clan, and family groups
were organized using sequence similarity to determine evolutionary distances by MEROPS (5).
The main unifying feature of metalloproteases is that one or two metal cations are located within
the catalytic site. These metal cations are usually zinc, however, some proteases also utilize
nickel, cobalt, copper, or manganese (6). Amino acid ligands within the catalytic site function to
hold these metal cations in the correct conformation. The most common amino acid ligands are
histidine, glutamate, asparagine, and lysine (6). However, an additional amino acid catalytic
residue, usually glutamate, that acts a base or electrophile within the catalytic site is required (6,
7). Typically, metallopeptidases with co-catalytic zinc ions, including those in the MH clan, have
five zinc ligands (Fig. 1). The first zinc ligand forms a His-X-Asp motif, where X is variable but
usually is a glutamic acid residue. This ligand binds the first zinc ion. The second zinc ion is
bound by the other three zinc ligands, His-Asp-Asp, which are all contained on the same alpha
coil of the protein. The His-X-Asp motif is conserved for most co-catalytic zinc
metallopeptidases. However, the ligands that bind the second zinc ion are variable. The histidine
may be replaced with an aspartate and the second aspartic acid can be replaced with glutamine
(6, 8).
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Figure 1. Schematic representation of a typical co-catalytic zinc active
site of a Zn-metallopeptidase (9).

With some variation, this motif is considered traditional indicators of a co-catalytic zinc
binding metalloprotease (also referred to as dizincins) (Fig. 2) (6, 7). Altogether, the interactions
between the metal cation(s), the amino acid ligands, catalytic residue, and nearby water
molecules within the catalytic site facilitate nucleophilic attacks on peptide bonds of the
substrate (6, 7).
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Figure 2. The classification of the clans of metallopeptidases. GCPII belongs to the MH clan
of co-catalytic dizincin exopeptidases (10).

1.2 M28 family of Metalloprotease
The 16 clans of metalloproteases have been further divided into 76 distinct families, many
of which are even further divided into two or three subfamilies (5, 6). One of these is the MH
clan of metalloproteases (5, 6). All metalloproteases within the MH clan contain co-catalytic zinc
ions within the active site (6). Additionally, all co-catalytic metallopeptidases are
endopeptidases. There is only one exception, the HmrA endopeptidase from Staphylococcus

20

aureus (11). The rest of the members of the MH Clan are no exception to this rule (6). There are
four families of metallopeptidases within the MH Clan, M18, M20, M28, and M42 (6, 12).
However, the M28 family of metalloproteases is of key interest to this study. The M28 family is
distinctive because it contains both aminopeptidases and carboxypeptidases. Only one other
family of serine peptidases, the S12 family, contains both types of endopeptidases (5, 6). Within
the M28 family of metalloproteases there are four subfamilies, M28A, M28B, M28C, and M28E.
One of the most notable members of the MH clan of M28 family of metalloproteases, and the
main subject of this study, is glutamate carboxypeptidase II (5, 6).

1.3 Glutamate Carboxypeptidase II (GCPII)
Glutamate carboxypeptidase II (GCPII) is a transmembrane, metalloprotease composed of
750 amino acids with a total molecular weight of 84,000 (13). GCPII is a homodimer and each
identical half contains three regions, the intracellular region (AA 1-18, purple), transmembrane
region (AA 19-43, green), and the extracellular region (AA 44-750) (14). There is no stable
secondary structure of the intracellular region (8). The secondary structure of the transmembrane
region is predicted to be a single pass alpha helices that cross through the membrane (8). The
extracellular region secondary structure is 7 beta sheets that alternate direction surrounded by 10
alpha helices (8). The tertiary structure of the extracellular region is divided into three domains:
the protease domain (AA 57-116 and 352-590, orange), apical domain (AA 117-351, dark blue),
and the C-terminal domain (AA 591-750, yellow) (Fig. 3) (15). GCPII’s dimerization is
stabilized via the interaction of a calcium ion with the Glu-433, Glu-436, Thr-269, and Tyr-272
amino acids located between protease and apical domains (8). Altogether, the protease domain,
apical domain, and C-terminal domain combine to create the substrate binding cavity.
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Figure 3. The overall structure of glutamate carboxypeptidase II, depicting the three
domains, cytoplasmic (purple), transmembrane (green), and extracellular. The extracellular
domain is composed of several regions, protease (orange), apical (dark blue), active site
(red), and C-terminal (yellow) (16).

The substrate selectivity and binding are defined by the set of amino acids in the active
site and substrate binding pocket. Each of these specific structures and sites is depicted in Figure
6. The base of the substrate binding cavity contains the S1 site, the active site, and the S1¢ site
(Fig. 4).
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Figure 4. (A) A schematic representation of the interactions shared by the active
site of an enzyme and the substrate. P2, P1, P1¢, and P2¢ represent the specific
regions of the substrate that interact with the enzyme while S2, S2, S1¢, and S2¢
represent the corresponding regions within the active site of the enzyme (17). (B)
The structure of natural GCPII substrates, N-acetyl-aspartyl-glutamate (NAAG)
and polyglutamated folate (FolGlun) (18).

The active site contains five amino acid ligands, His-377, Asp-387, Glu-425, Asp-453,
and His-553 (Fig. 5). The catalytic zinc ion interacts with the His-553 and Glu-425 and the cocatalytic zinc ion connects with His-337 and Asp-453. The Asp-387 residue acts as a bridge
between the two zinc ions. In cooperation with a water molecule, Glu-425 acts as transport the
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proton from the water molecule to the target peptide bond on the substrate to complete the
hydrolysis (8, 19, 20, 21).

Figure 5. The active site of GCPII. The blue oval represents the S1 site.
The amino acid residues associated with the S1 (green) and the S1¢ site
(orange) are labeled. The glycine residue that interacts with the amino
group on the glutamine of the substrate is pictured in grey. The co-catalytic
zinc ions are pictured in blue and the chloride ion in yellow (22).

The S1¢ site also has a flexible section of amino acids, from Tyr-692 to Ser-704, that cover
its opening that forms a “glutarate sensor”. The closed conformation occurs when a glutamate
binds within the S1¢ site (Fig. 6). The S1¢ site, made up of Phe-209, Arg-210, Asn-257, Glu-424,
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Glu-425, Gly-427, Leu-428, Gly-518, Lys-699, and Tyr-700 residues, is highly specific for
glutamate. This high degree of specificity plays an important role in GCPII’s substrate selection
(8, 23, 24).
A flexible section of the protein structure, from Trp-541 to Gly-548, form an “entrance
lid”. The conformation of the entrance lid determines the ability of a substrate to enter and bind
within the substrate binding cavity (Fig. 6A). A closed conformation, which seals the S1 site
from the surrounding media, occurs when a substrate is bound and an open conformation occurs
when no substrates are bound (19). Located on the entrance lid, the Trp-541 residue with the
Arg-511 and Arg-463 residues form the arene-binding site (Fig. 6B). The arene-binding site
functions to bind to arene-containing substrates, which once bound, hold the entrance lid open
and increase the affinity for these large substrates (25). In particular, the pteridine moiety found
in dietary folates is known to bind to this site and play a role in the folate hydrolyzing activity of
GCPII (15). Just beneath the entrance lid is the beginning of the substrate binding cavity, which
is a hollow funnel that extends through the enzyme (8). A positively charged area within this
funnel is called the arginine patch (Fig. 6C). Composed of the Arg-534, Arg-536, and Arg-463
residues and a stabilizing chloride ion, the arginine patch attracts GCPII’s predominantly
negatively charged substrates (8).
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Figure 6. Diagram of the active site in one dimer of GCPII, each region of the enzyme is
indicated by the color surrounding the letter. (A) The conformational change of the
glutarate sensor with an unoccupied S1¢ site (yellow) and after binding with a substrate
(red). (B) A detailed representation of the arene-binding site (orange) when a substrate is
bound. (C) The structure of the arginine patch (teal) when a substrate is bound. (D) The
hydrophobic S1 pocket opens when a substrate is bound. (E) The hydrogen bonds
between the bound substrate and the residues within the S1¢ site. (F) Examples of
artificial GCPII substrates with phosphonate (top) and urea (middle) zinc binding groups
and one naturally occuring substrate, NAAG (bottom) for comparison. Throughout all
images zinc ions are depicted in purple, water molecules in red, carbon atoms on GCPII
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inhibitors in green, carbon atoms of GCPII residues in grey. For E and F, nitrogen is
depicted in blue, oxygen in red, and phosphorus in orange, and hydrogen bonds are
indicated by dashed lines (8).

1.3.1 Known functions of GCPII
The first, and most widely studied, physiological function of GCPII is the degradation of
N-acetyl-aspartyl-glutamate (NAAG) in the nervous system. A neuropeptide, NAAG, is the third
most common neurotransmitter, after glutamate and GABA, and ranges from high micromolar to
low millimolar concentrations (26). NAAG is the most frequently expressed peptide
neurotransmitter in the mammalian nervous system, particularly in the brain stem, spinal cord,
and peripheral nerves (27, 28). The NAAG hydrolyzing function of GPCII was discovered in
1984 (29). This enzyme was given the name NAALADase I. However, when NAALADase I
was sequenced in the late 90s, the enzyme’s true identity was determined to be GCPII (30, 31).
GCPII is expressed by glial cells in the central nervous system and Schwann cells in the
peripheral nervous system (32, 33, 34). Once excess NAAG leaves the synaptic cleft and enters
the extra-synaptic space it is capable of interaction with GCPII expressed on the membranes of
the glial cells. The main role of GCPII expressed in the nervous system is to hydrolyze NAAG
into its initial components, N-acetyl-aspartate (NAA) and glutamate (35, 36, 29).
The NAA and glutamate are transported into the glial cell via a glutamate-aspartate
transporter (GLAST) or glutamate transporter (GLT-1), both of these are also referred to as
excitatory amino acid transporters (EAAT1 and EAAT2, respectively) (37, 38). Once inside the
cell, glutamate undergoes a recycling process and eventually returns to use as an excitatory
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neurotransmitter (38, 39). NAA is degraded to produce aspartate, which is used in several
metabolic pathways, including glycolysis and the tricarboxylic acid cycle (40).
Overexpression of GCPII has been shown to cause an accumulation of excess glutamate
within the extracellular space (41). This build-up of excess extracellular glutamate leads to the
development of glutamate excitotoxicity, which causes dysfunction and degeneration of neurons
(42). These effects are caused by the hyperactivation of glutamate channels, particularly NMDA
receptors, and the associated influx of calcium that initiates numerous signaling pathways
responsible for free radical generation, caspase generation, ionic homeostasis imbalance, and
nitrous oxide generation. These excessive products of signaling pathways lead to neuronal cell
death (29, 42, 43). Glutamate excitotoxicity has been shown to play a role in numerous
neurodegenerative diseases including, Alzheimer’s disease, Parkinson’s disease, Huntington’s
disease, stroke, and Schizophrenia (44, 45, 46, 47, 48). For these reasons, it has been
hypothesized that the synthesis of NAAG allows for the transfer of large amounts of glutamate
from within neurons to the extracellular space, without the damaging effects of excitotoxity due
to excess free glutamate (49). Inhibition of GCPII has been shown to decrease the amount of free
extracellular glutamate in excess and reduce the amount of resulting neuronal cell death that
characterizes these neurodegenerative diseases (50). As a result, treatments for these diseases
may include GCPII specific inhibitors such as, 2-phosphonomethyl pentanedioic acid (2-PMPA)
and 2-3-mercaptopropyl pentanedioic acid (2-MPPA) (51, 52, 16). These inhibitors prevent the
binding and catabolism of extra-synaptic NAAG to yield free glutamate by GCPII, thereby
preventing glutamate excitotoxicity (53).
The second known, and comparatively less studied, function of GPCII is the hydrolysis
of poly-γ-glutamylated dietary folates (54, 55, 56). The hydrolysis action of GCPII cleaves
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excess glutamate(s) from the polyglutamylated tail of dietary folates to create the biologically
available form, monoglutamated folate (57). Next, the monoglutamated folate must be
transported across the apical brush border membrane of the small intestine by a folate
transporter. Once absorbed, the folate undergoes transformation through the folate cycle and is
provided via the blood throughout the body’s tissues (58). A detailed description of the folate
hydrolase function of GCPII and the conversion and transport of folates is discussed in Chapter
2.
GCPII and its associated folate hydrolase function have been recognized to play a role in
cancer progression, particularly prostate cancer. Expression of GCPII is increased in primary and
metastatic cancers and its expression increases with cancer progression (59, 60, 61). In a study
by Yao et al., prostate adenocarcinoma cells transfected to express GCPII showed a significant
increase in growth and proliferation, which was reversed in the presence of a GCPII inhibitor
(62). This indicated that increased GCPII expression does increase the rate of folate uptake,
however, the exact role of GCPII in cancer progression and metastasis remains unclear (16).
Folate deficiency during pregnancy has also been associated with an increased risk for
the development of neural tube defects (63). Supplementation with folic acid during pregnancy
has proved effective in reducing the occurrence of neural tube defects by approximately 70%
(64, 65). Additionally, folate deficiency has been associated with anemia, cardiovascular
abnormalities, such as coronary heart disease, and immunodeficiency due to decreases in
immune cell synthesis (66, 67, 68). Both of the known functions of GCPII, are summarized in
Figure 7 (15).
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Figure 7. The N-acetyl-aspartyl-glutamate (NAAG) and poly-glutamated folate
hydrolyzing activities of GCPII (15).

1.3.2 GCPII Splice Variants, Paralogs, and Orthologs
Glutamate carboxypeptidase II is encoded by the 62,035 base pairs that form the fohl1
gene (14). Due to its varied expression and functions, GCPII is referred by several names
including Prostate Specific Membrane Antigen (PSMA), N-acetylated a-linked Acidic
Dipeptidase (NAALADase2), Folypoly-g-glutamate Carboxypeptidase (FGCP), and Folate
Hydrolase (FOLH). There are nineteen exons and eighteen introns in the GCPII gene sequence,
which allows for alternate splicing to occur (Fig. 8A) (14). This allows for the synthesis and
expression of multiple splice variants of the gene (Fig. 8B). PSMA refers to the entire gene and
its splice variants are PSM¢, PSM-C, PSM-D, PSM-E, and PSM-F (Fig. 8). The PSM¢ splice
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variant contains a deletion of nucleotides 114-379, which translates to the first 57 amino acids in
the original PSMA. As a result, the PSM¢ variant does not contain an intracellular or
transmembrane region and is believed to be located within the cytoplasm (69). PSM¢ is expressed
at higher levels in healthy prostate tissues and the ratio of PSMA to PSM¢ increases in cancerous
prostate tissue (70). Similar to PSM¢, the PSM-C and PSM-D splice variants have the deleted
segment of the first exon. However, PSM-C contains a new exon (exon 1b*) composed of 133
nucleotides while this exon (exon 1c*) is 101 nucleotides in length for the PSM-D splice variant
(71). PSM-D is expressed in high levels in metastatic prostate cancer compared to its expression
in the primary tumor (72). The final two splice variants that have been identified are known as
PSM-E and PSM-F. These splice variants share a high degree of similarity to each other and to
PSM-D. However, PSM-E and PSM-F both contain the entire first exon, identical to the first
exon of PSMA, and both contain a new exon that is 97 nucleotides in length. However, exon 18
is deleted in PSM-E (73).
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Figure 8. The splice variants of PSMA. (A) The mRNA of wild type PSMA with a total
of 19 exons. The exons highlighted in yellow indicate exons that are not included in some
transcripts. (B) Depiction of the 5¢ end of the mRNA transcript of the splice variants
where most of the alternative splicing occurs. The alternative exons 1b and 1c are
represented in green and red, respectively. The name of each splice variant is included on
the left. The number of nucleotides (nt) that encode it and amino acids (aa) that make up
the final protein product are on the right. The numbers below the exon boundaries
indicate the first number of each exon. (C) A list of known PSMA exons with the number
of nucleotides and location within the folh1 gene. (69)

Altogether, there are four paralogs of GCPII, prostate specific membrane antigen-like
(PSMAL), glutamate carboxypeptidase III (GCPIII), N-acetylated alpha-linked acidic
dipeptidase-like (NAALADase L), and N-acetylated alpha-linked acidic dipeptidase-like 2
(NAALADase L2). These paralogs are summarized in Table 1.
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Table 1. Summary of GCPII Paralogs.
Paralog

Gene

Shared Sequence Similarity to GCPII

Ref.

GCPII

FOLH1

---

14

PSMAL

FOLH1B

98%

69, 74, 75

GCPIII

NAALAD2

69%

69, 76

NALAADase L

NAALADL1

37%

69, 77

NALAADase L2 NAALADL2

20%

69

PSMAL is encoded by the gene FOLH1B and shares 98% sequence identity with GCPII,
which makes it the closest related paralog to GCPII (69, 74, 75). In humans, PSMAL is
expressed primarily in the liver and kidney (74). PSMAL is predicted to be a result of a
duplication event of homologous chromosomal regions from GCPII (78). However, there is one
key difference between GCPII and PSMAL. PSMAL lacks the first 1000 base pair section of
GCPII, which makes up the first exon and the beginning of the first intron of GCPII, indicating
that PSMAL has no intracellular or transmembrane region (74).
The second closest related paralog to GCPII is GCPIII, which shares a 69% sequence
identity and is encoded by NALAAD2 (69, 76). The paralogous relationship shared by GCPII and
GCPIII is believed to be the result of the duplication of a shared ancestral gene. Interestingly,
GCPII and GCPIII share the NAAG and folate hydrolyzing functions, however, GCPIII is also
capable of hydrolyzing b-citryl-L-glutamic acid (BCG) (76, 79, 77). Although GCPIII has the
ability to hydrolyze NAAG, folate, and BCG, it hydrolyzes BCG at a much faster rate compared
to the other substrates. As a result, the primary function of GCPIII is believed to be the
hydrolysis of BCG (76). BCG has been detected in the newborn rat brain, kidneys, and heart and
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the testes of sexually mature rats (80, 81). Although the exact biological role of BCG remains
unclear, the compound is expected to have a physiological role in brain development and
spermatogenesis (82, 83).
Next, the NALAADase L paralog, which is encoded by NAALADL1, and has a 37%
shared sequence identity with GCPII (69, 77). NALAADase L shares many structural similarities
to GCPII. NALAADase L does have similar divisions of the intracellular, transmembrane, and
extracellular regions. Additionally, the extracellular region contains the apical, protease, and Cterminal regions and the active site includes the zinc binding amino acid residues (77, 84).
Despite these similarities, NAALADase L and GCPII are not believed to have a shared function,
instead, NAALADase L is predicted to function as an aminopeptidase. Currently the overall
physiological role of NAALADase L in biological systems is unclear (84).
The final known GCPII paralog, NAALADase L2, is encoded by NAALADL2 and has a
20% shared sequence identity with GCPII. The highest levels of NAALADase expression have
been detected in the adult human kidney and placenta, and in the human embryo pancreas, small
intestine, stomach, mesonephros, and metanephros. The structure of NAALADase L2, is not well
understood, however, a transmembrane domain at the N-terminal end of the NAALADase L2
transcript has been detected, which indicates it may have an extracellular region similar to
GCPII. NAALADase L2 does not have an active site similar to that of GCPII or the zinc-binding
amino acids. Currently, it is believed that NAALADase L2 has a distinct, unique function from
GCPII, however, the exact function is unknown (85).
Human GCPII has orthologs in many different organisms, including roundworms, fish,
lizards, chickens, mice, rats, dogs, pigs, and monkeys (86). There are three key criteria that are
typically considered when characterizing the relationship between the human version of a gene
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and an ortholog from another species: enzyme activity, inhibitory profile, and tissue distribution
(87). As a result, mice, rats, and pigs are the most common vertebrates used as model organisms
for the study of GCPII. The GCPII orthologs expressed in mice, rats, and pigs share a high
degree of similarity with human GCPII with 86%, 85%, and 91%, shared sequence identity,
respectively (88, 89, 90).
There are two known catalytic activities of human GCPII hydrolysis of NAAG and
hydrolysis of polyglutamated folate, the details of both will be elaborated on in subsequent
sections (54, 55). The catalytic activities of the GCPII orthologs in mice, rats, and pigs have been
studied. The orthologs from all three mammalian model organisms have the NAAG-hydrolyzing
activity (87, 88). However, only the pig GCPII ortholog has folate hydrolyzing activity while rats
and mice rely on g-glutamyl hydrolase (90, 91, 92).
There are numerous compounds that are known to inhibit GCPII, including 2phosphonomethyl pentanedioic acid (2-PMPA) and 2-3-mercaptopropyl pentanedioic acid (2MPPA). The activity of human, mouse, rat, and pig GCPII can be inhibited through the use of 2PMPA suggesting high structural similarities of the active site and/or substrates binding sites
among orthologs (87, 88).
There is an extreme amount of variation by species in tissue specific expression patterns
of GCPII. In humans, GCPII is highly expressed in the prostate, small intestine, kidney, and
brain. Moderate to low amounts of GCPII are expressed in the testes, seminal vesicles, heart,
lung, spleen, thyroid gland, small intestine, colon, breast, ovary, skin, salivary gland, urinary
bladder, stomach, esophagus, and adrenal gland (93, 94, 95, 96, 97). Although GCPII is
expressed in high levels in the human prostate, mouse rat and pig prostate have very low levels
of prostate GCPII expression (87, 88, 98). However, GCPII is expressed in the brain and kidney
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of mice, rats, and pigs and in the small intestine of pigs (87, 88, 99). Based on these
characteristics, model organisms with the appropriate ortholog for the specific enzyme activity
and type of study are selected for GCPII research.

1.4 Model Organism: Caenorhabditis elegans and GCPII Gene expression
Sydney Brenner first proposed C. elegans as an ideal model organism for the study of
eukaryotic development and the nervous system in 1965 (100). Since then, many important
discoveries have been made about biological systems using C. elegans as a model organism
including, the discovery of apoptosis related genes (101), the introduction of GFP as a biological
marker (102), and the discovery of RNAi (103). The success of C. elegans as a model organism
stems from numerous characteristics of the organism. C. elegans has a rapid life cycle, relatively
simple anatomy with a transparent body and an unvaried number of somatic cells, and welldefined genetics that may be manipulated relatively easily (104, 105, 106). Additionally, C.
elegans are easily maintained in the lab on solid agar plates fed a diet of bacteria, typically
Escherichia coli (107).
1.4.1 The Life Cycle of C. elegans
C. elegans has a rapid and easily traceable life cycle, which has been summarized in
Figure 9. At 20 °C, C. elegans undergo embryogenesis for approximately 16 hours. After
fertilization, an impermeable eggshell develops and within it, the rapid DNA synthesis and cell
division characteristic of embryogenesis begins (108). Embryos are kept within the parent
hermaphrodite until there are 24 cells present and the egg is then laid. The embryo continues to
develop within the egg, utilizing the nutrients provided in the yolk, until there are 558 cells and
then it hatches into an L1 stage larva (107, 109). The L1 stage is approximately 16 hours long
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and the subsequent L2, L3, and L4 stages are approximately 12 hours long (107). The
development of the hermaphroditic reproductive organs begins during the L3 stage and ends at
the beginning of the L4 stage (110). As the reproductive organs are formed hermaphrodites first
undergo spermatogenesis followed by oogenesis (111). At the L4 stage, the hermaphrodite
contains 959 somatic cells and reproduction begins (107, 112). Adult hermaphrodites are capable
of reproduction for 2-3 days until their self-produced sperm has been depleted (107). At the end
of each life stage there is a period of inactivity during which a new, larger cuticle is produced
called lethargus (113).
C. elegans also have an alternative life stage called dauer larva. This life stage occurs
when L2 larva are in an environment where there is overpopulation and the food is depleted.
Instead of proceeding to the L3 stage as usual, the worms will molt into the dauer (or L2d) stage
(114). During this stage, the cuticle completely surrounds the worm forms a plug around the
mouth which prevents feeding and further development. This cuticle is more resistant to
environmental stressors and chemicals. When in the presence of food once more, the mouth
plugs are lost and the worm undergoes a molt and continues to the L4 stage (107).
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Figure 9. The life cycle of C. elegans (115). Rapid DNA synthesis occurs during
embryogenesis and during the L3 and early L4 stages. DNA synthesis occurs more in
L3 stage because spermatogenesis and oogenesis occur primarily during this phase
(111). The life stages predicted to have increased nucleotide synthesis are indicated by
*.

1.4.2 The General Anatomy of C. elegans
There are two sexes, a self-fertilizing hermaphrodite and male. However, the male
phenotype is extremely rare in a population of hermaphrodites (0.1%) (115). Due to this and the
fact that this study utilized only hermaphrodites, only the relevant details of the hermaphrodite
will be discussed. The body of C. elegans is shaped like a cylindrical tube that is narrowed at
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each end. The body wall consists of the cuticle, epidermis, excretory system, neurons, and
muscles. A pseudocoelom space separates the body wall layer from the innermost layer that
consists of a second tube composed of the pharynx, intestine, and gonad (Fig. 10) (115). The
cuticle is secreted by the epithelium and covers the entire outside of the worm and lines the
pharynx and rectum. There are several openings in the cuticle, the excretory pore, vulva, anus,
and lateral lips for the amphid sensilla, and papillae for the anterior deirids (115).

Figure 10. The anatomy of the C. elegans adult hermaphrodite (107).
Altogether, the C. elegans nervous system consists of 302 neurons. The nervous system
of the worm consists primarily of ganglia located in the head and tail regions of the worm and
the dorsal and ventral nerve cords that connect the two regions. In the head, there are two
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ganglia, the retrovesicular and ventral ganglia, and nerve ring wrapped around the pharynx.
Combined these three structures are typically referred to as the “brain” of the worm. In the tail
region, there are two ganglion present, the lumbar and preanal ganglia. Even with a relatively
simple nervous system, C. elegans are capable of mechanosensation, proprioception (i.e. sense of
self movement), nociception (i.e. sense of harmful stimuli), chemosensation, thermosensation,
light sensation, and oxygen and carbon dioxide sensation (Fig. 11) (116).

Figure 11. The nervous system of C. elegans labeled with GFP (117).

The alimentary system of C. elegans is partitioned into three sections, the foregut,
midgut, and hindgut (Fig. 12A). The foregut consists of the buccal cavity and the pharynx. The
pharynx is approximately 100 µm long and 20 µm wide and connects the buccal cavity to the
intestine (118). There are three muscular sections of the pharynx that combine to function in
feeding: the corpus, isthmus, and terminal bulb (Fig. 12B). The corpus, the most anterior section,
collects and traps bacteria. The isthmus, the middle section, is a narrow tube that controls the
flow of bacteria from the corpus to the terminal bulb. The terminal bulb grinds bacteria using
“teeth” formed by the cuticle and pushes the debris into the intestine through the pharyngealintestinal valve (118, 119). These actions performed by the pharynx allow it to act as a pump that
powers the movement of the ingested material through the intestine (118). The midgut is
comprised of only the intestine (120). The intestine has multiple functions, including digestion of
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food, absorption of nutrients, synthesis and storage of macromolecules, initiation of the innate
immune response, and production of yolk for germ cells (121, 122, 123, 124).

Figure 12. (A) The anatomy of the alimentary system of C. elegans (120). (B) The
anatomy of the C. elegans pharynx (118).

The intestine is composed of 20 epithelial cells form bilateral pairs to create a tube with a
lumen. The intestine is not attached to the body wall, but only to the pharynx and rectum. The
intestine of C. elegans is not a muscular organ, however, the end does contain the
stomatointestinal muscles that force waste material into the rectum (120). The intestinal
epithelial cells secrete digestive enzymes into the lumen and take up the available nutrients.
These nutrients can then be distributed to peripheral tissues and/or stored within storage granules
within the intestinal cells (112). In hermaphrodites, the intestinal cells are capable of synthesis
and secretion of yolk to the body cavity. Once in the body cavity the yolk is transported to the
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gonad for delivery to the oocytes (121). The yolk is composed of nutrients required for
embryogenesis, mainly vitellogenin lipoproteins (125). The presence of folates in the yolk has
not been confirmed in C. elegans, however, folates have been detected in the yolk of other
oviparous organisms such as, chickens and fish (126, 127). Additionally, folates provided by
bacterial diet are required to stimulate the growth and proliferation of C. elegans germ cells
(128). C. elegans that cannot absorb dietary folate are unable to reproduce due to drastically
reduced germline cell proliferation (129).
The hindgut consists of the end of the intestine, rectum, and anus. The rectal valve is
located at the end of the intestine, to control the amount of digested material that enters the
rectum. The rectal gland, positioned on the intestinal lumen posterior the rectal valve, may
secrete digestive enzymes. Four muscles are present within the hindgut, two stomatointestinal
muscles, the anal sphincter muscle, and the anal muscle. Together these muscles function to
expel waste material from within the rectum to the outside the body through the anus (130).

1.4.3 The Reproductive System of C. elegans
The hermaphroditic reproductive system consists of three main parts, the somatic gonad,
the germ line, and the egg laying apparatus (Fig. 13). Additionally, the somatic gonad is
composed of numerous parts, from most distal to proximal, the distal tip cell, gonadal sheath,
spermatheca, spermathecal-uterine valve, and uterus. The germ line cells are located throughout
the somatic gonad, however, germ cells located in the more distal regions are mitotic and
undifferentiated. As these cells travel more proximal, they undergo the stages of meiosis.
Likewise, the egg laying apparatus consists of numerous structures, the vulva, uterine and
vulval muscles, and the uterus. Once the oocytes have traveled to the proximal somatic gonad
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they undergo maturation (131). One key part of the maturation process is the receptor mediated
transport of yolk proteins into the oocyte. (132) Mature oocytes are ovulated one at a time into
the spermatheca where fertilization occurs (133). Once fertilized the eggs move into the uterus
and are forced out of the body through the vulva by the action of the uterine and vulval muscles.
The embryo continues to develop within the egg, utilizing a portion of the yolk to fuel growth
and development. There is an excess amount of yolk included in the egg, evidenced by the
presence of yolk proteins in the intestine of the L1 larval stage (132, 134). An individual
hermaphrodite is capable of producing approximately 300 self-fertilized embryos (131).

Figure 13. The reproductive system of the C. elegans hermaphrodite (131).

1.4.4 C. elegans Genetics
C. elegans was the first multicellular, eukaryotic organism to have its complete genome
sequenced in 1998 by the C. elegans Sequencing Consortium (135). The C. elegans genome
consists of 5 pairs of autosomal chromosomes (I-V) and one set of sex chromosomes which
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varies between hermaphrodites (XX) and males (XO) (136). Encoded within these chromosomes
are an estimated 20,512 protein-coding genes (wormbase data release WS237) (136). Of the
entirety of C. elegans protein-coding genes, 38% have human orthologs (137). Similarly, the
human genome contains 60-80% protein-coding genes that have a C. elegans ortholog (138).
Additionally, 40% of human genes that have a known association with a disease have an
ortholog in C. elegans (139).
The genome of C. elegans is well understood and shares a high degree of similarity to the
human genome, which makes C. elegans a useful model organism for the study of enzyme
function, specifically in the case of glutamate carboxypeptidase II.

1.4.5 GCPII in C. elegans
Compared to the five paralogs of GCPII present in the human genome the GCPII ortholog
in the C. elegans genome has three paralogs referred to as gcp-2.1, gcp-2.2, and gcp-2.3 (140). The
mRNA for gcp-2.1 is produced as three splice variants known as, isoform a, isoform b, and isoform
c (Fig. 14) (141).

Figure 14. mRNA sequence for each paralog of cGCPII. (A) The three isoforms of gcp-2.1
(142). (B) gcp-2.2 (143). (C) The pseudogene, gcp-2.3 (144).
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Recently, gcp-2.3 was classified as a pseudogene (144). A pseudogene is a duplicate of a
pre-existing gene that has been rendered nonfunctional by a random mutation. There may be a
reason that gcp-2.3 is present in the genome, either it is evolutionarily conserved to serve a purpose
or the mutation in the gene was relatively recent and it is currently in the process of disappearing
(136). As a pseudogene, gcp-2.3 may play a role in regulating the expression of the other paralogs
of GCPII (145). Although the specific function of gcp-2.3 is currently unknown, three possible
mechanisms of pseudogene function have been determined (Fig. 15). First, a pseudogene may be
transcribed to antisense RNA, which then interacts with the mRNA transcript of a homologous
coding gene and prevents translation. This results in reduced or silencing of the expression of the
coding gene (146). Second, pseudogenes may be translated into small interfering RNA (siRNA),
which function to silence gene expression. Third, the antisense RNA formed from a transcribed
pseudogene may compete with the mRNA transcript of the coding gene for stabilizing or
destabilizing factors (147, 148, 149). One example of this utilizes a noncoding type of RNA that
functions to destabilize mRNA, miRNA (150). The miRNA binds to the pseudogene, which
reduces the amount of miRNA that binds to the mRNA transcript of the coding gene and allows
for the gene to avoid miRNA control over its expression levels (151). This third pseudogene
mechanism using miRNA is known to have a role in the upregulated expression of oncogenes (151,
152).
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Figure 15. Three potential mechanisms of pseudogene function (153). (A) The
pseudogene is transcribed to anti-sense RNA, binds to the mRNA of the coding gene,
and prevents translation (146). (B) Translated pseudogenes in the form of siRNA may
silence gene expression (154). (C) Anti-sense RNA transcribed from a pseudogene may
compete with mRNA from a coding gene for stabilizing factors or degradation by
miRNAs, which alters the expression levels of the gene (147, 148, 149).

The exact comparisons between functional profile of C. elegans GCPII, hereafter referred
to as cGCPII, and human GCPII, hereafter referred to as hGCPII, is not currently understood.
However, hGCPII and cGCPII share a high degree of structural similarity in the extracellular
domains. The right image in Figure 16 was generated using the homology based Modeller
program (unpublished data from Periyannan lab) and the published crystal structure of hGCPII
(23). This evidence further supports the idea that hGCPII and cGCPII may have similar
biological functions.
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Figure 16. Comparison of the extracellular domain crystal structure of human
(hGCPII) (23) and C. elegans GCPII (cGCPII) (unpublished data from
Periyannan lab).

1.5 Hypothesis and Experiments
The central hypothesis that governs the broader scope of the GCPII study in Dr.
Periyannan’s lab, as well as the study described in this thesis, is that cGCPII is a functional
model for human GCPII; thus, cGCPII and C. elegans are a suitable model protein and organism,
respectively, to study the broader biological functions of GCPII. The overall goal of the
Periyannan lab group is to determine the tissue-specific biological, functional, and molecular
properties of cGCPII and apply these to further understand hGCPII. The specific goal of this
study was to characterize the expression patterns and functional profile of cGCPII under the
folate metabolism and related amino acid metabolism context and establish experimental
protocols for cGCPII gene expression analysis of its paralogs within C. elegans. To accomplish
this, two main groups of experiments were carried out, folate-limited and supplemented
longevity and brood size assays (Chapter 2) and gene expression analysis (Chapter 3).
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CHAPTER 2: INVESTIGATION OF THE ROLE OF GCPII IN FOLATE
METABOLISM
2.1 The Structure and Characteristics of Folate
Poly-γ-glutamylated folates are composed of three moieties: a pterin ring connected via a
methylene bridge to a para-aminobenzoic acid (PABA), which is connected via a peptide bond to
a glutamate chain of one to seven glutamates (Fig. 17) (155). The term “folate” is used as a
general term to refer to numerous compounds with this general structure that occur naturally in
biological systems. The term folic acid typically refers to the completely oxidized synthetic form
that is generally included in dietary supplements; however, natural folic acid exists as well.
Despite this technicality, both folate and folic acid share identical base structures and are
generally classified as vitamin B9 (156).

Figure 17. The general chemical structure of folate (54).

48

2.2 The Folate Metabolic Cycle
The conversion of dietary folates through the folate cycle to produce different
biologically active forms occurs by following a specific series of metabolic conversions. Figure
18 summarizes the conversions that occur between different versions of folate and the structure
of each form. There are three key aspects that vary from the tetrahydrofolate (THF) base
structure which determines the identity of the folate derivative present; the number of terminal
glutamates, the oxidation state of the pteridine ring, and the identity of the one-carbon group.
The one-carbon group may be formate, formaldehyde, or methanyl, and is attached to the 5th
position nitrogen on the pteridine ring and 10th position nitrogen of the PABA moiety (128). In
particular there are three specific forms of folate, 5,10-methylene-tetrahydrofolate (5,10-MTHF),
5-methyl-tetrahydrofolate (5-MTHF), and 10-formyl-tetrahydrofolate (10-formyl-THF), that
have important roles in different biosynthetic functions (157).
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Figure 18. The cellular interconversions between the folate derivatives within the folate cycle
(157).

The folate cycle is compartmentalized within the cell, occurring in both the cytosol and
the mitochondria, with a full set of enzymes within each (Fig 19). Once inside either cellular
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compartment, a polyglutamate tail is attached to ensure it remains in that compartment. Only
monoglutamated folates may be transported freely within the cell or travel freely via system
circulation (158). Attached one-carbon groups also prevent the transport of folates across the
mitochondrial membrane (159). However, few non-folate intermediates are able to pass through
the mitochondrial membrane for use in the cytosol (158). The existence of two independent
folate metabolism pathways is hypothesized to help prevent interruption of glycolysis in the
cytosol. The breakdown of glucose relies on a redox balance between NADPH and NAD+. The
concurrent reactions occurring in the cytosol would disrupt this balance (157).
The amino acids serine and glycine play an important role in folate metabolism. Within
the mitochondria, serine acts as a carbon donor for THF to form glycine and 5,10-MTHF by the
action of serine hydroxymethyltransferase (SHMT). Next, methylenetetrahydrofolate
dehydrogenase 2 (MTHFD2) oxidizes 5,10-MTHF to a 5,10-me+-THF intermediate followed by
further oxidization by the same enzyme to 10-formyl-THF. Formate and THF are formed from
10-formyl-THF by the action of methylenetetrahydrofolate dehydrogenase 1 like (MTHFD1L).
The formate then exits the mitochondria and is used in cytosolic folate cycle by
methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) to catabolize THF into 10-formyl-THF
(158). At this point, 10-formyl-THF may be used as a substrate for purine synthesis. In
proliferating mammalian cell cultures, purine synthesis is responsible for the largest demand for
one-carbon units generated by the folate cycle. Two formyl-THF units are required to form the
backbone of each purine (157). However, cytosolic 10-formyl-THF may undergo further
reductions by MTHFD1 to form 5,10 me+-THF (158). 5-formyl-THF may be formed from 5,10methenyl-THF by SHMT. 5-formyl-THF serves as a reserve for one-carbon units and is returned
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to the folate cycle after conversion back to 5,10-methenyl-THF by methenyltetrahydrofolate
synthase (MTHFS) (157, 160).
Intracellular storage of folate is maintained for use in folate deficient conditions, when an
insufficient amount of folate is available through the diet. In humans, the total supply folate
stored within cells may last for 2-3 months (161). If intracellular folate storage is not required
due to adequate availability of dietary folate and existing stored folate, then MTHFD1 will
further reduce 5,10-methenyl-THF to form 5,10-methylene-THF. Similar to 10-formyl-THF,
there are multiple uses for 5,10-methylene-THF depending on the requirements of the cell. First,
it may be used by SHMT to remethylate glycine to form serine and THF and complete the folate
cycle. Next, it may be consumed by thymidylate synthase (TYMS) to convert deoxyuridine
monophosphate (dUMP) to dTMP and produce DHF. dTMP is required for DNA synthesis. If
these molecules are not needed, 5,10-methylene-THF is reduced by methylenetetrahydrofolate
reductase (MTHFR) to form 5-methyl-THF. This folate derivative plays an important role in the
synthesis of the methionine, an essential amino acid (158). A summary of the steps of the folate
cycle and its compartmentalization between the cytosol and mitochondria are provided in Figure
19.
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Figure 19. The steps and compartmentalization within the cytosol and mitochondria of the
folate cycle (157).

2.2.1 The Role of the Folate Cycle in One Carbon Metabolism
Together, the folate metabolic cycle and the methionine metabolic cycle are referred to as
one-carbon metabolism. The complete set of reactions involved in one-carbon metabolism is
summarized in Figure 20.
Bacteria, including the C. elegans feeding strain E. coli OP50, are capable of
synthesizing all 20 amino acids in large enough quantities for survival. However, eukaryotes
(thus C. elegans) cannot synthesize ten amino acids. Amino acids that cannot be synthesized in
large enough quantities for survival and must be brought in through the diet are referred to as
essential dietary amino acids, or simply, essential amino acids. In most eukaryotes, including C.
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elegans and humans, methionine is an essential amino acid (162). The non-essential amino acid,
homocysteine, is not used for protein synthesis. Instead, it functions as an intermediate for
methionine synthesis (163).

Figure 20. Combined folate and methionine cycles showing the significance of one-carbon
metabolism on these and extended pathways (164).

In the folate cycle, MTHFR converts 5-methyl-THF to THF (165). Cobalamin (or
vitamin B12) binds the freed methyl group from the 5-methyl-THF to THF conversion.
Methionine is synthesized from homocysteine by the addition of a methyl group provided by
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cobalamin and the action of methionine synthase (MS) (158). Next, methionine is converted to
S-adenosyl-methionine (SAM), a universal methyl donor by methionine adenosyl transferase 2A
(MAT2A). The methyl group is removed from SAM by methyl transferases (MTs) and SAM is
converted to S-adenosyl-homocysteine (SAH). The removed methyl group may be used for
DNA, RNA, protein, or histone methylation. SAH is converted to homocysteine by adenosyl
homocysteinase (AHCY) and the methionine cycle is complete. The generated homocysteine can
either be converted into methionine to continue the cycle or be consumed in the transsulfuration
pathway for glutathione synthesis. Alternatively, methionine can be recycled from SAM via the
methionine salvage pathway. This pathway utilizes SAM to synthesize polyamines, which
produces a by-product, methylthioadenosine (MTA). The MTA is phosphorylated by
methylthioadenosine phosphorylase to produce adenine and methylthioribose. The adenine may
be utilized for purine synthesis while the methylthioribose undergoes a series of reactions to
convert it to methionine (164, 166).
Issues may arise in one-carbon metabolism under conditions of folate deficiency. Limited
folate availability prevents the conversion of homocysteine to methionine by limiting the
availability of the methyl group from the 5-methyl-THF to THF conversion (158). As a result,
homocysteine accumulates and causes a condition known as hyperhomocysteinemia (167). There
are many shared similarities in the effects of folate deficiency and hyperhomocysteinemia.
Hyperhomocysteinemia has been associated with vascular diseases, including coronary artery
disease and stroke (168, 169). Additionally, numerous complications of pregnancy, such as
placental displacement and disturbed vascularization, pre-eclampsia, neural tube defects, and
frequent pregnancy loss, are known to be caused by hyperhomocysteinemia (170, 171, 172).
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Despite a clear understanding of the folate and methionine cycles individually, the extent
that the two cycles influence on each other within one-carbon metabolism remains unclear. In
humans, including mammals, methionine is an essential amino acid and must be primarily
acquired through the diet. However, limited methionine synthesis can occur through the use of an
alternative methyl source, which is not tied to the folate cycle, for the synthesis of methionine
from homocysteine. Betaine may be used as an alternative methyl group source for the
methylation of homocysteine to methionine by the enzyme betaine-homocysteine
methyltransferase (BHMT) (173). BHMT is expressed in the cytosol of the liver, kidney, and
lens of the eye and makes up for approximately half of the homocysteine methylation that occurs
in the human body (174, 175). However, BHMT is only found in the genome of humans and
mammals (176). The model organism used in this study, C. elegans, lacks an alternative route for
homocysteine methylation that is independent of the folate cycle. This allows for the direct
observation of the effects on the folate cycle due to manipulation in the methionine cycle (or vice
versa).

2.3 The Instability and Degradation of Folates
Both natural and synthetic folates possess key physical and chemical characteristics that
are important to consider when differentiating between each form. In general, folates have very
low solubility in water and acidic solutions (pH 2-4) and solubility increases as the pH rises
(177). Additionally, each of the forms of folate are readily susceptible to interconversions and
oxidative degradation due to changes in pH, temperature, and exposure to oxygen and ultraviolet
light (156, 178, 179). In low pH and/or with heat, tetrahydrofolate is oxidized to briefly to a
dihydrofolate intermediate then to folic acid, the most oxidized form of folate (Fig. 18) (180).
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However, when heat is applied to solutions with ascorbate, formaldehyde is produced, which is
utilized in the conversion of tetrahydrofolate to 5,10-methylene-tetrahydrofolate. The folate
derivative, 5,10-methylene-tetrahydrofolate is only stable in this form at pH 10 and dissociates at
physiological pH to form formaldehyde and tetrahydrofolate (178).
5-methyl-tetrahydrofolate remains stable at varied pH values and temperatures; however,
it may be oxidized to 5-methyl-5,6-dihydrofolate. Under acidic conditions, the C9-N10 bond of
5-methyl-5,6-dihydrofolate is cleaved (181). With prolonged and/or high exposure to oxidative
conditions, both 5-methyl-tetrahydrofolate and 5-methyl-5,6-dihydrofolate are converted to an
intermediate, 4-a-hydroxy-5-methyl-tetrahydrofolate. Without another reducing agent present,
the structure of this intermediate is oxidized and rearranged to form a pyrazino-s-triazine
derivative (182, 183).
A pH dependent equilibrium is maintained between 10-formyl-tetrahydrofolate, 5formyl-tetrahydrofolate (folinic acid), and 5,10-methylene-tetrahydrofolate. 10-formyl-THF
predominates at neutral and basic pH, at slightly acidic pH (4.0-5.5) the equilibrium shifts to
favor folinic acid, and 5,10-methyl-tetrahydrofolate is the form present at highly acidic pH (1.52.6) (128). Additionally, 10-formyl-tetrahydrofolate can be easily oxidized to form a 10-formyldihydrofolate intermediate. The 10-formyl-dihydrofolate intermediate is then further oxidized to
form 10-formyl-folic acid, which retains folate activity (184). The relationships between each of
the folate derivatives and the degradation of each are summarized in Figure 21 (161).
In vivo cytoplasmic and mitochondrial folate derivatives maintain the proper
conformation by binding with proteins. These folate-binding proteins bind to the vast majority of
intracellular folates (185, 186,187). The folate-binding proteins have been identified as
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mitochondrial sarcosine and dimethylglycine dehydrogenase (188), and glycine-Nmethyltransferase (189) and 10-formyltetrahydrofolate dehydrogenase (190) in the cytoplasm.

Figure 21. The pH and heat dependent interconversions and degradation of folates (161).

2.4 The Role of GCPII in Folate Metabolism
The second known physiological function of GCPII is the hydrolysis of poly-γglutamylated dietary folates (Fig. 7) (54, 56). In humans and pigs, GCPII-mediated folate
hydrolysis occurs in the apical brush border of the proximal jejunum (90).
Although dietary folate contains a mixture of predominantly poly-γ-glutamylated folates
with lower concentrations of monoglutamated folates, only monoglutamylated folates can be
transported directly into the enterocyte (57, 58). The most common dietary folate is 5-methyl-
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tetrahydrofolate (191). The conversion of polyglutamated folates to monoglutamated folates is
performed by GCPII. The specific role of GCPII in folate hydrolysis is to cleave excess
glutamate(s) from the polyglutamylated tail of dietary folates to form the biologically available
mono-glutamated folate (57). Interestingly, studies have shown that polymorphism in the GCPII
gene may play a role in folate metabolism which may cause downstream effects on the
development of neural tube defects, cancer, and cardiovascular disease (192, 193, 194, 195).
Once cleaved, the mono-glutamated folate must be transported across the apical brush border
membrane of the small intestine.
Three types of folate transporters are expressed in humans, the proton-coupled folate
transporter (PCFT), reduced folate carrier (RFC), and folate receptors (FRs) (Fig. 22) (58).
PCFTs are the predominant folate transporters in the small intestine and function optimally in
acidic pH (~ 5.5) (196). RFC is ubiquitously expressed in both normal and malignant tissues and
its expression has been confirmed at varied levels in 68 different tissues. High expression of RFC
occurs in the placenta, liver, kidney, lung, bone marrow, duodenum, brain, and other parts of the
central nervous system (197). However, RFCs only function near physiological pH (~7.5) (198).
There are three types of FRs, FR-a and FR-b, and FR-g (199). FRs function in environments
where the pH ranges from 5.6 to 7.2, however, the average pH of vesicles that contain FR ranges
from ~6.6-6.8 (200). FR-a and FR-b are anchored to the cell membrane and function in the
transport of folate into cells (199, 201, 202). FR-a is expressed in the kidney, choroid plexus,
retina, uterus, and placenta (199, 203). FR-b is expressed in the placenta, spleen, and thymus
(204). Folate binds to the FR on the cell surface, which is then brought into the cell via
invagination of the cell membrane. Inside the cell, the folate remains bound to the FR inside a
vesicle until the pH of the vesicle is decreased (~6.5) (200). The folate is then released from the
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FR and exported into the cytoplasm. PCFT is suspected to be responsible for the transport of
freed folate from the vesicle to the cytoplasm (196, 205, 206). The absorption of
monoglutamated folates within the apical membrane of the jejunum by PCFTs is mediated by a
transmembrane proton concentration gradient (58). The proton concentration within the cell and
the electrochemical gradient between the enterocyte and the intestinal lumen are maintained by a
Na+/H+ Exchanger (NHE) (58).
Once suspended in the cytoplasm, 5-methyl-tetrahydrofolate directly pass through the
enterocyte unchanged. However, all other forms of monoglutamated folate must undergo
conversion through the folate cycle to 5-methyl-tetrahydrofolate before it can exit through the
basolateral membrane. This makes 5-methyl-tetrahydrofolate the predominant form of
monoglutamated folate in blood (207). High levels of accumulated folate within the enterocyte
result in folate efflux through the basolateral membrane and into the hepatic portal system (58).
Although it is currently unclear, a member of the multidrug resistance protein (MRP) family,
most likely MRP3, is suspected to be responsible for folate transport across the basolateral
membrane (Fig. 22) (207, 208).
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Figure 22. Absorption of dietary folate from in the intestinal lumen, across the apical brush
border membrane, into the enterocyte, and dispersal to the hepatic portal vein for systemic
distribution (58).
List of abbreviations: dietary polyglutamated folate (Fol-pg), glutamate carboxypeptidase II
(GC II), monoglutamated folate (Fol-), organic phosphate (OP-), Na+/H+ Exchanger (NHE),
proton-coupled folate transporter (PCFT), reduced folate carrier (RFC), multidrug resistance
protein (MRP)

Folates travel through the hepatic portal vein and end up at the hepatic sinusoid. At this
point, there are three potential paths for the monoglutamated folates. The folate may enter
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systemic circulation for distribution to peripheral tissues via the hepatic veins. Alternatively, the
folates can be transported into hepatocytes by PCFTs. Within hepatocytes, the monoglutamated
folates may be converted to polyglutamated folate for storage by folylpolyglutamate synthase
(FPGS) or secreted into bile and re-released into the digestive tract for re-absorption in the
jejunum and duodenum or excretion in feces (57, 58, 209). Stored polyglutamated folates in
hepatocytes are hydrolyzed to monoglutamated forms through the action of g-glutamate
hydrolase (GGH) and released into system circulation when needed (58, 209). Dual PCFT and
RFC expression have been confirmed along the length of apical brush border membrane of the
gastrointestinal tract, however, the shifting pH along the length of the duodenum make the exact
mechanism of re-absorption in the large intestine unclear (57, 210, 211). Due to the unfavorable
pH, the rate of net folate absorption in the duodenum is approximately one tenth of the
absorption form the jejunum. GCPII is responsible for the cleavage of polyglutamated folates in
the large intestine (57).
System circulation is maintained at a pH of 7.4 which allows the RFC to mediate the
transport of folate from blood circulation into peripheral tissues. Specialized absorption of
folates occurs in the kidneys, blood-brain barrier, choroid plexus barrier, and into the placenta.
FR-a functions in the kidney by receptor-mediated endocytosis as previously described (58, 199,
202, 212, 213). The folate re-absorptive process occurs during filtration of waste from the blood
within the glomerulus and proximal tubules of the kidney (213, 214). There are two possible
methods of folate provision to the brain, either through the blood brain barrier at the cerebellar
epithelium or the blood-cerebral spinal fluid (CSF) barrier at the choroid plexus. Folate transport
at the blood-brain barrier is mediated by RFC and PCFT, however, the exact pH and role of each
transporter at this site remains unclear. At the blood-CSF border, FR-a in conjunction with
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PCFT function to transport folates into the cytoplasm and RFC on the basolateral membrane
maintains a folate concentration gradient, finally exporting excess folate across the blood-CSF
barrier and into the brain (58, 210). The exact mechanism of placental transport of folates is
unclear. RFCs, PCFTs, FR-a, and FR-beta have been detected, however, the interactions
between them that allow for the transport folate from the maternal to fetal sides of the placenta
are ambiguous (196, 197, 204, 215).
In C. elegans the cleavage, absorption, and dispersal of folate occurs in a similar method
as in humans (216). As previously discussed in Chapter 1 Section 1.4.5, cGCPII and hGCPII
share a high degree of structural similarity, which alludes to a shared biological function(s). As a
result, one of the expected functions of cGCPII is to cleave dietary folate within the intestine of
C. elegans. However, C. elegans relies on a human RFC (hRFC) ortholog, folt-1, which shares
40% homology with hRFC (216) for the uptake of folates (216). The folt-1 gene encodes the
folate transporter FOLT-1, which transports monoglutamated folate from the intestinal lumen
into enterocytes (129, 216). Unlike hRFC, FOLT-1 functions best in a slightly acidic pH (~5.5)
(216). The highest expression levels of FOLT-1 were localized to the pharynx and posterior
intestine (216). However, similar to hGCPII expressed in the kidney and prostate, the roles of
cGCPII expressed in the pharynx of C. elegans remains unclear (42). Lower expression levels of
folt-1 have been detected in the gonadal sheath cells, indicating a role in the transport of folate
through gap junctions to developing oocytes (216, 217, 218). Once folate, and other nutrients,
are absorbed, they are transported through the basal membrane of the intestinal cell and into the
pseudocoelomic space. The pseudocoelomic fluid contacts all other tissues of the body and is
believed to distribute nutrients to all other tissues (219).
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2.5 Folate Biosynthesis in Bacteria
De novo folate biosynthesis occurs only in bacteria, fungi, and plants. Animals, including
C. elegans, are capable of converting folate to different forms within the folate metabolic cycle
(Fig. 18), however, cannot synthesize folate de novo (220). The bacterial folate biosynthesis
pathway is summarized in Figure 23.
As previously stated in Chapter 2 Section 1, a folate molecule consists of a pteridine ring
connected via a methylene bridge to a para-aminobenzoic acid (PABA), which is connected via a
peptide bond to a glutamate chain of one to seven glutamates (155). This molecule is synthesized
in bacteria in two main steps, the conversion of chorismate to PABA and the formation of 6hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPPP) from guanosine triphosphate (GTP).
The final product of folate biosynthesis is formed after DHPPP and PABA condense, followed
by the binding of a L-glutamate residue, which creates mono-glutamated dihydrofolate. This
product may then be converted to tetrahydrofolate and utilized through one carbon metabolism
(221).
Chorismate is a precursor for PABA and must be synthesized using the Shikimate
pathway. The Shikimate pathway is only utilized by microorganisms and plants for the synthesis
of aromatic compounds, including aromatic amino acids. The absence of the Shikimate pathway
in animals is specifically what prevents folate biosynthesis, as well as, the synthesis of dietary
essential amino acids. The initial substrates in the shikimate pathway, phosphoenolpyruvate and
erythrose-4-phosphate undergo a series of reactions to produce shikimate. Shikimate is
phosphorylated to shikimate acid triphosphate, which then undergoes an addition-elimination
reaction with phosphoenolpyruvate to produce 5-enolpyruvylshikimic acid 3-phosphate (EPSP).
EPSP is then converted to chorismate and can be utilized as an initial substrate for the synthesis
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of PABA (222, 223). The conversion of chorismate to 4-amino-4-deoxychorismate is facilitated
by aminodeoxychorismate synthase (E.C. 2.6.1.85). Pyruvate is then cleaved from the molecule
by 4-amino-4-deoxychorismatelyase (E.C. 4.1.3.38) which yields PABA (220, 221).
The synthesis of the pteridine ring structure requires numerous steps and the action of
several enzymes. First, GTP cyclohydrolase I (E.C. 3.5.4.16) rearranges GTP in a four-step
reaction to yield 7,8-dihydroneopterin triphosphate. Next, pyrophosphate is removed from the
7,8-dihydroneopterin triphosphate intermediate by dihydroneopterin triphosphatase (E.C.
3.1.3.1), which yields 7,8-dihydroneopterin monophosphate. The next intermediate, 7,8dihydroneopterin, is produced by the removal of the phosphate group on dihydroneopterin
monophosphate by nonspecific phosphatases (E.C. 3.6.-). Finally, dihydroneopterin aldolase
(E.C. 4.1.2.25) reacts with 7,8-dihydroneopterin to produce DHPPP. DHPPP is
pyrophosphorylated by hydroxymethyldihydropterin pyrophosphokinase (HPPK) (E.C. 2.7.6.3)
using ATP as the pyrophosphate donor. Once both folate precursors, the PABA and
pyrophosphorylated DHPP, have been produced they are bonded together by the action of
dihydropteroate synthase (E.C. 2.5.1.15) to form 7,8-dihydropteroate (DHP) (221).
Dihydrofolate (DHF) is formed through the addition of an L-glutamate residue to DHP by
dihydrofolate synthase (E.C. 6.3.2.12). From this point, DHF is converted to tetrahydrofolate
(THF) by the action of dihydrofolate reductase (E.C. 1.5.1.3). The newly formed tetrahydrofolate
is now biologically active and may be converted to the different folate forms as previously
described in Chapter 2 Section 2.2. Additional glutamate moieties may be attached to
tetrahydrofolate through the action of folylpolyglutamate synthase (E.C. 6.3.2.17) (220, 221).
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Figure 23. The biosynthetic pathway for folate in bacteria. The enzyme commission
number (E.C.) identifies the enzyme involved in each step (224).
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2.5.1 The Action of the Antibiotic Sulfamethoxazole in Folate Biosynthesis
The first known sulfonamide drug was discovered in 1910 (225). Since then, many more
sulfonamides have been discovered, including sulfamethoxazole (SMX), the most commonly
used sulfonamide class drug (226). Sulfonamides are bacteriostatic and prevent the growth of
bacteria by inhibiting folate biosynthesis. Sulfonamide drugs are structural analogs of PABA
(Fig. 24), which allows for competition between PABA and the sulfonamide drug for use as a
substrate by dihydropteroate synthase and subsequent condensation with DHPPP during the DHP
synthesis step of folate biosynthesis. The condensation of the sulfonamide drug with DHPPP
forms a sulfonamide-pterin adduct instead of the DHP molecule required for the next step of
folate synthesis (227). This competition within the cell for dihydropteroate leads to a drastic
reduction in the amount of dihydropteroate available for folate biosynthesis. Ultimately, the
folate deficiency caused by sulfonamides leads to inhibition of DNA, RNA, and protein
synthesis (228).
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Figure 24. The chemical structure of PABA and the structural analog
sulfamethoxazole (4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide)
(229).

2.6 Methionine Biosynthesis in Bacteria
There is variation among different prokaryotic species in the mechanism of methionine
biosynthesis. As E. coli is the species utilized in this work; the well-studied mechanism of E. coli
methionine biosynthesis will be discussed (Fig. 25). First, a succinyl group from succinyl-CoA is
transferred to the g-hydroxyl group on a homoserine molecule by homoserine Osuccinyltransferase to produce O-succinylhomoserine (230, 231). Next, transsulfurylation of
homoserine occurs in two steps. In the first step, cystathionine g-synthase transfers a thiol group
from cysteine to O-succinylhomoserine to produce cystathionine and the by-product, succinate.
During the second step cystationine b-lyase catalyzes the cleavage of cystationine to yield
homocysteine and the by-products, pyruvate and ammonia (232). Finally, homocysteine must be
converted to methionine via methylation of the sulfur. Two possible enzymes are capable of
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catalyzing this reaction, cobalamin-dependent methionine synthase or cobalamin-independent
methionine synthase (233). E. coli are not capable of cobalamin synthesis and must savage it
from the environment (234). The availability of the cobalamin cofactor determines which of
these enzymes is active. When present, cobalamin serves as an acceptor and donor of the methyl
group, however, in the absence of cobalamin the methyl group is directly transferred from 5methyl-tetrahydrofolate to homocysteine (233, 235). As a result, cobalamin-independent
methionine synthase is much less efficient (~50x) than the cobalamin-dependent enzyme (236).
Either of the enzymes catalyzes the removal of the methyl group from 5-methyl-tetrahydrofolate
to the homocysteine, with or without cobalamin as a cofactor, to yield methionine (233, 235).
This final step is the intersection of the folate and methionine cycles within one carbon
metabolism (Fig. 20) (164).
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Figure 25. The reaction scheme of mechanism of methionine biosynthesis in E. coli (237). 5methyl-tetrahydropteroyl (Me-THPTG) may act as an alternative methyl donor for the
methionine synthesis step by the action of betaine-homocysteine methyltransferase (BHMT).
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2.7 Potential in vivo use of hGCPII Inhibitors for the Inhibition of cGCPII Actions
The structure of most GCPII inhibitors is similar to the structure of N-acetylaspartylglutamate (NAAG). All inhibitors share a general structure that consists of a zinc binding
group, a glutamate mimic moiety that contains a carboxylic acid group, and a linking group that
connects them (Fig. 26A). GCPII inhibitors are categorized into four classes based on the
identity of the zinc binding group: phosphonates, thiols, ureas, and hydroxamates (238, 239). As
previously mentioned in Chapter 1 Section 1.3.2, 2-phosphonomethyl pentanedioic acid (2PMPA) and 2-3-mercaptopropyl pentanedioic acid (2-MPPA) are two commonly used GCPII
inhibitors (Fig. 26B). Both of these inhibitors share three characteristics, like other inhibitors, (i)
2-PMPA and 2-MPPA share structural similarity to NAAG, (ii) have a strong affinity for the
GCPII active site, and (iii) inhibit GCPII activity via competitive inhibition. Either inhibitor
binds with a high affinity to the active site of GCPII, which prevents NAAG from binding and
the subsequent cleavage to NAA and glutamate (238). Prevention of the generation of excess
free glutamate reduces the effects of glutamate neurotoxicity present in neurodegenerative
disorders (42).
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Figure 26. (A) The general structure and binding modes of hGCPII inhibitors (B) and the
specific structures of 2-PMPA and 2-MPPA used in this study (238).

The inhibitor 2-PMPA is a phosphonate class inhibitor with an IC50 value of
approximately 1 nM (in vitro) (239, 240). The inhibitory interactions of the enzyme, GCPII, with
the substrate and the inhibitor 2-PMPA, have been well studied using X-ray crystallography
(238). The C-terminal a-carboxylate group forms an ionic bond with Arg210 and hydrogen
bonds with Tyr552 and Tyr700. The g-carboxylate group interacts with Asn257 and Lys699 as
depicted in Figure 27. The first oxygen of the phosphonate moiety is positioned between the two
zinc ions while a second oxygen from the phosphonate moiety interacts with one zinc ion and the
Tyr552 residue. The third oxygen is positioned away from the zinc ions and does not impact the
binding of the inhibitor. The glutarate moiety binds the S1´ pocket of GCPII. The strong affinity
of bonds between GCPII and the phosphonate and glutarate moiety of the inhibitor allow for
high levels of inhibition (238).
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Figure 27. The inhibitor, 2-PMPA (teal), and its interactions with amino acids
(green) and zinc ions (grey) within the active site of GCPII (238).

The second inhibitor, 2-MPPA, is a thiol with an IC50 value of 90 ± 26 nM (in vitro) (52,
239). The thiol group interacts with one of the zinc ions within the active site while the glutarate
group interacts with the S1´ site. A more detailed description of the mechanism of GCPII
inhibition by 2-MPPA is not yet available as an X-ray crystal structure of this complex has not
been imaged (238). This knowledge of the interaction between the substrates NAAG and the
inhibitors lead to the mapping of the ‘carboxylate recognition site’ and the ‘glutamate
recognition site’ in GCPII.
As previously mentioned in Chapter 1 Section 1.3.2, other mammalian orthologs of GCPII
share a high degree of similarity to human GCPII regarding enzyme activity and inhibitor
binding function. GCPII orthologs expressed in mice, rats, and pigs have a shared sequence
identity of 86%, 85%, and 91%, respectively (88, 89, 90). Additionally, the inhibition profiles
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are similar, 2-PMPA has been shown to inhibit GCPII activity in mouse, rat, pig, and human
models (87, 88). The second inhibitor, 2-MPPA has been shown to inhibit GCPII activity in
mice, rats, and humans (52, 241).
2-PMPA was the first GCPII inhibitor to be developed in 1996 and was found to be highly
specific and effective towards hGCPII (242). However, the highly polar nature (Fig. 26) of this
compound greatly limits its ability to reach the target site due to low oral bioavailability and cell
penetration. As a result, many studies that utilize the 2-PMPA inhibitor administered the
inhibitor via injection. Prodrugs of 2-PMPA are in development that aim to increase phosphonate
stability and subsequently increase oral bioavailability and cell penetration (243). Despite these
difficulties, there have been signs of promise with the use of 2-PMPA for the treatment of
neurodegenerative diseases and cancer. 2-PMPA has shown to be neuroprotective during
ischemic stroke and reduce short term memory deficits associated with schizophrenia (244, 245).
2-PMPA has also been tagged with biomarker and therapeutic agents to allow for targeted
treatment and visualization of prostate cancer tumor margins, growth, and progression (246). 2PMPA has been administered intranasally to non-human primates, which reached the brain in
therapeutically relevant dosage (247).
The thiol class of GCPII inhibitors was developed in an attempt to increase the oral
bioavailability of the phosphonates (52). 2-MPPA was the first GCPII inhibitor that was
determined to be orally bioavailable to rats (71%). Additional studies have demonstrated that
oral administration of 2-MPPA was capable of reducing neuropathic pain and preventing motor
neuron death in amyotrophic lateral sclerosis (52, 248). 2-MPPA was the first GCPII inhibitor to
be tested in humans. The results of this study demonstrated that 2-MPPA caused no negative
effects within the central nervous system at blood plasma levels equivalent to those administered
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to other animal models which reduced neuropathic pain. However, further study of 2-MPPA use
in humans was halted after the inhibitor was determined to have the potential for immune
toxicity and a low potency in humans (42, 241).
Mice have been the predominant model organism for the study of GCPII inhibition with
these compounds. However, due to the fact that mice do not utilize GCPII for the hydrolysis of
folate, very little investigation of the effects of these inhibitors on the growth and progression of
prostate cancer have been implemented (41). The development of a successful protocol for the
use of these inhibitors in C. elegans could allow for these types of studies to be performed in this
simple model organism to closely monitor protein-drug interaction in vivo. Due to the amount of
structural similarity between hGCPII and cGCPII these inhibitors could be expected to have a
strong affinity for cGCPII (Fig. 12). However, there is a lack of reported use in C. elegans. As a
result, an experiment was designed and performed to determine the potential for 2-PMPA and 2MPPA use in C. elegans for the study of GCPII related pathology.

2.8 Hypothesis and Chapter Objectives
The overall hypothesis of this chapter is that the three paralogs of cGCPII, gcp-2.1, gcp2.2, and gcp-2.3, have different roles in the cellular biochemistry of C. elegans that impacts the
reproductive and physiological biology of C. elegans. To characterize these roles a number of
experiments will be designed and completed. The effect of limited folate availability on the
longevity of each cGCPII paralog will be determined. First, to determine the effects of folate
limitation on the food source of C. elegans, the level of E. coli OP50 growth under folate limited
conditions will be quantified. Additionally, the relative amounts and types of different folate
derivatives present in the bacterial food source will be identified using HPLC. Second, a specific
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folate derivative, tetrahydrofolate, will be supplemented under folate limited conditions to
determine the ability of each cGCPII paralog to recover reproduction. Third, the suitability of
GCPII inhibitors, 2-PMPA and 2-MPPA, to act as in vivo inhibitors on C. elegans will be
assessed. Finally, a method for the growth of E. coli OP50 under methionine limited conditions
will be developed to test the indirect effect of folate deficiency as it impacts methionine
biosynthesis. The relationship between limited methionine and cGCPII paralog and its effect on
reproduction will be determined and compared to folate limitation. This will characterize the
intersection of the folate and methionine cycles within one-carbon metabolism with regards to
the paralog of cGCPII present.

2.9 Materials and Methods
2.9.1 Worm Strains
The N2 (wild type) and RB1055 (gcp-2.1 mutant) C. elegans, and E. coli strain OP50 starter
culture were acquired from the Caenorhabditis Genetics Center (CGC). The TM6632 (gcp-2.2
mutant) and TM5414 (gcp-2.3 mutant) C. elegans were acquired from the National BioResource
Project (NBRP) of Japan.
2.9.2 Bacterial Food Source
All C. elegans strains were fed E. coli OP50 throughout all experiments and stock
maintenance on NGM plates. Frozen stock frozen cultures of OP50 were stored at -80°C. 50 µL
of the frozen stock OP50 was used to inoculate 100 mL of Luria Bertani (LB) broth (Fisher
BioReagents) under sterile conditions. The LB broth was created using 25 g of LB powder
(Casein Peptone 10 g/L, Yeast extract 5 g/L, and Sodium Chloride 10 g/L) thoroughly mixed
into 1 L of nanopore filtered water. The LB media was sterilized by autoclaving for 50 minutes.
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The culture was incubated at 37 °C for 12-16 hours at 250 rpm on an incubated orbital shaker
(New Brunswick Scientific E24). A bacteria pellet was acquired by centrifuging for 1 minute at
9500 rpm (Thermo Scientific Sorvall ST8R). Based on the weight of the pellet, the bacteria was
resuspended in sterile, nanopore water to a final cell concentration of 200 mg/mL. All NGM
plates were seeded at 200 mg/mL bacterial cell concentration.
2.9.3 Preparation of Nematode Growth Media (NGM)
For 1 L of NGM preparation, 3 g NaCl (Fisher Scientific), 17 g technical agar (Difco),
2.5 g bacto-peptone (Difco), and nanopore water were mixed thoroughly and autoclaved for 50
minutes. After removal from the autoclave, the media was allowed to cool at room temperature
for approximately 15 minutes before it was placed in a 55 °C water bath (Fisher Scientific
Isotemp 205) until the temperatures equilibrated. Once the NGM reached 55 °C, 1 mL CaCl2 (1
M), 1 mL MgSO4 (1 M), 25 mL potassium phosphate buffer (1 M, pH 6.0), 1 mL cholesterol in
ethanol (5 mg/mL), 1 mL streptomycin (100 mg/mL), and 1 mL nystatin (10 mg/mL) were added
and mixed thoroughly by swirling. For plates that contained 5-fluoro-2'-deoxyuridine-5'phosphate (FuDR), 330 µL of 150 mM FuDR per liter of NGM was added at this stage. 5 mL of
the NGM was aseptically dispensed to 60 x 15 mm petri plates (Fisher Scientific) using a
peristaltic pump (Drummond Scientific) in a sterile hood. The plates were allowed to solidify at
room temperature under the sterile hood with the lid slightly open to avoid condensation. Once
solid, the plates were stored inverted to preserve moisture at 4 °C.
2.9.4 Seeding Plates
For each solidified NGM plate, 100 µL of the 200 mg/mL OP50 was dispensed onto the
center of the surface of the plate using sterile techniques. The plates were then closed and gently

77

swirled to spread the OP50 to an approximately 1-inch diameter. The plates were allowed to dry
for at least 1 day before use. Unused seeded plates were stored inverted at 4 °C.
2.9.5 General C. elegans Maintenance Techniques
Each strain was maintained on the solid NGM plates seeded with E. coli OP50 and incubated
at a constant temperature of 20 °C. To minimize contamination and ensure food availability, the
worms were transferred to identical, new plates once a week. The tool used to transfer a single or
a few worms at a time was called a worm pick. A worm pick consisted of a short piece of
platinum wire heat-fused into the end of a glass Pasteur pipet. The platinum wire was bent
slightly, and the end was flattened to aid in the transfer of the worms. Prior to use, the end of the
platinum wire was sterilized in an ethanol flame for approximately 7 seconds. Once cool, the
pick was gently dragged across the surface of the new plate to pick up a small amount of OP50.
Special care was taken to ensure the media was not damaged. Next, the OP50 covered tip was
gently tapped on the worms to pick them up. Finally, the pick was gently tapped or dragged
across the surface of the media without 0P50 to deposit the worms on the new plate. Another
method that was occasionally used to move worms was called “chunking”. For this technique, a
spatula was sterilized and used to cut a small section of the media from the old plate. The media
was then placed on the surface of the new plate. This method allowed many worms to be moved
to a new plate at once and was primarily used to generate large populations for age
synchronization.
2.9.6 Age Synchronization of C. elegans Populations
The age synchronization protocol was used prior to all experiments to generate
populations of worms of the same age for all strains and/ or treatment groups. This protocol, also
referred to as “bleaching”, allows for the isolation of eggs from gravid L4 adult stage worms and
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for the removal of bacterial or fungal contamination. For each strain and/or treatment group
combination, three 3-day-old plates were used. The plates were ready if there were a large
number of gravid adults and/or eggs on the surface of the media, and there was still E. coli
available (i.e. non-starving conditions). The age synchronization was performed using a slightly
modified protocol from Amrit et. al. (249). The synchronized eggs were resuspended in 20 mL of
M9 solution in a 50 mL conical tube. The conical tubes were then incubated at room temperature
overnight with gentle rocking (on the nutating shaker). 100 µL of M9 containing the hatched
larvae was deposited onto the media surrounding the E. coli OP50. After a few minutes, the
larvae were observed under a microscope to verify that they were alive. The worms were
incubated at 20 °C until they reached the desired life stage. At this point, the appropriate number
of worms was transferred to the experimental plates.
2.9.7 Longevity Assay Under Folate Limited Conditions on Solid Media
There were five sulfamethoxazole (SMX) treatment groups, a control (no added SMX), of
1 µg/mL, 100 µg/mL, 1000 µg/mL, and 2000 µg/mL. The SMX was added to the LB media
immediately prior to the addition of the stock E. coli OP50 food. Prior to age synchronization,
each of the four populations of each strain (i.e. N2, gcp-2.1, gcp-2.2, and gcp-2.3) were grown on
NGM plates seeded with one of the SMX treatment groups. SMX addition to the NGM media is
necessary as experiments with SMX treated food only failed to induce significant effect on worm’s
brood size or longevity. Age synchronized L4 stage worms were transferred to NGM plates that
contained FuDR and E. coli OP50 food that has been treated with appropriate amounts of SMX.
Approximately 10 worms were transferred to each plate. Each combination of the four strains and
five SMX treatment groups were tested. The number of living worms on each plate were counted
every 2-3 days. Worms were counted as living if they moved when gently tapped on the head with
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the worm pick tool and dead if they did not respond. Dead worms were removed from the plate
and burned in the ethanol flame. Worms were counted as “Fled” if they crawled up the side of the
plate and desiccated or if they burrowed under the surface of the media. “Fled” worms were
removed from the total sample size. Every 7 days, the living worms on each plate were transferred
to a new plate of the same treatment. This prevented the accumulation of contamination and
ensured food availability. Each strain and treatment group combination was tested with three
replicates for an initial total sample size of 30 approximately worms.
2.9.8 OP50 Culture Growth with Limited Folate Through the Use of Sulfamethoxazole
In order to understand the impact of SMX on OP50 cell growth cultures were raised
under different SMX concentrations and OD600 was monitored as a measurement of growth.
Under aseptic conditions, six cultures of 100 mL of LB were prepared in 250 mL Erlenmeyer
flasks. To each flask, 50 µL of frozen OP50 cells from a single stock was added. Finally, a
different sulfamethoxazole concentration, either 0 µg/mL, 1 µg/mL, 10 µg/mL, 100 µg/mL, 1000
µg/mL, or 2000 µg/mL, was added to each flask. The flasks were placed in the orbital shaker at
37 °C and 250 rpm. Absorbance measurements were taken routinely for the next 188 hours. A
similar protocol was followed for another set of six OP50 cultures. The cultures were prepared
with 250 mL of LB broth and 125 µL of frozen stock OP50 in 500 mL Erlenmeyer flasks. Each
flask had a different concentration of sulfamethoxazole, either 0 µg/mL, 1 µg/mL, 100 µg/mL,
1000 µg/mL, 2000 µg/mL, or 5000 µg/mL. The absorbance (OD600) and pH of each of these
cultures was recorded routinely over a 48-hour period.
2.9.9 Characterization of 2-PMPA and 2-MPPA Inhibition of GCPII in C. elegans
To determine the most efficient delivery mechanism of the 2-PMPA and 2-MPPA to the
worm, three sets of NGM plates and a liquid soak were prepared. For the first group of plates the
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drug was included in the NGM. The media was cooled after autoclaving to ~57 °C to prevent
degradation of the drug due to the heat. Then the drug (white solid) was mixed into the liquid
media to a final concentration of 100x, 300x, and 500x the IC50 value for either 2-PMPA (IC50
of 1 nM; 0.1 µM, 0.3 µM, or 0.5 µM) and 2-MPPA (IC50 of 90 nM; 9 µM , 27 µM, or 45 µM)
just before pouring the plates. The other two treatment groups used NGM that was prepared as
previously described in Chapter 2, Section 2.9.3. However, the second group consisted of plates
in which 200 µL of either 0.1 µM, 0.3 µM, or 0.5 µM of 2-PMPA or 9 µM, 27 µM, or 45 µM 2MPPA was aseptically spread across the surface of the NGM. Once dry, these plates were seeded
with OP50 as previously described in Chapter 2, Section 2.9.4. The third group of plates
contained a final concentration of 0.1 µM, 0.3 µM, or 0.5 µM 2-PMPA and 9 µM, 27 µM, or 45
µM 2-MPPA mixed with the OP50 seeded onto the plates just prior to seeding. The final group
was soaked in 500 mL of solution, which contained either 0.1 µM, 0.3 µM, or 0.5 µM of 2PMPA or 9 µM, 27 µM, or 45 µM of 2-MPPA, 200 µL of regular OP50, and M9 solution in a
24-well plate. The 24-well plates were incubated on a rotator at room temperature while the
NGM plates were maintained at 20 °C.
Phenotypic observations were recorded over the course of three generations of wild type
worms for each treatment group. The phenotypes recorded include, activity, response to touch,
location relative to food source, healthy appearance/body size, reproduction, and life stages
present. These data are compiled for comparison in Table 2 and Table 3.
2.9.10 C. elegans Brood Size Assay under Limited Folate Conditions and Tetrahydrofolate
Supplementation
A folate supplementation brood size assay was performed to determine the ability of
tetrahydrofolic acid to rescue reproduction on a folate limited system. The treatment plates were
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prepared as previously described in Chapter 2, Section 2.9.3 with a few key differences. The E.
coli OP50 was cultured with 1000 µg/mL sulfamethoxazole to inhibit folate biosynthesis. There
were a total of four treatment groups in this assay. The first group of treatment plates was seeded
with OP50 that was not cultured with sulfamethoxazole and had no added tetrahydrofolate. The
second contained only the OP50 cultured with 1000 µg/mL sulfamethoxazole. The third and
fourth treatment groups contained OP50 cultured with 1000 µg/mL and 10 and 250 µM
concentration of tetrahydrofolate added. The ages of the wild type and three mutant strains were
synchronized using the population synchronization procedure previously described in Chapter 2,
Section 2.9.6. Each strain was allowed to reproduce for three generations on treatment plates
before one L3 stage worm was transferred to each test plate seeded with E. coli OP50 of the
same treatment group. Approximately 36 hours later (approximately 12 hours after reproduction
began) eggs and hatched larvae we counted at the same time every day until reproduction ended.
2.9.11 Preparation of Folate Standards for HPLC Analysis
Dihydrofolic acid ≥ 90% (Sigma-Aldrich), tetrahydrofolic Acid ≥ 65% (Sigma-Aldrich),
5-methyl-tetrahydrofolic acid disodium salt ≥ 88% (Sigma-Aldrich), folic acid (Sigma-Aldrich),
and folinic acid calcium salt hydrate (Alfa Aesar) standards were all analyzed to determine the
retention time (RT) under specific HPLC running conditions to use in the determination of folate
derivatives in OP50 cultures. Folate derivatives susceptible to oxidation were kept in an Ar filled
glove box (Dr. He’s lab) until used. The standards were prepared in low light immediately before
HPLC analysis. The solid folate was dissolved in a freshly prepared folate extraction buffer. The
pH of the folate extraction buffer was 7.1-7.5 for the dihydrofolic acid, tetrahydrofolic acid, 5methyl-tetrahydrofolic acid disodium salt, and folic acid standards. Just before use, the folate
extraction buffer was bubbled with nitrogen for approximately 1 minute. The pH of the
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extraction buffer used for the folinic acid calcium salt hydrate standard was 6.1 in order to
prevent the changes in structure that occurs at neutral pH.
2.9.12 Folate Extraction from E. coli OP50
Total folate was extracted from the E.coli OP50 food source of C. elegans. An E. coli
OP50 culture was prepared as previously described in Chapter 2, Section 2.9.2. After 14 hours of
growth, the culture was centrifuged at 5000 rpm for 5 minutes and the supernatant was
discarded. Once the entire culture had been pelleted it was resuspended in 10 mL of sterile water
and centrifuged again. The supernatant was discarded, and the bacterial pellet was resuspended
in 10 mL of freshly prepared extraction buffer. The sample was then vortexed and flushed with
nitrogen for 30 seconds. The sample was sonicated while on ice in 20 second bursts. The samples
were allowed to cool for 30 seconds between each round of sonication. This was repeated 9
times before the sample was flushed with nitrogen for 1 minute and incubated in a bath of
boiling water for 10 minutes. The sample was cooled on ice for 5 minutes and then centrifuged at
9500 rpm for 14 minutes at 4 °C. The supernatant, henceforth referred to as the folate extract,
was transferred to another tube and saved for downstream applications. The pellet was
resuspended in a 5 mL extraction buffer, vortexed, and flushed with nitrogen for 30 seconds. The
sample was then placed on the rotator at 4 °C for 10 minutes. The sonication step was repeated in
an identical fashion. The sample was flushed with nitrogen for 1 minute and incubated in a bath
of boiling water for 10 minutes. The sample cooled on ice for 5 minutes and was centrifuged at
9500 rpm for 15 minutes at 4°C. The supernatant was combined with the folate extract that was
preserved from the first round of extraction. All folate extracts were filtered through a Whatman
filter Grade No. 4 (20-25 μM) prior to any analysis via HPLC. The procedure described above
was utilized for both control OP50 and 1000 µg/mL sulfamethoxazole treated OP50 cultures.
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2.9.13 HPLC Analysis of Folate
The HPLC instrument (Hitachi Chromaster) component units used to analyze folates
were the gradient quaternary pump (5110), autosampler (5210), thermostatted column
compartment (5310), diode array detector (DAD-5430), and fluorescence detector (5440). All
samples were prepared in a folate extraction buffer composed of 0.1 M phosphate buffer (pH
6.1), 2% sodium ascorbate (w/v), and 0.1% 2-mercaptoethanol (v/v). 5 N sodium hydroxide was
used to maintain a pH of 6.1-7.5, depending on the range of pH stability for each standard.
Samples were run for 65 minutes with a flow rate of 0.8 mL/min at 4 °C through a Hypersil ODS
C18 analytical column, 5 μm x 4.6 mm x 200 mm, with a guard column (Thermo Scientific).
Two mobile phase buffers were used to analyze the folates. Buffer A (1L), 28 mmol dibasic
potassium phosphate and 60 mmol phosphoric acid in HPLC grade water. Buffer B (1L), 28
mmol dibasic potassium phosphate and 60 mmol phosphoric acid in 200 mL acetonitrile and 800
mL HPLC grade water. The gradient of Buffer A and Buffer B gradually shifted during the 65
minute program as follows: 3 minutes with 100% Buffer A, 10 minutes with 70% Buffer A and
30% Buffer B, 17 minutes with 45% Buffer A and 55% Buffer B, 15 minutes with 43% Buffer A
and 57% Buffer B followed by 10 minutes with 100% Buffer A (elution profile is provided in
Appendix 1. The fluorescence intensity of folates was monitored with a fluorescence detector
(excitation at 295 nm and emission at 360 nm). The identities of peaks were determined on the
basis of the retention time of the folate standards.
2.9.14 Analysis of Folate Standard Spiked Folate Extracts from E. coli OP50
A supplementary method to direct HPLC analysis of folate derivatives was developed to
determine the identity of the folates present in the folate extracts of both control OP50 and 1000
µg/mL sulfamethoxazole treated OP50 cultures. Standard solutions of a known concentration of
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folate derivatives were prepared and added to each type of folate extract. The folate derivatives
present in the folate extracts were confirmed by the overlapping standard peak. The relative
concentration of the solution was determined by comparing the size of the peak in each
previously run standard to the size of the peaks in the folate extracts. Due to this estimation, 0.5
mg/mL folic acid and folinic acid standards were prepared in a freshly prepared extraction
buffer. Both of these solutions were each combined with the two folate extracts so the final
concentration of the respective standard was 0.005 mg/mL. These samples were then filtered
through a Whatman filter Grade No. 4 (20-25 μM) and analyzed via HPLC. The identity of peaks
could then be verified using the expected retention time from the standards and by comparing the
folate extract to the folate extract spiked with a known quantity of a standard folate derivative
solution.
2.9.15 Analysis of E. coli OP50 Folate Synthesis Over Time on NGM Plates
Three cultures were prepared, an SMX untreated, a 100 µg/mL SMX treated, and a 1000
µg/mL SMX treated OP50 culture were prepared as previously described. Each of the cultures
were split into three equal 100 mL portions. The portions of each culture were centrifuged at
9500 rpm for 2 minutes. The pellets were resuspended in sterile water and pelleted again under
the same conditions. One washed pellet from each treatment was kept frozen at 20°C until
needed. The second and third sets of pellets were resuspended to a final concentration of 200
µg/mL and seeded in 200 µL aliquots on standard NGM plates (prepared as previously
described). The plates that contained the second pellet were labeled “Day 1” and the plates that
contained the third pellet were labeled “Day 5”. The plates were left at room temperature until
the bacteria had dried. After approximately 8 hours, the plates were stored upside down at 4°C
until needed. 24 hours after seeding, the bacteria were rinsed from the Day 1 plates with sterile
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water and collected in 50 mL tubes. The bacteria were pelleted, washed with sterile water and
resuspended in 10 mL of extraction buffer. The folate was extracted using the previously
described protocol and the folate profile was analyzed using HPLC. This procedure was repeated
for the frozen pellets on day 1 and 5 days after seeding for the day 5 plates.
2.9.16 M9-glu Defined Culture and Met Supplemented Culture Growth
An M9-glu (M9 with glucose) defined media was developed to culture the E. coli OP50
for use in methionine supplementation experiments. The M9-glu defined media was created
following the protocol established by Endy and Knight Labs with some changes (250). The M9
salts, glucose, MgSO4, CaCl2, and sterile water were autoclaved at ~121 °C for 50 minutes.
Instead of 0.2% casamino acids, an amino acid solution that contained all amino acids, excluding
methionine, at levels similar to those found in the LB broth was created by dissolution in water
and sterilized using vacuum filtration (0.22 micron) (251). Aseptically, methionine was dissolved
in sterile water to create a methionine solution. Each component was combined using sterile
technique just before use. Finally, the E. coli OP50 stock and 1mM thiamine hydrochloride was
added to each culture. Cultures were grown on the rocker at 250 rpm and 37 °C.
2.9.17 C. elegans Brood Size Assay under Limited Methionine Conditions
A methionine limited brood size assay was performed to determine the effects of
methionine restriction on the reproductive ability of C. elegans. Standard NGM plates were
using in all treatments (preparation described in Chapter 2 Section 2.9.3). Three different
treatment groups were used in this experiment: (i) E. coli OP50 cultured in LB broth, (ii) the
bacteria cultured in the Met-glu defined media that was supplemented with 100% methionine
(relative to the amount of methionine present in Difco LB broth), and (iii) bacteria cultured in the
Met-glu defined media that contained no methionine. The E. coli OP50 food source was prepared
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and cultured for each of these treatments as described in Chapter 2 Section 2.9.16. The E. coli
OP50 was resuspended to a final concentration of 100 µg/mL and 40 µL was seeded onto the
center of each plate and the plates were swirled to evenly spread the bacteria. These steps were
taken to ensure visibility of any eggs laid within the bacterial lawn. NGM plates were seeded the
day before use throughout the experiment to reduce the influence of bacterial growth.
Synchronized wild type (N2), gcp-2.1 mutant strain, and gcp-2.2 mutant strain worms
were prepared (as described in Chapter 2, Section 2.9.6) and allowed to develop on NGM plates
that were seeded with the appropriate food source to the L3 stage. Approximately 36 hours
before reproduction began, individual worms were placed on treatment plates. A total of 7
worms per strain were used across each of the three treatment groups (n = 7). Once reproduction
began eggs and hatched larvae were counted every day until reproduction ceased.
2.10 Results
2.10.1 SMX Longevity Assay on Solid Media
A longevity assay was used to determine the effects of sulfamethoxazole treated E. coli
OP50 on the life span of wild type and the three gcp-2 mutant C. elegans strains. The average
median longevity of each strain at each SMX treatment group was calculated and is shown in
Figure 28. Each strain and SMX treatment group combination was composed of 3 replicates of
10 animals. The final sample sizes, after the removal of worms that fled, ranged from 8 to 27
worms.
Survival curves for a strain at each SMX treatment concentration were examined (Figure
29). Wild type C. elegans had a maximum longevity of 20-28 days. The 100 µg/mL SMX
treatment had a median longevity (50% survival) of approximately 14 days, while the control, 1
µg/mL, and 2000 µg/mL SMX treatments had a median longevity of approximately 15 days. The
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1000 µg/mL SMX treatment group had the highest median longevity at 23 days. Both the
maximum and median longevity of the gcp-2.1 mutant strain increased proportionally to the
sulfamethoxazole concentration. The gcp-2.1 mutant strain had a maximum longevity ranging
from 18-28 days. The median longevity of the gcp-2.1 mutant exposed to either the control, 1
µg/mL, 100 µg/mL, 1000 µg/mL, or 2000 µg/mL was 11, 12, 15, 17, and 20, respectively. The
gcp-2.2 mutant strain had a maximum longevity ranging from 22-28 days. The median longevity
of the gcp-2.2 mutant showed an increase as the SMX concentration increased. The 1 µg/mL
SMX treatment group had a median longevity of 12 days, while the control was 14 days. The
100 µg/mL SMX treatment group had a median longevity of 18 days, the 1000 µg/mL and 2000
µg/mL treatment groups had a median longevity of 20 days. The maximum longevity for the
gcp-2.3 mutant ranged from 20-26 days. Similar to the gcp-2.1 mutant, the median longevity of
the gcp-2.3 mutant increased proportionally to the SMX treatment concentration. The median
longevity for each of the control, 1 µg/mL, 100 µg/mL, 1000 µg/mL, and 2000 µg/mL SMX
treatment groups was 12, 13, 15, 17, and 19 days, respectively. However, the maximum
longevity did not follow the same trend, the control, 1000 µg/mL, and 2000 µg/mL SMX
treatment groups both had a maximum longevity of 26 days while the 1 µg/mL and 100 µg/mL
SMX treatment groups had maximum longevity of 20 and 24 days, respectively.
Additionally, survival curves that compared each strain at the same SMX treatment group
were generated (Figure 30). The median longevity was divided in the control treatment with the
gcp-2.1 and gcp-2.3 mutants showing a median longevity of 11 and 12 days, respectively.
However, the wild type and the gcp-2.2 mutant both had a longer median longevity of 15 days.
The maximum longevity of the gcp-2.1 mutant was 26 days, while the other three strains had a
maximum longevity of 28 days. The median longevity of the wild type and gcp-2.1, gcp-2.2, and
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gcp-2.3 mutants treated with 1 µg/mL SMX were 15, 12, 12, and 13 days, respectively. The
maximum longevity with 1 µg/mL SMX was 20 days for the wild type and gcp-2.3 mutant. The
maximum longevity of gcp-2.1 mutant was 24 days and 22 days for the gcp-2.2 mutant. The 100
µg/mL SMX treatment had median longevity of 14 days for the wild type, 15 days for the gcp2.1 and gcp-2.3 mutants, and 18 days for the gcp-2.2 mutant. The maximum longevity for these
same strains were 28, 18, 26, and 24 days, respectively. The trends in longevity displayed in the
1000 µg/mL sulfamethoxazole treatment were similar to those in the control treatment. The gcp2.1 and gcp-2.3 mutants had a median longevity of 17 days, while the wild type and gcp-2.3
mutant had median longevity of 21 and 20 days, respectively. The maximum longevity of the
gcp-2.1 and gcp-2.3 mutant was 26 days and 28 days for the wild type and gcp-2.3 mutant.
Finally, the 2000 µg/mL SMX treatment had median longevity of 15, 20, 20, and 19 days for the
wild type, and gcp-2.1, gcp-2.2, and gcp-2.3 mutants, respectively. The maximum longevity was
26 days for the wild type and gcp-2.3 mutant and 28 days for the gcp-2.1 and gcp-2.2 mutants.
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Figure 28. The median longevity of each strain in the five SMX treatment groups as
compared to the untreated control. Error bars represent ± standard error of the median. Data
acquired from three replicates of 10 worms each.
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Figure 29. (A) The comparison of the longevity of the wild type (N2) at each treatment
group. (B) The comparison of the longevity of the gcp-2.1 mutant (RB1055) at each
treatment group. (C) The comparison of the longevity of the gcp-2.2 mutant (TM6632) at
each treatment group. (D) The comparison of the longevity of the gcp-2.3 (TM5414) at
each treatment group. Data acquired from three replicates of 10 worms each.
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Figure 30. (A) The comparison of the longevity of each strain within the control
treatment group. (B) The comparison of the longevity of each strain within the 1 µg/mL
treatment group. (C) The comparison of the longevity of each strain within the 100
µg/mL treatment group. (D) The comparison of the longevity of each strain within the
1000 µg/mL treatment group. (E) The comparison of the longevity of each strain within
the 2000 µg/mL treatment group.

2.10.2 OP50 Culture Growth with Limited Folate Via Use of Sulfamethoxazole
The growth of an E. coli OP50 cell culture treated with an increasing concentration of
sulfamethoxazole over time was measured as an indicator of the effect of sulfamethoxazole on
bacterial folate biosynthesis. The cell density of each culture was measured
spectrophotometrically at 600 nm (OD600).
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The growth of six cultures treated with either 0 µg/mL (control), 1 µg/mL, 10 µg/mL,
100 µg/mL, 1000 µg/mL, or 2000 µg/mL sulfamethoxazole was measured over 188 hours
(Figure 31). A rapid logarithmic growth stage occurred in the 0 µg/mL (control), 1 µg/mL, and
100 µg/mL SMX treated cultures, which all reached similar cell densities and the stationary
phase after approximately 4 hours. Comparatively, the 1000 µg/mL and 2000 µg/mL SMX
cultures had a lower rate of growth during the logarithmic growth phase and took twice as much
time to reach the stationary phase. A sulfamethoxazole concentration dependent difference in the
OP600 measurement became visible after 24 hours of growth, indicating a decrease in cell
density as the sulfamethoxazole concentration increased. After 62 hours of growth, the five
cultures had similar rates of growth and remained in the stationary phase for the remainder of the
experiment.
Figure 32A shows the growth curves of six cultures treated with either 0 µg/mL (control),
100 µg/mL, 1000 µg/mL, 2000 µg/mL, or 5000 µg/mL sulfamethoxazole over a period of 48
hours. During the logarithmic growth phase, the cell density of each culture increased in an SMX
concentration dependent manner. Clear differences in the rate of growth became apparent after 4
hours. All cultures reached the stationary phase at 8 hours with concentration dependent decrease
in growth aligned with the SMX concentration.
The pH of all the same cultures were measured to determine the effects of adding the
strongly basic sulfamethoxazole stock solution to an E. coli OP50 culture (Figure 32B).
However, no clear trend related to the sulfamethoxazole concentration was visible in the pH of
each culture over time.
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Figure 31. The growth of six E. coli OP50 cultures in LB medium treated with different
concentrations of sulfamethoxazole were measured in absorbance over 188 hours. Cultures
were incubated at 37 °C for 188 hours at 250 rpm on an incubated orbital shaker.
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Figure 32. (A) The growth of six E. coli OP50 cultures treated with different
concentrations of sulfamethoxazole were measured in absorbance over 48 hours. (B) The
pH of six E. coli OP50 cultures treated with different concentrations of sulfamethoxazole
were measured over 48 hours.
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2.10.3 Characterization of 2-PMPA and 2-MPPA Inhibition of GCPII in C. elegans
Three generations of wild type C. elegans were exposed to different concentrations of the
GCPII specific inhibitors; 2-PMPA or 2-MPPA. The phenotypic observations of the worms
exposed to either 0.1 µM, 0.3 µM, or 0.5 µM 2-PMPA (100x IC50, 300x IC50, and 500x IC50,
respectively) by incorporating within the plate media, spread across the surface of the plate
media, or inclusion within the E. coli OP50 food source are shown in Table 2. The phenotypic
observations made of the wild type C. elegans exposed to either 9 µM, 27 µM, or 45 µM 2MPPA through identical methods are given in Table 3. The liquid cultures were not included due
to equipment failure. The rotator failed during the first day of the first generation, which allowed
the contents of the wells to settle, killing the worms. For either 2-PMPA or 2-MPPA, no clear
phenotypic effect was visible in any of the treatment groups under these experimental conditions.
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2.10.4 Brood Size Assay under Limited Folate Conditions and Tetrahydrofolic Acid
Supplementation
In order to revert the effect of the folate availability limitation induced by
sulfamethoxazole as well as the impact of GCPII paralogs on folate absorption in C. elegans a
supplementation study with tetrahydrofolic acid was utilized and the brood size recovery was
monitored in C. elegans. As previously mentioned, tetrahydrofolic acid is located at the top of
the folate cycle and is the starting chemical form for many of the downstream folate derivatives
(Figure 18). I hypothesized that tetrahydrofolic acid (THF) supplementation would restore
reproduction because THF has the potential to transform into other forms of folate derivatives
through the folate cycle. Folate availability was reduced by treating the food source, E. coli
OP50, with 1000 µg/mL of sulfamethoxazole to inhibit folate biosynthesis. Wild type and the
three gcp-2 mutant strains were exposed to four different treatment groups. Each of the treatment
groups, excluding the control, were seeded with OP50 cultured with 1000 µg/mL SMX. Overall,
the four treatment groups consisted of a control with untreated OP50 and no THF
supplementation, a 1000 µg/mL SMX treated OP50 without THF supplementation, and with a 10
µM THF supplementation and a 250 µM THF supplementation as summarized in Figure 33.
The average brood size for the wild type control treatment was 200.8, 158.2 with the
1000 µg/mL SMX treated OP50, and 170.3 and 96 with 10 µM and 250 µM THF
supplementation, respectively. For the gcp-2.1 mutant strain (RB1055), the control brood size
was 140.2, 120 with the 1000 µg/mL SMX treated OP50, and 156.8 and 97.2 with the 10 µM
and 250 µM THF supplementation, respectively. The average brood size for the gcp-2.2 mutant
control was 151.9,143.1 with the 1000 µg/mL SMX treated OP50, and 154.5 and 130.3 with 10
µM and 250 µM THF supplementation, respectively. Finally, the average brood size of the gcp104

2.3 mutant control was 151.6, 105 for the 1000 µg/mL SMX treated OP50, and 166.8 and 103
with 10 µM and 250 µM THF supplementation, respectively. Two sample t-tests were used to
determine the statistical significance of each treatment group compared to its respective control
group and between the control groups of the wild type and mutant strains (p = 0.05) The average
brood size was calculated using a sample size of 7 organisms per strain and treatment group.

Figure 33. The average brood size of C. elegans supplemented with tetrahydrofolic acid. Error
bars represent ± SEM (n = 7, ** p = .01, * p = .05).

2.10.5 HPLC of Folate Derivative Standards
Increasing concentrations of folate derivative standards dissolved in the extraction buffer,
including folic acid, dihydrofolic acid, tetrahydrofolic acid, 5-methyl-tetrahydrofolic acid, and
folinic acid, were analyzed using HPLC. The peaks were verified by increasing peak size at the
same retention time. Samples were monitored using a fluorescence detector set with excitation at
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295 nm and emission at 360 nm. Figures 34-38 show the fluorescence chromatogram of each set
of standards.
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Figure 34. Folic acid standards. (A) The fluorescence chromatogram for increasing
concentrations of Folic Acid standards. (B) Zoomed on the 15-19 minute region of the Folic
Acid standard chromatogram from (A). (C) Zoomed on the 29-31 minute region of the Folic
Acid standard chromatogram from (A). (D) Zoomed on the 41-53 minute region of the Folic
Acid standard chromatogram from (A).
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Figure 35. Dihydrofolic acid (DHF) standards. (A) The fluorescence chromatogram for
increasing concentrations of DHF standards. (B) Zoomed on the 15-18 minute region of the
DHF standard chromatogram from (A). (C) Zoomed on the 37-39 minute region of the DHF
standard chromatogram from (A).
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Figure 36. Tetrahydrofolic acid (THF) standards. (A) The fluorescence chromatogram for
increasing concentrations of THF standards. (B) Zoomed on the 15-18 minute region of the
THF standard chromatogram from (A). (C) Zoomed on the 25-40 minute region of the THF
standard chromatogram from (A).
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Figure 37. 5-methyl-tetrahydrofolic acid (5-MTHF) standards. The fluorescence
chromatogram for increasing concentrations of 5-MTHF standards.
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Figure 38. 5-formyl-tetrahydrofolate (folinic acid) standards. (A) The fluorescence
chromatogram for increasing concentrations of folinic acid standards. (B) Zoomed on the 15-42
minute region of the folinic acid standard chromatogram from (A).
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2.10.6 HPLC Analysis of SMX Standards
Increasing concentrations of sulfamethoxazole standards dissolved in HPLC grade water were
analyzed using HPLC. The peaks were verified by increasing peak size at the same retention
time. Samples were monitored using a fluorescence detector set with excitation at 295 nm and
emission at 360 nm. Figure 39 shows the fluorescence chromatogram of each standard.
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Figure 39. Sulfamethoxazole standards. (A) The fluorescence chromatogram for increasing
concentrations of SMX standards. (B) Zoomed on the 25-45 minute region of the SMX
standard chromatogram from (A).
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2.10.7 HPLC Analysis of Bacterial Folate Extract and Spiked Folate Extracts
Folate extracts from untreated OP50 and 1000 µg/mL sulfamethoxazole treated OP50
cultures dissolved in the extraction buffer were analyzed using HPLC. The peaks were compared
to standards for peaks located at similar retention times. Samples were monitored using a
fluorescence detector set with excitation at 295 nm and emission at 360 nm. Figure 40 shows the
fluorescence chromatogram of both folate extracts, as well as, zoomed images on each area of
the chromatogram to increase visibility. The same folate extracts were spiked with a known
concentration, 0.005 mg/mL, of folic acid and folinic acid. The chromatogram in Figure 41
displays the folate extracts and the spiked folate extracts together. Altogether, the retention times
of the peaks produced by the folate derivative standards and the folate derivative spiked extracts
were used to identify the peaks labeled in Figure 42.
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Figure 40. Folate extracted from E. coli OP50 and 1000 µg/mL treated E. coli OP50. (A)
The fluorescence chromatogram for the total folate isolated from the E. coli OP50 overnight
cultures. (B) Zoomed on the 0-13 minute region of the extracted folate chromatogram from
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(A). (C) Zoomed on the 13-25 minute region of the extracted folate chromatogram from (A).
(D) Zoomed on the 25-41 minute region of the extracted folate chromatogram from (A).
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Figure 41. Folate extracted from 1000 µg/mL treated E. coli OP50. Extracted folate was
spiked with either 0.005 mg/mL folic acid or 0.005 mg/mL folinic acid. (A) The fluorescence
chromatogram for the spiked total folate isolated from the E. coli OP50 overnight cultures. (B)
Zoomed on the 0-22 minute region of the spiked folate extract chromatogram from (A). (C)
Zoomed on the 22-55 minute region of the spiked folate extract chromatogram from (A).
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Figure 42. The folate extract labeled with the folate derivatives identified by comparison of
retention times with the standards and spiked folate extracts.

2.10.8 Quantification of E. coli Folate Synthesis on NGM Plates over Time
The amount of folate synthesized by E. coli after seeding on NGM plates was quantified
using HPLC. Standard NGM plates were seeded with either untreated OP50, 100 µg/mL SMX,
or 1000 µg/mL SMX treated OP50. After either 1 or 5 days the bacteria were rinsed off the plate
with sterile water, the folate was extracted, and the folate was analyzed using HPLC. Samples
were monitored using a fluorescence detector set with excitation at 295 nm and emission at 360
nm. The identity of the folate derivatives present was determined based on the retention times of
the peaks and comparison with the retention times of the folate derivative standards. Figure 43
contains the chromatograms for each of the treatments.
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Figure 43. Folate detected from plate extraction. (A) Untreated OP50. (B) OP50 treated with
100 µg/mL SMX. (C) OP50 treated with 1000 µg/mL SMX.

2.10.9 E. coli OP50 Growth in Methionine Limited Met-glu Defined Media
The growth of E. coli OP50 cell cultures cultured with decreasing final concentrations of
methionine over time was measured as an indicator of the effect of methionine on bacterial
growth and to verify the ability of the E. coli OP50 to grow in the Met-glu defined media. The
cell density of each culture was measured using UV spectroscopy.
Figure 44 depicts the growth of ten different E. coli OP50 cultures, untreated LB broth,
1000 µg/mL SMX treated LB broth, and SMX untreated and 1000 µg/mL SMX treated Met-glu
defined media with either 100% (control), 25%, 10%, and 0% methionine (based on the amount
of methionine present in Difco LB broth).
The culture grown in untreated LB progressed through the lag phase and logarithmic
growth phase rapidly and reached the stationary phase after approximately 10 hours. The
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fluctuation in optical density during the stationary phase may be attributed to the accumulation of
scratches on the outside of the culture test tube while in the incubated orbital shaker. The 1000
µg/mL SMX treated LB culture showed reduced growth compared to the untreated LB culture
and had an extended lag phase. This culture reached the stationary phase after 22 hours. The
SMX untreated Met-glu defined media cultures all demonstrated an increased lag phase
regardless of the amount of methionine present in the media. These cultures reached the
stationary phase after approximately 22 hours. However, the 100% methionine Met-glu culture
continued to grow until the optical density reach levels similar to the untreated LB culture. This
demonstrated that the Met-glu defined media provided similar types and amounts nutrients
compared to the LB broth. The other three Met-glu cultures with 25%, 10%, and 0% methionine,
respectively, did not have continued growth after reaching the stationary phase. The SMX treated
Met-glu cultures all had very slow, steady growth with no clear differentiation between the lag
phase, logarithmic growth phase, or the stationary phase. The bacterial growth in these cultures
was similar despite the amount of methionine present.
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Figure 44. The growth curve of E. coli OP50 cultured in increasing methionine limited
conditions with or without sulfamethoxazole.

2.10.10 C. elegans Brood Size Assay under Limited Methionine Conditions
To determine effects of methionine limitation and compare to the effects of folate
limitation on C. elegans reproduction, a methionine limited brood size assay was performed.
Methionine was limited through the use of the Met-glu defined media that contained no
methionine to culture E. coli OP50. E. coli OP50 cultured in LB broth and in 100% methionine
supplemented Met-glu defined media (relative to the amount of methionine present in Difco LB
broth) were used as positive controls for C. elegans brood size under standard conditions and to
ensure there were no effects on C. elegans reproduction due to the defined media, respectively.
The wild type (N2), gcp-2.1 mutant strain, and gcp-2.2 mutant strain were fed the E. coli OP50
from each of these three treatment groups.
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An average brood size for each treatment group (n = 7) was calculated and significance
was determined using a student’s t-test (p < .05). Ultimately, there were no significant
differences in the brood size of C. elegans fed E. coli cultured in each of the three treatments
(Figure 45).

Figure 45. The average brood size of C. elegans fed E. coli OP50 cultured in methionine
limited conditions. Error bars represent ± SEM (n = 7).

2.11 Discussion
The overall goal of Chapter 2 was to elucidate biological functional roles of each of the
three cGCPII paralogs in folate metabolism mediated reproduction, embryonic and postembryonic growth, and general development. Additionally, this study aimed at determining the
identities of the folate derivatives present in the bacterial food source to characterize the
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relationship between the role of each cGCPII paralog on folate intake and, subsequently, the
folate metabolic cycle. Finally, the intersection of the folate metabolic cycle and the methionine
cycle within the one carbon metabolic cycle was investigated to determine the indirect effects of
folate and methionine cycles on each other.
The results of the sulfamethoxazole longevity assay (Fig. 28) demonstrated that limited
folate availability increased the median longevity of C. elegans in all strains regardless of the
cGCPII paralogs expressed. However, there were inherent differences in longevity with regards
to the gcp-2 paralogs expressed. This trend of increasing median longevity was particularly
evident after comparison between the survival curves of the sulfamethoxazole treatment
concentrations of 0 µg/mL and 1000 µg/mL (Fig. 30A and D). Interestingly, the wild type,
expressing all three gcp-2 paralogs, and the gcp-2.2 deletion mutant had an increased longevity
compared to the gcp-2.1 and gcp-2.3 deletion mutant strains (Fig. 30A). The same relationship
between the paralogs was maintained after treatment with 1000 µg/mL sulfamethoxazole,
indicating a gcp-2 paralog independent mechanism of lifespan extension (Fig. 30D). This is
further supported by analysis of the survival curves by strain, where longevity clearly increased
in an SMX concentration dependent manner (Fig. 29).
However, there was one notable deviation from this general trend, the wild type
population treated with 2000 µg/mL sulfamethoxazole (Fig. 29E). The unaffected median
longevity of this population may be attributed to the relatively small sample size and indicates
the need for replication of this treatment to verify the accuracy of this result. Median longevity
was used as an indicator of longevity because it provided a more accurate representation of the
population longevity for each treatment. Although maximum longevity was recorded, it proved
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to be a less useful measurement because individual worms from each treatment would survive
long after the other worms in the population had died, introducing skewed data to the analysis.
The gcp-2 paralog dependent increase in longevity could be due to the difference in the
relative rates of enzymatic activity towards the hydrolysis of dietary folate by each gcp-2
paralog. For example, the combined expression of gcp-2.1 and gcp-2.3 may still have produced a
lower enzymatic activity compared to the level of hydrolysis that occurs when gcp-2.2 is
expressed and either gcp-2.1 or gcp-2.3 is functionally deleted. In other words, gcp-2.2 may be
the most efficient paralog for folate hydrolysis and when removed results in decreased enzymatic
activity and subsequent lifespan extension. Unfortunately, no studies have been published that
document the relative rates of enzymatic activity of gcp-2.1, gcp-2.2, or gcp-2.3.
The uniform increase in longevity under folate limited conditions has been previously
reported in several studies as stated above (252, 253). However, the exact cause of this lifespan
extension remains unclear. Initially, it was believed that accumulation of bacteria within the
intestinal lumen led to pathogenicity, thus shortening the lifespan of C. elegans (254, 255). As
adult stage C. elegans age, the intestine progressively loses its structural integrity and the rates of
pharyngeal pumping and defecation decreases (255, 256, 257, 258). Cumulatively, all of these
factors would contribute to accumulation and proliferation of bacteria within the intestinal lumen
and ultimately result in the death of the worm. Additionally, E. coli incapable of proliferation, by
either antibiotic treatment or UV killed, fed to C. elegans resulted in a lifespan increase of 3040% (259). However, a recent study by Virk et al. (2016) provided evidence that bacterial
intestinal accumulation may be merely a symptom of aging, not the true cause (258). Instead, this
study proposes that the inhibition of folate biosynthesis in E. coli removes a “pro-aging”
compound that is toxic to C. elegans. Although the identity of the suspected toxin and its
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mechanism of lifespan extension remains unclear, these results highlight the closely linked
influences of changes to the E. coli and its impact as an independent organism on C. elegans in
this biological system.
The effects on C. elegans due to metabolic and subsequent growth changes to the E. coli
made it evident that the effects of sulfamethoxazole treatment on E. coli OP50 needed to be
further investigated to more clearly understand downstream experiments on C. elegans. For this
reason, two growth curves and the pH of sulfamethoxazole treated E. coli OP50 cultures were
recorded. The growth curves demonstrated that there was a SMX concentration dependent
decrease in population growth. In other words, limitation of folate biosynthesis slowed the
growth of the population of bacteria. As previously stated in Chapter 2, Section 2.1, PABA is
one of the three compounds included in the folate structure. SMX is a structural analog of PABA
and competitively excludes PABA during folate biosynthesis. This results in a final product that
is not folate and a decrease in total cellular folate levels (252).
Previous studies have shown that SMX treatment of E. coli reduces folate synthesis to the
bacteria without limiting growth at concentrations up to 128 µg/ml (252). The growth curves in
Figures 31 and 32A support this claim, however, culture growth became noticeably impacted at
1000 µg/ml, 2000 µg/ml, and 5000 µg/ml. As previously stated in Chapter 2 Section 2.2, folate is
required for numerous biological processes including the synthesis of purines and pyrimidines,
and, through its interaction with the methionine cycle, methylation of DNA, RNA, and histones
(157, 164). These results suggest that with limited amounts of folate available, the E. coli growth
and proliferation becomes restricted in cultures of high SMX concentration.
The initial pH of the cultures (~6.5-7) was close to the target physiological pH (~7). This
indicated that the highly basic pH necessary to dissolve the SMX did not have a significant effect
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on the pH of the LB broth. However, over time the pH began to steadily increase and stabilized
at approximately 8.5 for all 0-2000 ug/ml treated SMX cultures. The pH of the 5000 ug/ml
treated SMX culture did increase steadily, however, only reached a maximum pH of
approximately 7.5 The pH of the E. coli OP50 cultures was important to track because the
structure and function of proteins and depends on the environmental pH (260). If the pH is not
optimal due to the addition of the highly basic SMX solution, then it would affect the
physiology, and subsequently, the growth rate of the bacterial population. As the E. coli
population increased and the associated metabolic reactions occurred, the pH increased. This
alkalization of the Luria-Bertoni medium due to E. coli culture growth has been observed in a
previous study, where an exhausted medium reached a maximum pH of 9 (261). However, it is
important to note that an electrode error became evident after approximately 8 hours that made it
necessary to switch the electrode being used to take measurements. This may have introduced an
unknown amount of variation into the trends in culture pH prior to the measurement taken at 8
hours.
As previously discussed in Chapter 2, Section 2.7, 2-PMPA and 2-MPPA are the two
most widely used and effective GCPII inhibitors that were developed using human or other
mammalian GCPII protein data and used in the study of mammalian systems (52, 87, 88, 241).
However, very little investigation into the use of GCPII inhibitors in C. elegans has been
performed. For this reason, in this study we attempted to orally deliver the GCPII inhibitors, 2PMPA and 2-MPPA, to wild type C. elegans in concentrations 100x, 300x, and 500x their
respective IC50 values. For 2-PMPA, these values were based on the IC50 value of 0.001 µM
(239, 240). The treatment concentrations were then 100x (.1 µM), 300x (0.3 µM), and 500x (0.5
µM). For 2-MPPA, these values were based on the IC50 value of 0.09 µM (52, 239). The
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treatment concentrations were then 100x (9 µM), 300x (27 µM), and 500x (45 µM) the IC50
value. The hundred-fold increase in the treatment concentrations compared to the IC50 values
were chosen to overcome complications due to ingestion, absorption through the cuticle, and the
poor oral bioavailability of 2-PMPA. High inhibitor concentrations served to ensure that enough
of the inhibitor was able to reach the GCPII expressed in the small intestine. Previous drug
development studies using C. elegans have demonstrated that the external treatment
concentration of a drug is typically higher than the internal concentration of the drug (262, 263).
As mentioned before, 2-PMPA has reduced oral bioavailability, however, this complication has
been overcome in mammalian models through the use of inhibitor injection (264, 265). Inhibitor
injection using C. elegans would have been impractical. As a result, the high inhibitor
concentrations were designed with these concerns in mind. Ultimately, administration of either
2-PMPA or 2-MPPA did not produce any phenotypic changes in reproduction, behavior, or
growth and development which would have indicated that the inhibitors were either not effective
inhibitors against cGCPII or were not delivered/able to reach the cGCPII target. Any future
attempt to inhibit cGCPII may require an in vitro inhibition assay using recombinant cGCPII
proteins to verify the efficacy of any potential compounds prior to attempting in vivo.
The results of supplementation of tetrahydrofolate via addition to the bacterial food
source demonstrated a concentration dependent response of C. elegans reproduction (Figure 33).
Treatment with a concentration of 1000 µg/ml SMX slightly reduced reproductive capability,
however, not as much as previously observed (266). This non-significant reduction in brood size
likely would have been significant if the SMX had been included in the NGM plate and folate
biosynthesis had been inhibited in the bacteria after seeding.
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The issues with the SMX affected the significance of the trends in the reproductive
capacity of the tetrahydrofolate supplemented worms. The 10 µM tetrahydrofolate had a slight,
non-significant increase relative to each strain’s untreated control. In particular, the gcp-2.1 and
gcp-2.3 mutant strains had an increased recovery in reproduction. Based on these promising
results, the 10 µM tetrahydrofolate supplementation and with 1000 µg/mL SMX treatments
should be repeated with proper use of SMX added into the NGM media. This replicate would
allow for a more accurate measurement of the true effects of low-level tetrahydrofolate
supplementation on C. elegans reproduction. Interestingly, there was a significant, concentration
dependent response to high levels of tetrahydrofolate supplementation in C. elegans
reproduction. The treatment concentration of 250 µM caused a drastic, significant decrease in
reproductive capability in the wild type and gcp-2.1 mutant strain. There was also a large but
non-significant decrease in the gcp-2.3 mutant strain. The gcp-2.2 mutant strain was the least
impacted by all treatments. Ultimately, these results suggest that the specific folate derivative,
tetrahydrofolate, serves an important role in the reproduction of C. elegans.
This conclusion is not surprising, based on the knowledge of the folate cycle (Fig. 18).
Tetrahydrofolate serves as the “starting point” for the folate cycle and the basic framework to
which methyl groups are added to synthesize the other derivatives (157, 165). It is reasonable to
conclude that the addition of tetrahydrofolate would allow for a general increase in other, highly
metabolically required, folate derivatives. This could be confirmed by tetrahydrofolate
supplementation to E. coli OP50 cultures followed by extraction of the total cellular folate and
HPLC analysis.
Folate analysis aimed to identify the different folate derivatives present in the folate
extracts and changes in their relative amounts to gain insight into the potential roles of different
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folate derivatives in C. elegans in conjunction with GCPII functions. The retention times of the
folate derivative standard peaks and of the peaks present in the spiked extracts were used to
determine the identities of the folate derivatives in the folate extracted from E. coli OP50
cultures. Multiple, increasing concentrations of the folate derivative in the standards were used to
verify the purity of the compound. Interestingly, the oxidation of THF and DHF under the
experimental conditions are visible in the chromatograms. In Figure 35, the size of the small
peak at ~37 minutes increases in a concentration dependent manner, however, the much larger
peak at ~16 minutes is the same peak present in the folic acid standard. A similar relationship is
visible between the THF peak at ~26 minutes and the folic acid peak at ~16 minutes in Figure
36. The other smaller peaks in Figure 36 represent different degraded forms of THF. To further
elucidate this relationship, particularly the role of DHF, these standards should be analyzed again
in smaller batches to allow for higher stability at the time of measurement. 5-MTHF is a highly
unstable folate derivative, which explains the presence of numerous peaks (Fig. 37) (267, 268).
This standard should be re-run in the future to attempt to provide an improved estimate of its
retention time. Similar to THF, folinic acid had numerous peaks potentially from degraded
forms, however, the tallest, concentration dependent peak at ~39 minutes was attributed to
folinic acid.
The folate extract was spiked with small, biologically relevant levels of folic acid and
folinic acid in order to help identify the retention time of the peak associated with each folate
derivative. A slight increase in the folic acid peak at ~16 minutes is visible, however, the folinic
acid was not visible at the expected 39 minutes because of an irregularity with the analysis. This
irregularity was most likely due to the folate extract as the same large, wide peaks are present in
all samples except the extraction buffer, indicating that the extraction buffer or a folate spike is

133

not responsible. For further confirmation of the retention times of each folate derivative peak,
folate extracts should be spiked with biologically relative amounts of each folate derivative.
Based on the information provided by the folate standards and the spiked folate extract,
the folate derivatives identified within the cellular folate sample extracted from E. coli were folic
acid, tetrahydrofolate, dihydrofolate, and 5-formyl-tetrahydrofolate (folinic acid). Identification
of the folate derivatives present in E. coli and their relative levels improves the understanding of
the dietary folates available to C. elegans to infer their potential metabolic roles.
Throughout the longevity and brood size experiments, the NGM plates were prepared and
seeded with E.coli OP50 for up to several days preceding their use. Upon observation, it became
clear that the bacterial lawn on the plates was thickening, indicating continued growth, even
when stored at 4 °C. After investigation, it was determined that one compound included in the
NGM, peptone, contains PABA (258). A previous study has demonstrated that PABA is capable
of diffusing through E. coli cell membrane for utilization in folate biosynthesis (269). The
antibiotic analog for PABA, sulfamethoxazole, was not included in the plate, only in the
bacterial culture. Due to this, there was suspicion that the living bacteria were able to uptake the
PABA from the NGM plate and synthesize folate after seeding. This would reduce the effect of
the SMX induced folate limited conditions, making dietary folate available for the C. elegans
living on the plate. The results of this experiment were inconclusive. Further investigation should
include standards of the compounds included in the NGM media and an increased bacterial
population.
The methionine limited E. coli growth curve in Figure 44 was intended to serve several
purposes. First, the suitability of the Met-glu defined media compared to the LB medium was
determined in order to establish that the only difference in bacterial growth between the two
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mediums was due to the amount of methionine. Comparison of the LB and 100% methionine
cultures demonstrated that the E. coli was capable of similar amounts of growth. However, the
100% Met-glu defined medium did have a slight delay in growth after the exponential growth
phase as it took approximately 34 hours to reach the same amount of growth as the LB medium.
Second, the use of multiple decreasing increments of methionine allowed for an estimate
of the minimum amount of methionine required for the bacterial growth. This was an important
detail because without enough bacterial growth there would not be enough food for the worms
and downstream experiments utilizing this food source would have been impeded.
Although it is a less common amino acid for protein synthesis, methionine has an
important role in both the initiation and elongation stages of protein translation for prokaryotic
and eukaryotic organisms (270, 271, 272).The initiation step requires the use of N-formylated
methionine (fmet) while the elongation step utilizes standard methionine (met). Known initiation
codons in E. coli are AUG, GUG, or UUG at rates of 90%, 8%, and 1%, respectively (273, 274).
However, regardless of the amino acid encoded by these codons, N-formylated methionine is
used (271). As previously mentioned, methionine is a precursor required for the generation of Sadenosyl methionine (SAM). SAM is a required cofactor for all methylation reactions including
DNA, RNA, and histone methylation (164). Due to these reasons, it is probable that the
limitation of methionine provided would impact the growth rate of E. coli by hindering protein
translation, epigenetic modification, and other methylation reactions.
Finally, the effect of methionine limitation on E. coli growth was determined and
compared to the cumulative effect of methionine limitation and SMX mediated folate limitation.
The growth curve in Figure 44 has interesting implications for the interaction of the folate cycle
and the methionine cycle within one carbon metabolism. The population growth of the SMX
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treated LB culture and SMX untreated Met-glu cultures followed similar trends. The SMX
treated LB cultures had a brief lag phase followed by an extended log phase, and an overall
decrease in growth at the stationary phase. The SMX untreated Met-glu cultures had an extended
lag phase, a rapid exponential growth phase, and overall decreased growth at the stationary
phase. Both culture types demonstrated delayed growth and a reduction in total growth. This
trend indicated that limitation of either folate biosynthesis or methionine availability produced
similar effects that resulted in limited cell growth in the bacterial cultures. This may be
accounted for at the intersection of the two cycles in a couple different ways. First, folate
biosynthesis does not occur correctly due to the use of SMX, which would prevent conversion
within the folate cycle and the conversion of homocysteine to methionine. Second, without
methionine available in the environment, the methionine dependent conversion of 5-methyl-THF
to THF cannot occur (165, 164). However, delayed growth can still occur as long as folate is
available, due to methionine biosynthesis. The results of the SMX untreated met-glu culture
growth indicated that the delay in growth of the E. coli was due to the time required for
methionine biosynthesis and the related folate cycle conversion to occur as previously described
in Chapter 2 Section 2.5. This conclusion explains the lack of significance in the results of the C.
elegans methionine limitation experiment (Fig. 45). The reproductive capability of C. elegans
fed E. coli OP50 cultured in the Met-glu defined media with no methionine demonstrated no
significant changes compared to the standard LB broth or the Met-glu defined media with an
equivalent amount of methionine. However, this result was not representative of methionine
limitation in C. elegans because the bacteria were able to synthesize methionine. As a result, the
C. elegans received an identical amount of methionine in all three treatments, which was
represented in nearly identical trends in reproduction.
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When both folate and methionine were limited, the growth of the Met-glu defined media
cultures was severely impacted. Without successful folate biosynthesis, there would not be the
required amount of 5-methyl-tetrahydrofolate needed to power the final conversion of
homocysteine to methionine in methionine biosynthesis. As a result, both the folate and
methionine cycles were greatly impaired, which prevented E. coli population growth. Altogether
these results emphasize the reliance of folate and methionine metabolism within one carbon
metabolism.
Future experiments to explore this relationship further should extract folate from E. coli
populations grown in SMX untreated and treated met-glu defined media with varied amounts of
added methionine. The results of this experiment would demonstrate the relative amounts of
folate. The development of a HPLC based methionine detection assay would allow for direct
comparison of the levels of 5-methyl-tetrahydrofolate, tetrahydrofolate, and methionine relative
to each other.
Altogether, there are a few main conclusions that can be made from this work that
provide further clues to answer the main research questions of the Periyannan lab. The
reproductive capability of the gcp-2.1 and gcp-2.3 mutant strains were partially restored after
supplementation with 10 µM tetrahydrofolate in folate limited conditions. Additionally, the wild
type and gcp-2.1 mutant strain demonstrated a strong, concentration dependent decrease in
reproduction under folate limited conditions with supplementation of 250 µM tetrahydrofolate.
The gcp-2.2 mutant strain was the least affected by folate limitation and supplementation of
tetrahydrofolate at 10 µM or 250 µM under folate limited conditions. These patterns indicate that
gcp-2.1 and gcp-2.3 have an important role in folate metabolism. Previous results from the
Periyannan lab, indicated that reproduction could be slightly restored to wild type C. elegans
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with supplementation of folinic acid (266). Together, these results indicate that supplementation
of different folate derivatives have varied and concentration dependent abilities to improve
reproduction in a GCPII paralog dependent manner.

2.12 Conclusions
Additionally, one treatment group of the tetrahydrofolate brood size study was folate
limited by treatment of the E. coli OP50 food source with 1000 µg/mL sulfamethoxazole.
Despite the reduced effectiveness of SMX, the gcp-2.1 and gcp-2.3 mutant strains appeared to be
more affected by the folate limitation compared to the gcp-2.2 mutant strain. This further
supports that gcp-2.1 and gcp-2.3 play a key role in folate metabolism mediated reproduction in
C. elegans. However, previous lab data indicated that reproduction of gcp-2.1 and gcp-2.2
mutant strains were the most strongly affected by folate limitation and concluded that these
paralogs are the most important for folate metabolism. Although the exact importance of gcp-2.2
and gcp-2.3 remain unclear, it is obvious that gcp-2.1 is highly important for folate metabolism
mediated reproduction (266).
Folate limitation increased median longevity in a cGCPII paralog independent fashion
and revealed inherent differences in longevity that corresponded to gcp-2 paralog. In this study,
the wild type and gcp-2.2 mutant strains had an increased median longevity compared to the gcp2.1 and gcp-2.3 mutant strains. This indicated that gcp-2.2 may be less efficient or play a less
important role in folate metabolism compared to the other two cGCPII paralogs. Previous lab
data from an untreated longevity assay demonstrated a similar trend in median longevity with
regards to gcp-2 paralog. Without treatment, the gcp-2.3 mutant strain had the lowest median
longevity (15 days), gcp-2.1 and gcp-2.2 mutant strains had an intermediate longevity (17 days),
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and the wild type had the longest median longevity (20 days) (266). Furthermore, an additional
study demonstrated that the gcp-2.1 mutant strain has a decreased lifespan compared to the wild
type (258). Together, these results suggest that the paralogs work together to increase longevity
and gcp-2.1 and gcp-2.3 may play key roles in folate metabolism mediated increases in
longevity.
In this study, HPLC analysis of bacterial folate extracts determined that folic acid, THF,
DHF, and 5-formyl-THF were present in detectable levels in the C. elegans food source.
Previous HPLC analysis of bacterial folate extracts identified THF, DHF, 5-formyl-THF, and 5methyl-THF in detectable levels. In both samples, THF and 5-formyl-THF were identified at
similar retention times (~27 and 40 minutes, respectively). However, the retention time of DHF
varied, which may have been resolved in this study due to the corresponding changes in peak
size for folic acid, THF, and DHF as oxidation occurred (266).
Altogether, the experiments in this chapter demonstrated that each gcp-2 paralog have
varied roles in the reproduction and longevity of C. elegans. However, the physiological
mechanisms for these differences remain unclear. Chapter 3 will focus on the development of a
method for the determination of relative, real-time gcp-2 paralog expression levels through the
different life stages of C. elegans.
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CHAPTER 3: DETECTION AND MEASUREMENT OF GCPII PARALOG
EXPRESSION IN C. ELEGANS
3.1 General Introduction
All somatic cells within a eukaryotic organism contain identical copies of the organism’s
genomic DNA (275). However, eukaryotic organisms must develop cells that are specialized for
specific biological role(s) or function(s) using the same genomic material. This process is
referred to as cell differentiation and is responsible for the development of specific cell types,
such as neurons and liver cells, from the same genome (275, 276). Cell differentiation is driven
by variation in the level of expression of certain genes in specific tissues and at specific times in
an organism’s development and life cycle (275). This spatiotemporal gene expression is
responsible for the biological and behavioral differences between young, developing organisms
and reproductive adults (277).
There are many factors that determine the profile of genes expressed in a cell through the
processes of transcription of DNA into RNA and translation of RNA into a protein. Certain
biological processes are common to all cells, such as the cytoskeletal structures and RNA
polymerases, and so all cells must express a certain set of these “housekeeping” genes, also
known as ubiquitously expressed genes (275, 278, 279). However, there are several mechanisms
that regulate spatiotemporal patterns of gene expression. Generally, these mechanisms operate on
the steps involved in the transcription and translation of the genetic information to create the
protein end product. At the DNA level, the frequency of transcription of a gene may be increased
or decreased through various coordinated regulatory mechanisms. Once an RNA transcript has
been produced, the transcript must undergo processing which may impact isoform expression or
formation of spliced variants of the particular mRNA transcripts that are exported from the
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nucleus for translation in the cytosol. Within the cytosol there are many translational
mechanisms of spatiotemporal regulation, including impacting the selection of the mRNA that
are translated by ribosomes or selective destabilization of mRNA transcripts. At the protein level
expression may be controlled by selective compartmentalization, degradation, or inactivation of
a protein (275).
To add another layer of complexity, there are numerous factors, both extrinsic and
intrinsic to the cell, that influence its spatiotemporal gene expression. Extrinsic influences of
gene expression range from environmental signals, such as temperature, oxygen, or pH, to
signals from other, nearby cells including, growth factors or cytokines, and other signaling
molecules. Intrinsic regulators of gene expression originate within the cell and are typically
epigenetic modifications to the DNA, including DNA methylation and histone methylation and
acetylation (280). Ultimately, each cell in an organism’s body must undergo differentiation
through its gene expression patterns as influenced by extrinsic and intrinsic influences to allow
for survival, growth, and development.
3.2 C. elegans gene expression traits in developmental stages
C. elegans has been widely used as a model organism for the study of spatiotemporal
gene expression due to the relatively few somatic cells (959) that make up its body and its
completely sequenced genome (112, 135, 281). Additionally, C. elegans possess the four somatic
cell types characteristic of metazoan organisms: muscle, nerve, intestine, and skin, which
function as accurate representatives of other eukaryotic tissues (115). Similar to other eukaryotic
organisms, studies have determined that gene expression changes significantly throughout the
life cycle and in different cell types of C. elegans (281, 277, 282).

141

One such study was able to detect 90% of all protein coding genes within the genome of
C. elegans. Of the 90% detected, 75% of these genes demonstrated significantly different
patterns of expression throughout the life stages and cell types of C. elegans (281). An additional
study performed by Kaletsky et al, confirmed the existence of a large amount of variation in gene
expression in both cell type and life stage (Figure 46A) (277). For example, genes expressed
during embryonic and larval life stages were unsurprisingly associated with development.
However, the genes expressed in adults allowed for adult specific behaviors, such as
reproduction, mating, and longevity (277).
Additionally, this study was able to detect and characterize the gene expression patterns
within four cell types of adult C. elegans, which estimated the expression of 8437 neuron, 7691
muscle, 7191 hypodermis, and 9604 intestine protein coding genes (Figure 46B) (277). For
example, Gene Ontology (GO) analysis of genes expressed in the intestine of adult C. elegans
indicated a high number of transmembrane proteins with function in digestion, response to
bacteria, and lipid metabolism. GO analysis of genes expressed in neurons of adult C. elegans
were associated with learning and memory, synaptic transmission, and neurotransmitter transport
(277). Another study has demonstrated that C. elegans gene paralogs have unique expression
patterns with variation in the levels of expression and within cellular and subcellular localization
(283). Altogether, the results of these studies demonstrate that the spatiotemporal expression of
genes plays a key role in the growth, development, and behavior of C. elegans. This indicates
that the expression of the three cGCPII paralogs display varied patterns of expression throughout
the life stages and cell types in the worm.
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Figure 46. Gene expression patterns of C. elegans largely vary with cell type and life stage.
(A) A Venn diagram representing the patterns of genes expressed in specific cell type and
different life stages of C. elegans. (B) The gene expression patterns four somatic cell types of
adult C. elegans (277).
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3.3 Literature analysis of theoretical prediction and experimental outcomes of cGCPII in
expression
Although cGCPII has not been specifically targeted in gene expression studies, collective
gene expression information can be used to predict theoretical expression patterns based on gene
sequence similarity and known function. A gene expression prediction tool was developed by
Kaletsky et al. at Princeton University (277). This tool relies on data from 4,343 microarray and
RNA-seq experiments from 273 independent datasets to predict the levels gene expression of
individual genes or gene classes in 76 different adult C. elegans tissues. The predicted expression
of each cGCPII paralog and the ubiquitously expressed controls, actin (act-1) and RNA
Polymerase II subunit A (ama-1) was generated by this predictive tool and provided the heat
map in Figure 47.
According to this tool, gcp-2.1 is predicted to be the predominately expressed paralogous
form compared to gcp-2.2 and gcp-2.3. The highest levels of gcp-2.1 expression are predicted to
be throughout the length of the digestive tract and in the muscular system. Additionally, a
relatively high level of gcp-2.1 expression is predicted to be hermaphrodite specific and in vulval
muscle cells. This may correspond with potentially increased folate hydrolase activity if cGCPII
is in fact expressed in the digestive tract at high levels. The predicted hermaphrodite specific and
vulval muscle cell expression could be due to the demand and transport of folates to the egg
yolk.
There is a low level of expression predicted for gcp-2.2, with its highest expression in the
pharynx gland cell. Interestingly, moderate expression of gcp-2.2 is predicted in neurons,
including the RID motor neuron, GABAergic neurons, dopaminergic neurons, head neuron, and
head ganglion. The expression of gcp-2.1 and gcp-2.3 is predicted to be lower or not expressed
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in these neurons. This suggests that gcp-2.2 may serve an important role within the C. elegans
nervous system, despite the absence of the reported mammalian neurotransmitter substrate, Nacetyl-aspartyl-glutamate (NAAG) as a neurotransmitter in C. elegans (284).
Overall, the predicted expression of gcp-2.3 is exceptionally low, which indicates a loss
of protein functionality associated with its classification as a pseudogene. As expected, the
predicted expression of ama-1 and act-1 was high in numerous tissues.

Figure 47. (A) Heat map of predicted expression of GCPII paralogs in adult C. elegans. (B) Heat
map of predicted expression of the expression patterns of positive control genes, act-1 (actin) and
ama-1 (RNA Polymerase II subunit) in adult C. elegans. Generated using the gene expression
prediction tool developed by Princeton University using the data from 4,343 microarray and RNAseq experiments from 273 independent datasets (277).

At this time there are no studies that have investigated the relative expression levels of
the cGCPII paralogs, as a result, the rates of expression of each of these paralogous genes
throughout the C. elegans life cycle are unknown. I hypothesized that all three gcp-2 paralogs:
gcp-2.1, gcp-2.2 and gcp-2.3, are expressed in the embryonic, L1, L3, and L4 life stages. First, a
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reliable protocol for the determination of expression patterns of gcp-2 in C. elegans was
developed. Second, relative expression levels of wild type (N2) C. elegans were measured using
real-time PCR (qPCR). Two sets of primers for each cGCPII paralog were designed to target the
C-terminal region and the protease domain to ensure detection of expression. These primers were
designed to bind to the target gene at sequences that are not affected by the insertion mutation in
the C. elegans gcp-2 mutant strains used in this study. As a result, any expression of these
paralogs may be detected, regardless of its successful translation to form a functional protein.
The theorized results have been summarized as follows:
(i) The wild type (N2) strain is expected to express all three cGCPII paralogs, which indicates
that all gcp-2 primer sets should bind to the cDNA. However, the expected level of gcp-2.3
expression remains unclear and may be dependent on its role as a pseudogene.
(ii) The gcp-2.1 mutant strain is expected to produce all three paralogs as mRNA but only the
gcp-2.2 and gcp-2.3 paralogs will lead to functional and potentially translated full length
proteins. The region within the gcp-2.1 primer sequences is not interrupted by the insertion
mutation, which allows amplification of all three paralogs to occur. However, lower expression
of gcp-2.1 and higher expression of gcp-2.2 is expected. Due to its identity as a pseudogene, gcp2.3 expression is expected to be similar to the level of expression in the wild type.
(iii) The gcp-2.2 mutant strain is expected to transcribe all three paralogs as mRNA but only gcp2.1 and gcp-2.3 will lead to functional protein. The gcp-2.2 primer sequence is not interrupted by
the insertion mutation sequence which will allow amplification of all paralogs. However, lower
expression of gcp-2.2 and higher expression of gcp-2.1 is expected. Once again, gcp-2.3 will be
similar to the level of expression in the wild type.
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As previously discussed in Chapter 1 Section 1.4.5, gcp-2.3 is a pseudogene. This
indicates that this cGCPII paralog is a nonfunctional copy of the functional version of gcp-2. For
this reason, gcp-2.3 may not function as a folate hydrolase. It may still produce an mRNA
transcript; however, it may not be translated into a functional protein. Instead, gcp-2.3 may have
a regulatory role in the expression of the other two cGCPII paralogs via one of the three
feedback loops presented in Figure 15. The predicted expression patterns of the gcp-2 paralogs in
C. elegans have been summarized in Table 4.

Table 4. Predicted patterns of the detection of cGCPII paralog expression within each C. elegans
GCPII mutant strain based on the design of the primers used in this study.
N2 (wild type)

gcp-2.1 mutant

gcp-2.2 mutant

gcp-2.3 mutant

mRNA

Expected

Detected

Expected

Detected

Expected

Detected

Expected

Detected

gcp-2.1

Yes

?

Yes, low

?

Yes

?

Yes

?

gcp-2.2

Yes

?

Yes

?

Yes, low

?

Yes

?

gcp-2.3

Yes

?

Yes

?

Yes

?

Yes, low

?

3.4 Materials and Methods
3.4.1 Primer Design
Two sets (forward and reverse) of primers for each of the three paralogs of cGCPII and
two sets of positive control primers were designed using the Integrated DNA technologies (IDT)
PrimerQuest tool (285). The cGCPII primers targeted the C-terminal domain (CT) and the protease
domain (PD). The positive controls chosen were designed using the mRNA sequence for the
ubiquitously expressed proteins, actin (ACT-1) and RNA polymerase subunit RPB1 (AMA-1).
The final primer sets were selected based on the following criteria: high degree of specificity to
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the target mRNA sequence, GC content ranging from 40%-60%, similar melting temperatures, and
final amplicon lengths of ~100 bp. Further information about these primers has been provided in
Table 5. The sequences used to design the primers for each cGCPII paralog and positive control
are provided in the Supplemental Materials section.
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Table 5. Primers designed for the detection of cGCPII gene expression analysis. Target sequence
locations are represented by P (protease domain) or CT (C-terminal domain).
Amplicon
Primer Name
GCPII_2.1a_PD

Primer Sequence

F: 5´-GCTCTATGACACGTGGATGAA

Length

Tm

(bp)

(ºC)

GC %

Location

94

54.5

47.6

P

54.9

50

55

47.6

55.2

50

54.7

50

54.1

40.9

54.3

40.9

55.2

47.6

54.8

47.6

54.5

43.5

54.8

47.6

54.1

40.9

55.2

50

55.1

47.6

54.9

50

54.9

50

R: 5´- AAATGGCGCGTGATCTGA

GCPII_2.1a_CT

F: 5´-GTGAATGCGGTCAATGAGAGA

91

R: 5´-CATGTCTAGCTGAGGGATTGTG

GCPII_2.2_PD

F: 5´- CATTGGGATGCCGAGGAATA

89

R: 5´- ACTGCAACTGCTCTTCTCATTA

GCPII_2.2_CT

F: 5´- TTGTTTCATCCAAGCCCTGATA

98

R: 5´-TCCTTGCTGTCTGTCGAATTG

GCPII_2.3_PD

F: 5´- CTGATTGGGTCCACAGAGTTT

97

R: 5´- ACTGGTTTCCTCCAATCATATCC

GCPII_2.3_CT

F: 5´- TCATAAACCCGCATGGTATCC

101

R: 5´- TACTTGAGAGATTGCGTTTCCA

act-1

F: 5´-GATCTGGCATCACACCTTCTAC

97

R: 5´-ACGGTTAGCCTTTGGATTGAG

ama-1

F: 5´- GCCTTCAAGCCCGAGATATT
R: 5´- GCGAGTACGTTGGAGATGTT

Target

86

Sequence

CT

P

CT

P

CT
-----

The primer sets for the glycoside hydrolase genes and 16S positive control gene in C. crescentus
are provided in Table 6.
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Table 6. Primer sequences and the corresponding amplicon lengths for C. crescentus
target genes used for protocol conformation.
Amplicon
Primer Name

Primer Sequence

Length (bp)

CC_0968

F: 5´-GACCATCAAGCACTATGCGCTGAA

180

R: 5´-TCTCGCAGGCATAGACCGAATTGA
CC_1756
CC_1757

F: 5´-AAGTGACCTCCTGGCCTTCCAAAT
R: 5´-TGAGCACCTTGTTGAGCAGGAAGT

125

F: 5´-TCAAGCGCGATAAGATCAAGACCC

140

R: 5´-TGAAGAACACCTCCTTGTCGGGAT
16S RNA

785F: 5'-GGATTAGATACCCTGGTA
805R: 5'-GACTACCAGGGTATCTAATC

21

3.4.2 Total RNA Isolation from whole C. elegans using the TRIzol Method (Protocol 1)
Whole worm RNA was isolated using a TRIzol (Invitrogen) based protocol modified
slightly from the Morimoto lab at Northwestern University (286). Approximately 10-20 worms
were picked using a worm picking tool onto a clean plate, allowed to crawl around briefly to
remove any attached bacteria, and then deposited into 10 µL of RNase-free, sterile M9 media in a
1.5 mL microfuge tube. The worms were pelleted by centrifugation at 14,000 rpm for one minute
in a benchtop microfuge centrifuge. The supernatant was removed without disturbing the worm
pellet, occasionally leaving the last few µL of M9 behind. Next, 250 µL of TRIzol was added and
the tubes were vortexed for twenty minutes, or until the worms were no longer visible under a
dissection scope, at 4 °C. 50 µL of chloroform was added, and the tubes were vortexed for 30
seconds and allowed to rest at room temperature in a microfuge tube rack for three minutes. The
phenol (present in the TRIzol reagent) and chloroform layers were separated by centrifugation at
12,000 rpm and 4 °C. The top, clear, aqueous layer was removed carefully into a clean RNase free
microfuge tube and another 250 µL of TRIzol was added and the previously described protocol
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was repeated, and the aqueous layers were combined. In order to easily locate the RNA pellet
during the subsequent steps, Glycoblue Coprecipitant (Invitrogen) was added at a final
concentration of 100 µg/mL according to the manufacturer’s instructions. After 10 minutes of
centrifugation at 12,000 rpm and 4 °C, the supernatant was removed and 250 µL of RNase-free
70% ethanol was used to wash the pellet. The RNA was pelleted once more by centrifugation for
5 minutes at 14,000 rpm at 4 °C. The supernatant was removed, and the remaining ethanol was
dried using an air vacuum desiccator. Finally, the RNA pellet was resuspended in 10 µL of RNasefree water and was used as a template for the generation of a cDNA library.

3.4.3 Alternate RNA Isolation using the RNeasy Mini Kit from Qiagen (Protocol 2)
An alternative method of RNA isolation from wild type C. elegans was performed using
the “Purification of Total RNA from Animal Cells Using Spin Technology” protocol provided in
the RNeasy Mini kit (Qiagen) with some modification. A minimum of 20 wild type (N2) worms
were picked into 10 µL RNase-free, sterile M9. The previously described RNA isolation protocol
was followed until the addition of the 70% RNase-free ethanol. The pelleted RNA was
resuspended in RNase free water and the solution was pipetted onto a RNeasy spin column in a 2
mL collection tube and centrifuged for 15 seconds at 10,000 rpm at 4 °C. The flow-through was
discarded and 700 µL RW1 buffer was added to the spin column. Once more, the tube was
centrifuged for 15 seconds at 10,000 rpm and the flow-through was discarded. Next, 500 µL of
RPE buffer was dispensed onto the spin column. Like before, the tube was centrifuged and the
flow-through discarded. Addition of the RPE buffer was repeated once more. The spin column
was transferred to a new 1.5 mL collection tube and 30 µL of RNase-free water was pipetted to
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the spin column. The tubes were centrifuged for 1 minute at 10,000 rpm. The eluate, which
contained the RNA, was utilized as a template for the generation of a cDNA library.

3.4.4 Alternative RNA Isolation Freeze-Crack TRIzol Method (Protocol 3)
An additional alternative RNA isolation protocol was developed based on the “C. elegans
Total RNA Isolation” procedure by the Zamanian lab (287) to increase the efficiency of the
worm/cell lysis to release RNA. For each preparation, two densely populated plates which
contained worms of all life stages were rinsed with a total of 5 mL of sterile M9 into a conical 15
mL tube. Another 5 mL of M9 were added and the tube was inverted multiple times to mix. The
samples were centrifuged at 1500 rpm in a benchtop clinical centrifuge for 1 minute and the M9
was removed. Another 5 mL of M9 was added and the wash step was repeated. All but
approximately 200 µL of M9 that contained the worms was removed and the worms were
transferred to a 1.5 mL Eppendorf tube. A final wash step was performed identically using 1 mL
of M9. Once the M9 had been removed 1 mL of TRIzol was added. The samples were flash frozen
in liquid nitrogen and then thawed in a water bath at 37 °C. This freeze-thaw cycle was repeated a
total of four additional times. After the final thaw was complete, the samples were vortexed in 30
second bursts and allowed to rest for 30 seconds. This step was repeated four additional times.
Next, 200 µL of chloroform was added and the mixed thoroughly by flicking with finger.
The sample was then allowed to rest at room temperature for 3 minutes and was followed by
centrifugation at 12000 xg for 15 minutes at 4 °C. After centrifugation, three separate layers
became visible. The top, aqueous layer was carefully removed without disturbing the thick, white
interphase. A volume of 500 µL of cold isopropanol (kept in ice) was added to the aqueous extract
and the sample was inverted to mix 8 times. After 10 minutes of incubation at room temperature
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the sample was centrifuged at 12000 xg for 10 minutes at 4 °C. The supernatant was removed
carefully, with a few µL remaining, to avoid loss of the pellet. 1 mL of RNase-free 70% ethanol
was used to resuspend and wash the pellet. The pellet was vortexed briefly and the sample was
centrifuged at 7500 xg for 5 minutes at 4 °C. The supernatant was removed, and the pellet was
allowed to air dry. Once the remaining ethanol was completely evaporated, the RNA pellet was
resuspended in 20 µL RNase-free water. Isolated RNA can be quantitated using a regular
spectrophotometer (or a NanoDrop device) but here no quantitation was carried out. Isolated RNA
was DNase treated (procedure below) and immediately used in the cDNA synthesis. Any
remaining RNA was stored at -80 °C.

3.4.5 RNA Isolation from Bacterial Source, Caulobacter crescentus
In order to confirm the efficiency of the RNA isolation protocol and to ascertain the quality
of the reagents used in RNA isolation and gene expression analysis of glycoside hydrolases from
Caulobacter crescentus (C. crescentus) was conducted using the TRIzol protocol. C. crescentus
was cultured in M2 minimal media (see Appendix 2) with either a glucose or cellobiose carbon
source for 22 hours on a shaker at 30 °C and 260 rpm. C. crescentus RNA was isolated using the
TRIzol based method provided by ThermoFisher Scientific without deviation from the
manufacturer’s instructions. Stepwise protocol is given in Appendix 3.

3.4.6 Total Worm Isolation of Genomic DNA
Genomic DNA was isolated from wild type (N2) C. elegans using a protocol developed by
the Chin-Sang lab (288). Three worms were picked into the cap of a PCR tube in a 10 µL drop of
worm lysis buffer (see Appendix 4). The tube was centrifuged briefly to collect the worms at the
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bottom and then frozen with liquid nitrogen for twenty minutes. Next, the tube was heated in a 65
°C heat block for 90 minutes and a 95 °C heat block for 15 minutes. Extracted genomic DNA was
used as a template in gene specific PCR.

3.4.7 DNase Treatment of Isolated RNA
DNA contamination was removed from the RNA isolated from C. elegans and C.
crescentus through the use of the TURBO DNA-free kit (Invitrogen). Due to the use of multiple
whole worms, the rigorous DNA treatment recommended was used, for all samples, according to
the manufacturer’s instructions.

3.4.8 Generation of a cDNA Library from RNA
GoScript Reverse Transcriptase and GoScript Reaction Buffer with random primers
(Promega) were used to generate a cDNA library from the isolated RNA of C. elegans and C.
crescentus after the removal of genomic DNA contamination. The reaction mix was assembled
according to the manufacturer’s instructions and the provided PCR protocol was used (Table 7).

Table 7. PCR protocol provided by Promega used to synthesize the cDNA library.
Step

Temperature

Time

Number of Cycles

Anneal Primer

25 °C

5 minutes

1

Extension

42 °C

60 minutes

1

Inactivation

70 °C

15 minutes

1

Hold

4 °C

Indefinite

1
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3.4.9 C. elegans Gene Specific Amplification
cGCPII paralogs and ubiquitously expressed genes were detected in the cDNA library
using the primers provided in Table 5. GoTaq Green Master Mix 2x (Promega) was used for all
gene specific PCR reactions. The general reaction mixture for each 25 µL PCR reaction is provided
in Table 8.
Table 8. Reagents included in the gene specific PCR reaction mixtures.
Components

Volume

GoTaqÒ Green Master Mix 2x

12.5 µL

Forward Primer (10 µM)

1 µL

Reverse Primer (10 µM)

1 µL

cDNA Template

1-3 µL

Nuclease Free Water

7.5-9.5 µL

The first gene specific PCR protocol utilized a temperature gradient ranging from 55 °C to 50 °C.
Specifically, the temperatures included in the gradient were 55 °C, 54.7 °C, 54.2 °C, 53.2 °C, 52
°C, 51 °C, 50.3 °C, and 50 °C. After this initial set of reactions, subsequent gene specific reactions
had an annealing temperature of 53 °C. The PCR program has been provided in Table 9.
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Table 9. Details of the gene specific PCR program for amplification of C. elegans
samples.
Step

Temperature

Time

Number of Cycles

Initial Denaturation

95 °C

2 minutes

1x

Denaturation

94 °C

10 seconds

32x

Annealing

55-50 °C gradient or 53 °C

40 seconds

32x

Extension

72 °C

40 seconds

32x

Final Extension

72 °C

2 minutes

1x

4 °C

Indefinite

---

3.4.10 C. crescentus Gene Specific Amplification
Target genes from C. crescentus cDNA library were amplified using the primers provided
in Table 6. Each reaction was assembled identically to the C. elegans samples, previously
described in Table 8. The PCR program for C. crescentus reactions has been provided below in
Table 10.
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Table 10. Details of the gene specific PCR program for amplification of C. crescentus
samples.
Step

Temperature

Time

Number of Cycles

Initial Denaturation

95 °C

3 minutes

1x

Denaturation

95 °C

30 seconds

35x

Annealing

55 °C

45 seconds

35x

Extension

72 °C

1 minute

35x

Final Extension

72 °C

5 minutes

1x

4 °C

Indefinite

---

3.4.11 Visualization of Products
The amplified products were visualized using a 3% agarose gel. A 50 bp DNA molecular
weight ladder (New England Biolabs N3236S) was used for the determination of the size of
amplified products.

3.4.12 Quantitative Reverse Transcriptase Polymerase Chain Reaction (qPCR)
Once again, cGCPII paralogs and ubiquitously expressed genes were detected in the
cDNA library using the primers provided in Table 5. However, the use of the Step One RealTime PCR System (Applied Biosystems) allowed for the relative quantification of any amplified
gene products. PowerUp SYBR Green Master Mix (ThermoFisher Scientific) was used for all
Real-Time PCR reactions. Each 25 µL reaction mixture was assembled as described in Table 11.
The volume of cDNA added to the reaction was determined based on the amount of RNA present
in the original sample (just prior to cDNA synthesis). In this case, the RNA was not quantified so
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a low volume was used to avoid producing a large amount of fluorescence that would overpower
the detector.

Table 11. Components included in the Real-time PCR reaction mixtures.
Components

Volume

PowerUp SYBR Green Master Mix

12.5 µL

Forward Primer (10 µM)

1 µL

Reverse Primer (10 µM)

1 µL

cDNA Template

1 µL

Nuclease Free Water

9.5 µL

The Real-Time PCR program has been provided in Table 12. The protocol was identical to the
gene specific PCR except for two notable changes: (i) the temperature of the annealing step was
increased to 59 °C and (ii) the number of cycles was increased to 40.
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Table 12. Details of the Real-Time PCR program for amplification and quantification of
C. elegans genes from cDNA samples.
Step

Temperature

Time

Number of Cycles

Initial Denaturation

95 °C

3 minutes

1x

Denaturation

95 °C

30 seconds

40x

Annealing

59 °C

45 seconds

40x

Extension

72 °C

1 minute

40x

Final Extension

72 °C

5 minutes

1x

3.5 Results
3.5.1 TRIzol Based Method of RNA Isolation
As this is the first attempt in our laboratory to analyze C. elegans gene expression our
primary intention was to optimize the method and therefore we used only wild-type worms for
gene expression analysis. In the initial attempts, total RNA was isolated separately from stage L3
and L4 wild type (N2) C. elegans using the TRIzol method. Half of the samples were DNase
treated while the other half were untreated. A complementary DNA (cDNA) library was generated
from the isolated RNA, which was then utilized as a template for gene specific amplification.
During the annealing stage of PCR, a heat gradient of 55- 50 °C was utilized to determine the
optimum annealing temperature. The amplified gene products were visualized using 3% agarose
gels containing ethidium bromide as a visual aid and band size was determined using a 50 bp
ladder (NEB, N3236S). The results of the initial TRIzol based RNA isolation are included in
Figure 48. Figure 48A and B include the RNA isolated from the L3 stage without DNase treatment
and the corresponding DNase treated samples are included in Figure 48E and F. In Figure 48B,
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light bands were present in the gcp-2.2 PD lane (expected amplicon size is 89 bp) and the act-1
positive control lane (expected amplicon size is 97 bp) slightly above 50 base pairs and at
approximately 100 base pairs, respectively. Similarly, the gels containing the end products of the
DNase untreated RNA isolated from the L4 stage are pictured in Figure 48C and D and the
corresponding DNase treated samples in Figure 48G and H. Bands are visible at approximately
100 base pairs in the act-1 lanes of Figure 48C, D, G, and H.
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Figure 48. Gel images of the gene specific amplification products that used a cDNA template
generated from RNA isolated from wild type C. elegans using the TRIzol Method (Protocol 1).
(A) DNase untreated RNA isolated from L3 stage worms. (B) DNase untreated RNA isolated
from L3 stage worms (independent replicate). (C) DNase untreated RNA isolated from L4 stage
worms. (D) DNase untreated RNA isolated from L4 stage worms (independent replicate). (E)
DNase treated RNA isolated from L3 stage worms. (F) DNase treated RNA isolated from L3
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stage worms (independent replicate). (G) DNase treated RNA isolated from L4 stage worms.
(H) DNase treated RNA isolated from L4 stage worms (independent replicate).

3.5.2 Isolation of Genomic DNA and Amplification of GCPII genes from C. elegans
Total genomic DNA was isolated and used as a template for gene specific amplification to
verify the specificity of the primers, the quality of the reagents, and efficiency of the procedures.
Genomic DNA was isolated from wild type worms of varied life stages. Two samples proceeded
directly to gene specific amplification (Figure 49A and B) while the third sample was treated with
DNase (Figure 49C). This was intended to verify the complete removal of DNA from any DNase
treated sample. The gels pictured in Figure 49A and B had identical bands present for each of the
cGCPII paralogs and actin and RNA polymerase controls. The gcp-2.1 CT lane had a band with a
size of approximately 125 bp. The gcp-2.2 CT, gcp-2.3 CT, gcp-2.1 PD, gcp-2.2 PD, gcp-2.3 PD,
and act-1 lanes all produced light bands of at approximately 80-100 bp. Finally, the ama-1 lane
contained a band of approximately 500 bp. The final three lanes, which contained the negative
controls, did not produce the amplified gene products that resulted in a band. Figure 49C did not
show any band as expected for effective DNase treatment.
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Figure 49. Gene specific amplification of genomic DNA isolated from a mixed stage population
of wild type (N2) C. elegans. (A) DNase untreated total genomic DNA. (B) DNase untreated
total genomic DNA (independent replicate). (C) DNase treated total genomic DNA.
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3.5.3 Comparison of TRIzol based and alternative RNeasy Mini Kit methods of RNA
Isolation
Since the TRIzol based method did not produce any bands (Figure 48), an alternative
method of RNA isolation was developed using the RNeasy Mini Kit. Two samples of isolated
RNA were acquired for each method used, henceforth referred to as the TRIzol or the RNeasy
method. The starting material for the first sample was L1 and L2 wild type (N2) worms and the
second sample’s starting material were L3 and L4 wild type (N2) worms. All samples were
treated with DNase. Figure 50A and B depict the gene amplified products of the TRIzol method
L1/L2 samples while the amplified products of the RNeasy method are included in Figure 50C
and D. None of these samples produced bands in the gel. Similarly, the L3/L4 amplified products
from the samples processed using the TRIzol and RNeasy methods are included in Figure 50E
and F and Figure 50G and H, respectively. In Figure 50E, a band in the act-1 lane was present at
approximately 100 bp. Finally, three negative controls for cDNA library generation were
performed in which either no RNA template was added (Figure 50I), template RNA isolated
from L3/L4 worms via the RNeasy method without reverse transcriptase in the reaction mixture
(Figure 50J), and template RNA isolated from L3/L4 worms via the TRIzol method without
reverse transcriptase in the reaction mixture (Figure 50K).
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Figure 50. The second attempt at RNA isolation optimization used the TRIzol method
(Protocol 1) and RNeasy Mini Kit (Protocol 2) to isolate RNA from L1/L2 and L3/L4 wild
type (N2) worms. All samples were DNase treated and replicates were independent of each
other. (A) RNA isolated from L1/L2 stage worms using the TRIzol method (Protocol 1). (B)
RNA isolated from L1/L2 stage worms using the TRIzol method (Protocol 1). (C) RNA
isolated from L1/L2 stage worms using the RNeasy method (Protocol 2). (D) RNA isolated
from L1/L2 stage worms using the RNeasy method (Protocol 2). (E) RNA isolated from L3/L4
stage worms using the TRIzol method (Protocol 1). (F) RNA isolated from L3/L4 stage worms
using the TRIzol method (Protocol 1). (G) RNA isolated from L3/L4 stage worms using the
RNeasy method (Protocol 2). (H) RNA isolated from L3/L4 stage worms using the RNeasy
method (Protocol 2). (I) No RNA was added to the reverse transcription reaction mixture.
Served as the first negative control for cDNA library generation. (J) RNA isolated from L3/L4
stage worms using the RNeasy method (Protocol 2) was used as a template for a cDNA
synthesis without reverse transcriptase. Served as the second negative control for cDNA
library generation. (K) RNA isolated from L3/L4 stage worms using the TRIzol method
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(Protocol 1) was used as a template for a cDNA synthesis without reverse transcriptase. Served
as the third negative control for cDNA library generation.

3.5.4 RNA Isolation and Gene Amplification from Caulobacter crescentus
RNA isolated from a bacterial source, C. crescentus, was utilized as a positive control for
the cDNA library generation step of the workflow. Figure 51A and B contained the amplified
glycoside hydrolase gene products of a C. crescentus culture grown with a glucose carbon
source. However, the isolated RNA of Figure 51A was treated with DNase while the sample in
Figure 51B was not. Figure 51C and D contained the amplified products of a C. crescentus
culture grown with a cellobiose carbon source. Like before, the sample in Figure 51C was DNase
treated while the sample in Figure 51D was not.
Identical bands, aside from the intensity, were present in all four gels. Bands of the
expected size, ranging from approximately 180-125 base pairs, for the 0968, 1756, and 1757
genes were present in all gels. Additionally, the four gels all contained a second 1756 band and a
band in the 1756/No DNA negative control at approximately 50 base pairs.
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Figure 51. Final amplification products of RNA Isolation from C. crescentus. (A) RNA was
isolated from a C. crescentus culture grown with glucose and treated with DNase. (B) RNA
was isolated from a C. crescentus culture grown with glucose and was not DNase treated. (C)
RNA was isolated from a C. crescentus culture grown with cellobiose and treated with DNase.
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(D) RNA was isolated from a C. crescentus culture grown with cellobiose and was not DNase
treated.

3.5.5 Optimization of TRIzol based method of RNA Isolation using the Freeze-Crack
TRIzol Method (Protocol 3)
Continued issues that prevented reliable isolation of total worm RNA led to the use of a
third RNA isolation protocol, the Freeze-Crack TRIzol method. For all samples, RNA was isolated
from a mixed stage and significantly larger population of wild type (N2) C. elegans than the few
worms used in the previous protocols. RNA was isolated from two independent replicates, which
were each split into halves that received (Figure 52A and C) or did not receive DNase treatment
(Figure 52B and D). Figure 52E and F contained the products that served as negative controls for
cDNA library generation, with no RNA template or no reverse transcriptase included in the
reaction mixture, respectively.
The DNase treated samples (Figure 52A and C) produced bright, identical bands of the
expected sizes, 80-100 base pairs, in the gcp-2.1 C-terminus, gcp-2.1 protease domain, act-1, and
ama-1 lanes. Additional faint bands were visible at the expected sizes in the gcp-2.2 C-terminus,
gcp-2.3 C-terminus, gcp-2.2 protease domain, gcp-2.3 protease domain, and at approximately 479
base pairs in the ama-1 lane. The DNase untreated samples (Figure 52B and C) produced the same
bands visible in the DNase treated samples, however, all of these bands were brighter. However,
two extra bands in the gcp-2.1 C-terminus lane of these figures were visible from approximately
150 to 125 base pairs. A similar band at 150 base pairs was visible in the gcp-2.1 C-terminus lane
of Figure 52F.
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Figure 52. Final amplification products of the Freeze-Crack TRIzol method (Protocol 3) to
isolate RNA from a mixed stage population of wild type (N2) worms. All identical replicates
were independent of each other. (A) Half of the first sample was DNase treated. (B) The
second half of the first sample was DNase untreated. (C) Half of the second sample was
DNase treated. (D) Half of the second sample was DNase untreated. (E) No RNA was added
to the reverse transcription reaction mixture. Served as the first negative control for cDNA
library generation. (F) RNA from the DNase treated first sample was used as a template for a
cDNA synthesis without reverse transcriptase. Served as the second negative control for
cDNA library generation.

3.5.6 Verification of the Removal of Genomic DNA Contamination
An unused portion of the second RNA sample isolated using the Freeze-Crack TRIzol
method (Figure 53A) was treated for a second time with the rigorous DNase treatment (Figure
53B). Identical bands were present at the expected size in the gcp-2.1 C-terminus, gcp-2.1
protease domain, act-1, and ama-1 lanes. The faint bands that were visible in the gcp-2.2 Cterminus, gcp-2.3 C-terminus, gcp-2.2 protease domain, gcp-2.3 protease domain, and in the
ama-1 lane of Figure 53A were no longer visible after a second round of DNase treatment
(Figure 53B).
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Figure 53. The sample from Figure 52 C (A) was treated with an additional DNase treatment
(two treatments total) (B).

3.5.7 Quantitative Reverse Transcriptase Polymerase Chain Reaction (qPCR)
The remaining portion of the cDNA generated by the Freeze-Crack TRIzol method of
RNA isolation from wild type C. elegans (gene specific amplification results from this sample
pictured in Figure 52 C and Figure 53A was used as a template for real-time quantitative PCR
(qPCR). Altogether this sample was treated with DNase once just prior to cDNA synthesis. The
relative amounts of gene specific amplification were quantified using the 2-!CT relative
quantification method using Equation 1 (289). All 2-!CT values were determined by comparison
to the actin control.
Equation 1:

Table 13A contains the well number, CT value, and 2-!CT value of each sample from the single
DNase treatment group. Table 13B contains the relative levels of gcp-2 paralog expression
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relative to the other two paralogs. These quantities were obtained by dividing the 2-!CT values
of the paralogs being compared.

Table 13. (A) Relative amplification of target genes from isolated RNA that was treated with
DNase once then transcribed to the cDNA template used in qPCR. (B) Relative expression
ratios were calculated for each gcp-2 paralog relative to the other two.

The remaining cDNA from the same source (wild type C. elegans) that had been treated
twice by the following the rigorous DNase treatment (gene specific amplification results from
this sample pictured in Figure 52C) and was used as a template for qPCR. The relative rates of
gene specific amplification were quantified using the 2-!CT relative quantification method using
Equation 1 (289). The 2-!CT value for each gene was determined by comparison to the CT of the
twice DNase treated actin positive control. Table 14A contains the well number, CT value, and 2174

!CT

value of each sample from the single DNase treatment group. Table 14B contains the relative

ratios of gcp-2 paralog expressions relative to the other two paralogs.

Table 14. Relative amplification of target genes from isolated RNA that was treated with
DNase twice then transcribed to the cDNA template used in qPCR. (B) Relative expression
ratios were calculated for each gcp-2 paralog relative to the other two.

Additionally, the amplification of the target genes was plotted graphically in Figure 54.
Figure 54A and B depicted the amplification of the gcp-2 paralog C-terminal primers and the
gcp-2 paralog protease domain primers, respectively, that underwent rigorous DNase treatment
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once. The positive control, act-1, and negative controls were included as well. Figure 54C and D
contain the samples that underwent rigorous DNase treatment twice. The gcp-2 paralogs Cterminal primers, act-1 and ama-1 positive controls, and negative controls are depicted in Figure
54C. The gcp-2 paralogs protease domain primers, act-1 and ama-1 positive controls, and
negative controls are depicted in Figure #D. Each sample is identified based on its corresponding
well number in Tables 12 and 13 and the color gradient provided.
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Figure 54. Real-time quantitative PCR amplification of gcp-2 paralogs and controls. (A)
Amplified products gcp-2 paralog C-terminal primers (B4-B6), actin (C2), and negative
controls (B1-B3). Isolated RNA underwent rigorous DNase treatment once. (B) Amplified
products gcp-2 paralog protease domain primers (B7-C1), actin (C2), and negative controls
(B1-B3). Isolated RNA underwent rigorous DNase treatment once. (C) Amplified products
gcp-2 paralog C-terminal primers (A1-A3), actin (A7), and negative controls (B1-B3).
Isolated RNA underwent rigorous DNase treatment twice. (D) Amplified products gcp-2
paralog C-terminal primers (A4-A6), actin (A7), and negative controls (B1-B3). Isolated
RNA underwent rigorous DNase treatment twice.

3.6 Discussion
The three methods of RNA isolation, the TRIzol based method (Protocol 1), the RNeasy
Mini Kit Method (Protocol 2), and the Freeze-Crack TRIzol method (Protocol 3) were all
performed in an attempt to optimize the procedure and yield from total worm RNA isolation. The
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results of the first method of RNA isolation, the TRIzol based method, provided a few key clues
for the development of a functional procedure. There was successful amplification of the gcp-2.2
C-terminal region (Figure 48B) and of the actin positive controls (Figure 48B, C, and D).
However, these gels were untreated by DNase, which indicates that the amplification were most
probably the result of genomic DNA contamination of the samples. Although these bands may
have been the result of genomic contamination; identical bands were present in the act-1 lane of
the gels in Figure 48G and H. The samples in these gels were DNase treated, indicating that
RNA for act-1 was successfully isolated, its complementary DNA was synthesized successfully,
and gene specific amplification was successful. Overall these results emphasized the necessity of
using a DNase treatment for all RNA samples.
Additionally, the ideal temperature for the annealing step of the gene specific
amplification PCR was determined using a heat gradient for the set of reactions pictured in
Figure 48. The ideal annealing step temperature of 53 °C was determined by comparison of the
act-1 band intensity DNase treated samples in Figure 48G and H. The actin band in Figure 48H
had an annealing temperature of 53.2 °C and an increased amount of amplification relative to the
actin band in Figure 48G, which had an annealing temperature of 52 °C. The DNase untreated
samples were disregarded because the increased amount of starting material due to genomic
DNA contamination had the potential to produce more amplification unrelated to the temperature
gradient.
Next, Wild type (N2) C. elegans genomic DNA was isolated to confirm the specificity of
each of the cGCPII and positive control gene primers and the quality and function of all reagents
used in gene specific amplification PCR. Figure 49A and B show the specific amplified products
of two independently isolated genomic DNA samples untreated by DNase. Additionally, one
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sample of genomic DNA was treated with DNase to confirm that all genomic DNA
contamination would be removed in RNA samples (Figure 49C). The bands present in the gcp2.2 CT, gcp-2.3 CT, gcp-2.1 PD, gcp-2.2 PD, gcp-2.3 PD, and act-1 lanes were all the expected
sizes. However, the bands in the gcp-2.1 CT and ama-1 lane were not the expected band size of
86 and 91 bp, respectively. The ama-1 primers produced an amplicon that was approximately
500 bp in length. To determine the reason for the differences in amplicon length, the forward and
reverse primer sequences were aligned with the complete genome of C. elegans using the NCBI
Primer-Blast tool (290). The tool revealed that the ama-1 primer set was specific for two regions
on the ama-1 gene, the expected 81 bp amplicon and another amplicon length of 479 bp. This
indicates that the ama-1 primers may have a higher affinity for locations 479 bp because there is
no band present at 91 bp.
The Primer-Blast tool only produced one amplicon of the expected 86 bp for the gcp-2.1
CT primer set. This ruled out complications due to poor primer specificity, however, there is one
other potential reason for the appearance of the 125 bp amplicon in the gcp-2.1 C-terminus lane.
The most probable explanation is due to the three gcp-2.1 isoforms (291, 292). This primer
targets gcp-2.1a (R57.1a.1), however, there are two other isoforms, gcp-2.1b (R57.1b.1) and
gcp-2.3c (R57.1c.1) (Figure 14A). The 125 bp band could be amplification of one of these
isoforms with alternative splicing that produced a slightly longer amplicon. Complications due to
the PCR program were unlikely as all reactions were set up in a batch and no other samples
contained unexplained band sizes.
Ultimately, the results of the genomic DNA isolation demonstrated that all the primer
sets, excluding the gcp-2.1 CT primer set, successfully amplified the target gene as demonstrated
by the presence of properly sized bands. The use of the negative controls confirmed that there
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was no contamination in the reagents used. This indicated that the failure to amplify specific
genes from cDNA synthesized from isolated RNA was not due to faulty reagents or errors in the
gene specific PCR program.
At this point, it was unclear if the lack of amplified gene products was a result of error(s)
within the RNA isolation, cDNA library generation, simple addition/mixing of reagents, or a
combination of errors in all procedures. Due to these issues with amplification, further
exploration with various RNA isolation techniques was performed to optimize the most effective
RNA isolation from C. elegans. For the second set of RNA isolations, the TRIzol method and the
RNeasy Mini Kit (Qiagen) protocols were performed synchronously to determine which protocol
would improve RNA yield. Additional negative controls were performed to detect any errors in
the cDNA library generation step.
The only method that produced amplified gene products was the TRIzol method (Figure
50E). As both kits started with the same number of worms and the cDNA generation step was
identical, it was evident that the TRIzol method was able to yield more RNA. Once again, act-1
was the only successfully amplified product from RNA. The absence of amplification in the
cDNA library generation negative controls (Figure 50I, J, and K) demonstrated that the reverse
transcriptase and buffer mixture were not contaminated. This result, combined with the DNase
treatment test on genomic DNA and the gene specific amplification negative control results,
confirmed that samples treated with the rigorous Turbo DNase protocol and amplified using the
GoScript Reverse Transcription kit and the gene specific PCR reagents were the direct product of
isolated RNA and not residual DNA contamination that remained after DNase treatment.
In order to reveal any errors in the cDNA synthesis procedure or reagents, a set of
positive control reactions for detection of glycoside hydrolase amplification using RNA isolated
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from the bacteria Caulobacter crescentus was performed. The C. crescentus cDNA synthesis
procedure was identical to the cDNA library generation protocol used in this study for C. elegans
RNA samples. Additionally, the RNA isolation and cDNA synthesis protocols for this organism
have been previously performed in the Periyannan lab successfully. The reagents utilized were a
previously prepared lab stock and the unexpected bands visible in the agarose gel indicated the
presence of DNA contamination in the CC_1756 primer set as these bands were present in
DNase treated and untreated samples. Additionally, faint bands were present in the CC_0968 and
CC_1757 lanes of Figure 51D, these bands were not visible in DNase treated samples, indicating
the presence of DNA contamination. Altogether, these experiments confirmed that the failure to
amplify gene specific products was due to a failure to isolate a large, representative sample of
RNA from the worm and not a failure of the cDNA library generation procedure.
In the TRIzol based and RNeasy Mini Kit RNA isolation protocols the number of worms
used (i.e. the amount of starting material) was low, just 10 and 20 worms per sample,
respectively. Subsequent procedures, such as centrifugal pelleting of worms and vortex-only
worm lysing, may have led to loss of materials or incomplete release of RNA. Therefore, the low
amount of starting material was believed to be the limiting factor in the ability to detect the target
genes, which have an unknown relative level of expression compared to the ubiquitously
expressed actin and RNA polymerase II. Additionally, as previously mentioned in Chapter 1
Section 1.4.2, the entire body of C. elegans is protected by a durable cuticle. The cuticle may
have prevented complete lysis of all the cells in the worm, which would have reduced the RNA
yield. Due to these reasons, a combination of increased starting material and a more aggressive
lysis step (i.e. multiple freeze thaw cycles) were included in the third RNA isolation protocol, the
Freeze-Crack TRIzol method.
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RNA samples isolated using the Freeze-Crack TRIzol method were split in halves just
prior to DNase treatment. Comparison of the DNase untreated samples from the Freeze-Crack
TRIzol RNA isolation method to the previous two methods demonstrated that these changes lead
to the successful amplification of the expressed target genes from the cDNA library generated
from the isolated RNA. Two independent replicates produced identical results, in which gcp-2.1,
act-1, and ama-1 were highly expressed while the other two cGCPII paralogs had much lower
expression levels (Figure 52A and C). Interestingly, these results concur with the predicted
expression generated in the Princeton University gene expression prediction tool (Figure 47).
The relative expression levels were estimated based on the relative band brightness; however, an
RNA or cDNA quantification step was not included in the workflow. As a result, this estimation
is tentative.
DNase untreated samples produced amplification of all cGCPII paralogs and the actin
and RNA polymerase positive control genes. Without a doubt, this was caused by genomic DNA
contamination, however, the intensity of the bands further demonstrated that the increased
amount of starting material and more vigorous lysis step did improve the yield when compared
to previous DNase untreated samples. If there was enough starting material in the other two
methods, it would be expected that amplification would be noticeable in all DNase untreated
samples, similar to what is visible in the Freeze-Crack Trizol method. Using earlier methods,
only the expression of actin was detected, likely due to the ubiquitous expression of this gene.
One complication in these results was the reoccurrence of the band at 125 base pairs in the lane
that contained the gcp-2.1 C-terminal amplicon (Figure 52F). This band was the only amplified
product present in the set of samples that underwent RT-PCR without the reverse transcription
enzyme. This indicates the amplification of one sample was due to an error in the reaction
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mixture preparation of this sample during cDNA synthesis that resulted in the inclusion of the
enzyme.
The Turbo DNase treatment of the same sample was repeated a second time to attempt to
verify the expression patterns were not influenced by genomic DNA contamination that was still
present after one round of DNase treatment. After a second round of treatment, the light bands
present in the gcp-2.2 and gcp-2.3 C-terminal and gcp-2.2 and gcp-2.3 protease domain lanes had
disappeared. The Turbo DNase Kit from Invitrogen is certified to be free of contaminating
RNase so it is unlikely that the bands that disappeared were removed by the DNase treatment.
Additionally, it is equally unlikely that there was excess DNA that could not be removed from
the first round as this kit is guaranteed to remove 50 µg DNA/mL of RNA. The most likely
scenario is that there were low amounts of RNase present in the reaction mixture during the
DNase treatment which combined an extended exposure to the heat treatment to degrade the
RNA. In the future, quantification of RNA before and after the DNase treatment step would
determine if this reasoning is true and verify the results of experiments that use the Freeze-Crack
TRIzol RNA isolation.
The gcp-2 paralogs and actin and RNA polymerase II subunit A positive controls were
targeted for amplification from the once and twice treated DNase samples (Figure 53A and B)
using qPCR to quantify the relative expression levels of each gene. Ultimately, the qPCR
analysis confirmed the tentative pattern established by the successful Freeze-Crack TRIzol
method of RNA isolation (Figure 54). This trend indicated that the gcp-2.1 paralog was
expressed at a much higher rate compared to the gcp-2.2 and gcp-2.3 paralogs. Using the cycle
threshold (CT) values of each gene, the expression levels of each gcp-2 paralog could be
compared relative to the actin control, and through the use of expression ratios, to each other.
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Due to the evidence of extensive RNA degradation in the samples treated twice with DNase, the
gcp-2 expression ratios may not reflect accurate patterns in gene expression (Table 13B). For this
reason, only the samples treated once with DNase were used for the comparison of gcp-2 paralog
gene expression levels (Table 14B). In this table, there was a large discrepancy in the expression
ratios of the corresponding C-terminal domain and protease domain primer sets. These ratios
were expected to be similar, however, the protease domain primer sets demonstrated much
higher ratios of gcp-2.1 expression compared to the gcp-2.2 and gcp-2.3 than the C-terminal
domain primer sets. This could be due to increased RNA stability of the region of the mRNA that
encodes the protease domain that improves yield for the cDNA library or a higher level of
specificity in this primer set. Without replicates of each sample, it is unclear which of these ratios
best represent the true expression levels of each of the gcp-2 paralogs. However, in both sets
there is a clear, established pattern that gcp-2.1 is expressed at a higher level relative to gcp-2.2
and gcp-2.3.

3.7 Conclusions
Together, the experiments in this chapter produced an optimized, high yield method of
RNA Isolation from whole worm C. elegans. The successful isolation of RNA and the
subsequent workflow allows for the analysis of gene expression in real-time throughout the life
cycle of C. elegans. Additionally, the use of real-time quantitative PCR allows for the
quantification and comparison of relative levels of gcp-2 paralog expression. The methods
developed in this chapter will be useful in future experimentation to determine the role of each
gcp-2 paralog in folate metabolism throughout the life of C. elegans.
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CHAPTER 4: CONCLUSIONS AND FUTURE STUDIES
In conclusion, this study has presented evidence that cGCPII serves an important role
within C. elegans for folate-mediated reproduction and aging. Additionally, the data suggest that
each of the cGCPII paralogs plays a differential role in these biological processes. In
reproduction, the gcp-2.1 and gcp-2.3 paralogs have been identified to play significant roles thus
opening up opportunities for further exploration of the paralogous gene functions. Similarly, the
gcp-2.1 and gcp-2.3 paralogs were associated with a decrease in longevity, indicating increased
efficiency of these enzymes or increased importance of these paralogs in folate-mediated aging
processes. Altogether, the characterization of cGCPII function established in this study serves as
a representation of GCPII function in human folate metabolism and related biochemical
implications, which is complicated to study in a complex organism, such as humans. Many
suggestions for future experimentation to further the functional characterization of the cGCPII
paralogs have been previously discussed throughout Chapter 2, Section 2.12 and are briefly
summarized here with the expected outcomes.
The highest priority of these are a replicate of the 2000 µg/mL sulfamethoxazole
treatment of wild type C. elegans in the longevity assay and a replicate of low level (10 µM)
tetrahydrofolate supplementation on C. elegans brood size. These replicates are expected to
improve the significance of the trends and support the results of this study to provide further
characterization of each cGCPII paralogs’ role in reproduction and aging. Furthermore, brood
size, body length, and longevity assays of each C. elegans strain that was fed folate and
methionine deficient E. coli OP50 should be conducted. The results of these experiments would
further characterize the role of each cGCPII paralog on reproduction, development, and aging
within the broader effects of one carbon metabolism. Additionally, an in vitro inhibition assay
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using the 2-PMPA and 2-MPPA inhibitors and recombinant cGCPII proteins should be
performed to determine the efficacy of these inhibitors. Upon successful inhibition of cGCPII
under these conditions, any functional inhibitors could be used for an attempt at in vivo cGCPII
inhibition. This would reinforce the theory of the structural similarity of hGCPII and cGCPII and
allow for the characterization of cGCPII inhibition on folate metabolism. Finally, further analysis
of the bacterial food source using HPLC should be performed. A replicate of each folate
derivative standard solution should be analyzed to verify the retention times associated with the
peaks of each standard and account for any slight technique differences between individual
researchers. Next, total cellular folate should be extracted from E. coli OP50 and spiked with
known amounts of 5-MTHF, THF, and DHF. This would confirm the retention times of the
peaks associated with these folate derivatives by observing the changes in fluorescence intensity.
Lastly, a method of total cellular methionine extraction and HPLC program for analysis should
be developed. This would allow for comparison of the total amount of folate and methionine
available to C. elegans through their bacterial food source and completely characterize the
interdependence of one carbon metabolism.
Together, the experiments in Chapter 3 produced an optimized, high yield method of
real-time gene expression analysis in C. elegans. Consequently, the primary focus of future
experimentation should be to use these methods to determine the real-time expression patterns of
gcp-2 paralogs in C. elegans throughout the life stage of each gcp-2 mutant strain. The addition
of nucleic acid quantification steps after RNA isolation and after DNase treatment would
improve the understanding and interpretation of the final amplification products of gene specific
PCR and quantitative PCR. Furthermore, the design and use of cGCPII paralog primer sets that
are interrupted by the mutation sequence would allow comparison with the currently used primer
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sets that are capable of detecting both mutated and native versions of the gcp-2 paralogs. This
would increase the understanding of the amount mRNA transcripts produced for each gcp-2
paralog relative to its final, functional expression of each paralog.
Additional future experimentation should be developed using reverse genomics
techniques to characterize GCPII function in C. elegans. Reverse genomics rely on the alteration
of a gene to affect its function and the subsequent phenotypic traits of an organism (293). Two
reverse genomic techniques, RNA interference (RNAi) and CRISPR-Cas9, would be useful for
the study of GCPII function in C. elegans. RNAi can be used to generate knockdown of a target
gene’s function without altering the genomic DNA of the organism. RNAi functions through the
delivery of double stranded RNA (dsRNA) to C. elegans, which causes degradation of the
corresponding RNA. The function of the gene can then be characterized based on the loss-offunction phenotype produced in C. elegans. In C. elegans one method of dsRNA delivery is
through feeding with a bacterial vector that contains plasmids of the target gene(s) (293).
RNAi has been previously attempted in the Periyannan Lab. E. coli H115 feeding strains
for 4 different treatment groups were generated, untreated (vector control), GCP-2.1, GCP-2.2,
GCP-2.3, and a mixture of all feeding strains to induce knockdown of all cGCPII paralogs. The
successful insertion of these plasmids was verified by sequencing. The complete RNAi protocol
and plasmid sequences have been provided (Appendices 6 and 7). Wild type C. elegans were fed
each from each of these treatment groups and the brood size and longevity were measured.
However, these experiments produced no significant results, nor the noticeable phenotypic
changes associated with the gcp-2 mutant strains (266). Many other studies have used RNAi to
observe differences in phenotype associated with the silenced gene (294, 295, 296). The
development of a successful RNAi assay for the silencing of GCPII would produce a clear
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profile of functional characterization for each cGCPII paralog. qPCR could be used to
troubleshoot the previously established RNAi protocol by quantifying the amount of knockdown
of mRNA in C. elegans fed dsRNA from each treatment. Additionally, a western blot could be
used to measure the knockdown of protein expression for comparison to the amount of mRNA
generated.
However, western blots could also be used in C. elegans on a broader scale to detect the
levels of protein expression in each of the gcp-2 mutant strains. The use of western blots would
also allow for the comparison of gcp-2 mRNA generated versus the amount of GCPII protein
synthesized and expressed. Western blots rely on three key steps: (i) separation of proteins based
on size, (ii) transfer to a solid surface, (iii) detection of the target protein using specific primary
and secondary antibodies for the target gene (297). As a result, western blots would require the
use of GCPII specific antibodies to target GCPII expressed in C. elegans. Unfortunately, cGCPII
specific antibodies are not readily available commercially. However, many studies have
successfully used western blots to detect proteins expressed in C. elegans through the use of
antibodies specific for the human homolog of the target gene (298, 299). Likewise, the detection
of cGCPII expression has potential for success through the use of antibodies specific for hGCPII.
The high shared sequence and structural similarity of cGCPII and hGCPII (Chapter 1 Section
1.4.5) provide further evidence for the potential use of hGCPII antibodies for the detection of
cGCPII.
Finally, the CRISPR-Cas9 method of genome editing allows for the deletion, insertion,
replacement, labeling, and other modifications of genomic DNA within an organism. The
CRISPR-Cas9 system utilizes a single stranded, guide RNA specific for the target region of a
gene and the Cas9 enzyme that functions as a pair of molecular scissors to cut open DNA at the
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target sites (300). CRISPR-Cas9 has been demonstrated to be a useful gene editing tool in C.
elegans in multiple studies (301, 302). Through the use of CRISPR-Cas9 each cGCPII paralog
could be targeted for the generation of new mutant strains with the paralogs completely removed
from the genome. Additionally, double mutants that remove two of the three paralogs could be
generated. This would be particularly useful for direct characterization of the functional role gcp2.1, gcp-2.2, or gcp-2.3 without the suspected involvement of the gcp-2.3 pseudogene in the
expression of the other two paralogs.
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APPENDICES
Appendix 1: Elution Profiles of a Blank Sample in HPLC Analysis of Folates

A chromatogram of a blank sample from the HPLC analysis of folates. The
elution profile of the extraction buffer that was used as the solvent in folate
extraction and Buffer A and Buffer B that were used as the mobile phase in the
HPLC analysis. These three solutions were present in all HPLC samples.

Appendix 2: Defined Media Preparations

M9-Glu Defined Media (250):
The following stock solutions were created:
5x M9 Salts: 64 g of Na2HPO4.7H2O, 15 g of KH2PO4, 2.5 g of NaCl, and 5 g of
NH4Cl were dissolved in 1 L Millipore filtered water. Sterilized in the autoclave at 121°C for 50
minutes. Stored at room temperature.
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5x Amino Acid Solution: 3g of alanine, 3.15 g of arginine, 0.55 g of asparagine, 3.925 g
of aspartic acid, 0.2 g of cysteine, 9.9 g of glutamic acid, 0.1 g of glutamine, 1.6 g of glycine,
1.257 g of histidine, 3.5 g of isoleucine, 4.775 g of leucine, 4.25 g of lysine, 3.25 g of
phenylalanine, 3.8 g of proline, 1.5 g of serine, 1.3 g of threonine, 0.525 g of tryptophan, 0.95 g
of tyrosine, and 3.825 g of valine were dissolved in 1 L sterile Millipore filtered water. To aid in
complete dissolving, the flask was put on the shaker at room temperature and ~250 rpm until all
the solid had dissolved. The amino acid solution was sterilized using a 0.22 micron vacuum
filter. Do not autoclave. Stored at room temperature.
25x methionine stock solution: Using sterile technique, 6.25 g methionine was
dissolved in 1 L sterile Millipore water. Do not autoclave. Stored at room temperature.
10% glucose solution: 5 g of glucose was dissolved in 50 mL of Millipore filtered water
and autoclaved at 121°C for 50 minutes. Stored at 4°C.
1 M CaCl2 stock: 5.6 g of CaCl2 was added to 100 mL sterilized Millipore water and
stirred until dissolved. Stored at 4°C.
1 M MgSO4 stock: 24.4 g of MgSO4 was added to sterilized Millipore water up to 100
mL and stirred until dissolved. Stored at 4°C.
10 mg/mL Thiamine Hydrochloride: Just prior to the addition to individual cultures,
100 mg of thiamine hydrochloride was dissolved in 10 mL of sterile Millipore filtered water.
Stored at 4°C.
Each culture contained:
1. 1x M9 salts
2. 1x amino acid solution
3. 1x (100%), 0.25x (25%), 0.1x (10%) or no methionine solution
4. 0.4% glucose
5. 0.5 mM CaCl2
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6. 2 mM MgSO4
7. 0.3 mg/mL thiamine hydrochloride
8. Dilute to target volume with sterile Millipore water.

M2 Minimal Media Culture Preparation
1. Make C. crescentus cultures in 90 mL autoclaved de-ionized water in a wide mouth 250
mL culture/Erlenmeyer flask
2. Add a carbon source (0.2% = 0.2 g/ 100 mL)
3. Add 20x stock solutions of M2 salts and divalent metal ions and other components as
shown below to a total volume of ~100 mL:
5 ml of 20x M2 salts media
5 ml of 20x DVM solution
0.2 g of a carbon source for a final concentration of 0.2%
25 μl of C. crescentus cell stock (all test cultures must be inoculated from the
same stock solution with same amount inoculum)

Appendix 3: RNA isolation protocol from Caulobacter crescentus
1. Pellet the cells by centrifugation in a 1.5 mL Eppendorf tube and discard the supernatant.
2. Add 0.75 mL of TRIzol per 0.25 mL of sample (1x107 for bacterial cells) to the pellet.
3. Pipet the lysate up and down multiple times to homogenize.
4. Incubate for 5 minutes at room temperature.
5. Add 0.2 mL of chloroform per 1 mL of TRIzol used in the lysis step. Cap the tube and mix
by shaking.
6. Incubate at room temperature for 3 minutes.
7. Centrifuge for 15 minutes at 12000 x g at 4 ºC. The separation of the red phenol-chloroform
(bottom), white interphase (middle), and clear aqueous (top) layers should be visible after
centrifugation.
8. Carefully transfer the aqueous phase to a new tube. Do not disrupt the interphase as this will
result in DNA contamination the RNA sample.
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9. Add 0.5 mL of ice-cold isopropanol to the aqueous phase per 1 mL of TRIzol used in the
lysis step.
10. Incubate for 10 minutes at 4 ºC.
11. Centrifuge for 10 minutes at 12000 x g at 4 ºC. A white RNA pellet should be visible at the
bottom of the tube.
12. Remove the supernatant while carefully avoiding the pellet.
13. Resuspend the pellet in 1 mL of 75% EtOH (diluted using RNase-free water) per 1 mL of
TRIzol used in the lysis step.
14. Vortex briefly and centrifuge for 5 minutes at 7500 x g at 4 ºC.
15. Carefully remove as much of the supernatant as possible without disturbing the pellet.
16. Air dry or vacuum dry (using a desiccator) the pellet completely.
17. Ensure no ethanol remains in the tube and dissolve the RNA pellet in 10-20 µL RNase-free
water. Proceed directly to DNase treatment and cDNA synthesis or store RNA at -20 ºC
(short term) or -80 ºC (long term).

Appendix 4: Genomic DNA Worm Lysis Buffer (288)
Prepare 10X PCR Buffer: 100 mM Tris, 500 mM KCl, and 15 mM MgCl2 (pH 8.3).
Stored at 4°C.
20 mg/mL Proteinase K: 10 mg of proteinase K was dissolved in .5 mL of sterile
Millipore water. Stored at 4°C.
Worm Lysis Buffer: 10X PCR buffer was diluted to 1X. 95 µL of 1X PCR buffer was
combined with 5 µL of 20mg/mL Proteinase K solution in the lid of a PCR tube.
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Appendix 5: cGCPII Paralog Sequences used for Primer Design
The untranslated regions are highlighted with grey. The exons are indicated in alternating yellow
and orange highlights.

gcp-2.1 isoform a (R57.1a.1) (141)
aacaatagtttatatgtaaATGCCGTACGTCGGAGTTGGAGCACAAACAGTTTCCACAAGCTTAACAGGAGCGCCTATGGTGAAGG
CATACATTGCAATTGCTGCCTCTTTGATTTTTGTTTTTTGTATTGCTGCGTTGGGTGTTCATCACTCGGAAAGAAAGTTCAACAAA
TTCAATAAAGTTTCAATTGATGACATTCATAAATCTGATGCAGGAGTTATTCAAGACAACATAAAAACGGAAAACATCAAAAAGTA
CCTCCGAATATTCACAAAAGATCCACATGTAGCTGGAACAGAAGCTAACAAAAAAGTCGCTTACGAAATTGCAAATGCGTGGTCGG
AAGCAGGATTGGAAGATGTTCACACATTACCGTATGAAGTTTTGCTGTCGTATCCTGACTTTGAAAATCCAAATTCTGTTATAATA
AAGTCGTCGGCTGGAAAAGAAGTATTCAAGAGCAAGGGAGTTAGTCCAGTTATTATACCAGACGAGCAATCAGGAAAGTATGCTGG
GCACCAGTGGCTTGCATATGCCGGCAATGGATCCGCTTCTGCAGACGTCGTCTACATTAATCACGGAACAGCCAACGATTTCAAGA
ACTTGAAGCTAATGGGTGTAGATATTAAAGGAAAAATTGCTCTGATGAGATACGGTCATGGTTTCCGGGGTGACAAAATTCATAAA
GCACAGCAGGCGGGTGCGATTGGAGCTATACTGTTTTCGGATACACAGGATGTTGCTCAGGATGGTGTAGAATCAGAGAATGTTTA
TCCAAAAAAAATTTGGATGCCTAATGAGGGTGTTCAGAGAGGATCCCTTATGCATGGAGATGGAGATGCACTCTCTCCTTACTATC
CTTCCAAAAAAGAACTTTTCAAAGGAAGAACTATTGAAGAGGCTAAAGAAGACGGCGTTCTACCTTCAATACCAGTTCTCCCTGTC
TCCTATACAACAGGATATGAAATTCTGAAACGATTATCCGGTCGGCCGGCTCCATCGGACTGGCAAGGATTTGTCGGTGGAAACCT
CACTTACAAGCTTGGTCCAGGCTTTGTGAATGGAGAGAAATTGTCCATCAATGTGCACAGTGAGCTGAGGACAAAACGAATTAGAA
ATGTTATTGGATATATTCGTGGGTCTGAAGAGCCCGATAGCTATATTATGCTTGGAAACCATTTCGACGCATGGGTCTATGGATCA
ATTGATCCTAATTCTGGAACAGCTGTGTTGGCGGAGGTTGCGAGAGCCATGATGCAAACTATTAACGAAACCAGTTGGAAACCAGC
TCGCACTATCGTATTCAACGCATGGGATGCCGAAGAGTTTGGACTTATTGGATCAACAGAATTCGTCGAAGAATTTGTAAATATTT
TGCAGAAAAGAGCTGTGGTCTATATTAACATGGATTGTATTCAAGGAAACATAAGTCTGCACGTCGACACAGTTCCGATTCTCGAG
CACGCCGTCATTGAAGCATCAAAACAAGTGGAAAATCCATCAAAACGTGAGAGATCTCGCGGAAGAAAAACGCTCTATGACACGTG
GATGAAAGTGTTTCCTGATAAGAAAGCGGGTGTTCCAAAAATAAGAGTTCCCGGCGGCGGATCAGATCACGCGCCATTTTTGAATT
TTGCTGGTGTTCCGGTGATCAACTTCACTTTCAAAAACTACACAACATGGGACACGTATCCACTGTACCATACAATGTACGAGACG
CCGTTTTCCAACATTCATCTATTGGATACAGACAACTTATCAGTGCACAAAGCAATTGGGCAGTATTGGGCTGAGTTGGCGAAGAC
GTTTGCGGATGATGTAATTCTCCCAATGAATACCACACATTTTGCGTCAGTCATGCTGAAAACCTATCTCCCACAACTGAAAACAA
CAATCTCCGGAATAAATGTTTCGAGAAGCGATTTCGAAGATATACGCACACAGTATGCACTTCTCTCAAAAAGTGCTCAAGATTTA
CTTACAATGTCAAAAAAATTCCAAGAAACCATCCATTTTACACAACACAGCTTCTCTCAGAATCCATACGACCCGAAACACGTGAA
TGCGGTCAATGAGAGATTAAAGAGCACGGAAAGATGCTTCATCAACCCCCGTGGCGTTTCAATGCACAATCCCTCAGCTAGACATG
TCCTGTTTTCAGTCAGCGATTCTGATTCATACTCGAGTTCTTTAATGGCAGGAGTACAGAATGCGATCAACAGTTACGACTTGAAT
CCAACCAAAAAAGGCTTGAGGGAAATAATCAACCAAATCTCCATTGTCCAGTACTCTGTTATTTGCGTTGTAAACACTCTACGTGA
TGTTATTTGAtgggttttactgtaataatgaacaattcacattataaaactgaatctctaaaaatgaagtaccaaatagttt
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gcp-2.2 (C35C5.2.1) (143)
atacttttatgggcgttgaaacgacaacccacattttcccaaaaaattttcttccttgactactctgaatatatttctattaaatt
catttttgtaaaatttgatcctaatttaagtgtagaaaATGATAACAGCTCGGAACCGGTTTACACAAGGTTGTAGTTGTATGAAG
TATTATAACAATAATGGAGACAAAGTATTCCAAAAGTCTAAAAGAAATAGAGGAATGAAAGCTAGCGGTGTGGTTCTTGTTGCAGT
TTCTACTGTTGCTTTGACTATTATTTTATCTAATGCGATACATCAATCTTACAAATCAAATTCAAAGCCTCTTCCTAAATTATCAA
TTGCAACAAATATCAAACAACTAATCAACGTTGACAACATTCGCTCCAATCTTCATTCGCTTACTAAAAAACCTCATGTGGCCGGA
ACAGAAAATAATTTACGAGTGGCTGAAATGATTCGAGATCAGATGATCACTCAAGGACTCGAAAATGTGCATTTCAATGAGTACAA
TGTAATGTTATCATATCCGAATTGGACAACTCCCAACATTATTGAAATACTGAAAGAAAATAGAGATTTGGTTTTTAGTACAACTG
GACGGAGTGTTTCAGTTATTAAAGAAGAACAAAATGATCCACTGGCTGAAATTCAGTGGCTCGCGTATTCAGCAGCAGGCACAGTC
GAAGGAGATATAGTATATGTGAACAACGCTAATCCAAGCGATATTGAATATTTAGAGTCGTTAGGAATTGATCTCAAGGATAAAAT
ATTTCTGGCAAGGTATAGTTCTAATTACCGAGGGAATATTGCCCAAATGGCTGTAAAGAAAGGTGCAAAAGCATGTCTTGTTTATT
CGGATCCAAAACAGGTAGCCAGTTTGGGAACAGGGCCAAATGAAACTTATGGAAACACAGACAAAATGCCGTCAAATACAGTCCAG
ATGGGATCAGTCTACATTGGCCTAGGTGATCCACGAACACCTGCGTTCCCATCAATCGGAGATCTTTTCAAAGAGAAAACTGAACA
AGATTTGTTAGATGAAAAGAAAATACCTACCATTCCCATGCTCCCAATTACATATGCCACAGCACAAATATTATTTGAGAATATGA
AAGGCGATGCAGTGAATGCAGATTTTCAAGGAAAGTTAAATGTTACATATCGTTATGGACCTGGCTTGATAAACAATCAGAAACTT
CGTGTTACCGTTCATGCTGAAAACGAAGAACGAAAAATTCAAAATATAATGGGATATATCAAAGGAAGTCAGGAACCGGACAAGTT
TGTTCTAGTGAGCAATCATTATGATGCTTGGACTTATGGGGCTGTTGATCCAAACAGTGGAACATCTACGCTTTTAGAAGTTTCCA
GAGCGTTGAAACAATATCAAAATCAAACCGGCTGGATACCAGCGCGATCAATTCTGTTCGCTCATTGGGATGCCGAGGAATATGGT
CTGATAGGATCCACTGAGTTTGCGGAAGAATACCGTCTTCAATTAATGAGAAGAGCAGTTGCAGTTATTAATATGGATCTTATTGG
TGGCAACCAGACTTTACTTGGGTTATCGAATCCTACCGTCGCCAATGTTCTCCGGTCTGCAGCGGCAAATGTTGAGCAGCCAAATC
CGACAGAAATGGAACAAGGGAGAAAAACACTATACGATTCCTGGAAATACTATGCGCCATCAAAGAACAATCGATCAACCCATCCT
TATCAAAGAATCCCCGCTGGTGGAAGTGATCATCTTCCATTTTTTGATTATCTTGGAATCCCAATTGTCTTTTTCATCACTTCATC
CCTAGATGCACCTCCAACTTATCCACTGTATCATACAATTTATGAAACACCATATCTGATTGAAAATATTATGGATCCTGGCTACA
AGGTTCATAAAGCCATTGCCGGGATGTTTATAGAATGCATTTTGAAGTTTACCGAGAGTAAAATCCTTCCTTATGATCTGAATGAA
CTTATGGATGACTCGATCTTTGAATATTTGCCAAAACTAGAAGATCGTCTAAATAAAACGTTAATGATTGGAACTAAGACTGATTA
TTTGCTGGATGCACAGAAACAGTTCAAACTGTTACAAAAAACAGTTTTGGAACTTTCTGAGATCGTACAAAGAAGAAATGTCTCGA
AACTTGAAGAGCTACCATTCGGCAGTAGAGTGGACATAAATAATCGGCTTATCGAATTTGAAAAATGTTTTATAAACCCACATGGG
GCAATTGGAAATCCTCAAGCTCGACATGTATTGTTTCATCCAAGCCCTGATAATTGGTATGATGGAGATGCAATTTCACAAGTTCA
CGATTTGATATCAAAAATTAGCAATTCGACAGACAGCAAGGAGTTGGGAAAATTGTCGAGACAACTAGCAAAAGAAATTGCTCTAG
TTAATGTTGCTTACATATGTGCCAAACATTCCCTCGGCGAATTTTTCACAATGTGAtcacgtttgatagactctcagagtaataat
tatttaaatgtcaactttttaaagtgtaaggtggagtagtgcaagtggggaaagtgtttaaatggtgaaaatgaccaaaaataatt
gcaaa
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gcp-2.3 (C35C5.11) (144)
aaatcgaacATGAAAAAAGGATTACAAATATTCGGCGTTGTATTACTTCTAGCAGCGACAGTTGTTGTAACTGTACTCATTTCAAA
TTATGTACATCAGCTTTCAATGTCGAGTGGGACACCTACAATACAAAATACAGTTTCAATCGCAAATAATATCAGACAGCTTATTA
ACACTGACAAAATTCGCTCCAATCTTCATTCGCTCACTAAAAAAGCTCATGTGGCCGGAACAGAAAACAACTTGCGAGTGGCTGAA
ATTATTCGAGATCAAATGATCTCTCAAGGTCTCGAAAATGTTCATTTTAACGAGTATAATGTGTTGCTATCATACCCTGATTGGAC
GACTCCCAACATTGTTGAAATACTCGAAGAAAATGGAGATGTATTTTATAAAACTACGGGACGGAGCATATCTATTATTGAAGAAG
AACAGAATGATTTGGTTTCTGAAATACAATGGCTTGCATATTCGGCTGATGGAACAGTTGAAGGAGATATTGTTTATGTCAACAAA
GGTACTCCAAAGGATATCGAGCATATAGAATCGTTGGGGATAGATCTGAAGGACAAAATTGTTCTCGCTAGATACAGTTCTAACTT
CCGTGGTAACATAGCTCAAATGGCCGTCAAAAAAGGAGCAAAAGCATGTCTTCTCTACTCAGACCCTATGCAAGTAGCAAGTCTTG
GAACCGGACCAAGTGAGTTTTTCAAAATAATACAAGCAAACTTCAATCCGTTTTTTGTAATAGATAGTACATATGGAAGAACAGAT
AAGATGCCATCACATGCCGTTCAAAGAGTTGTTGGATGGAAAAAAGATCCCAACTATTCACTACTTCCAATTCCATATAGCGCAGC
GCAAATTTTATTCGAAAAAATGAAAGGAGACGCCGTCATTGCAGATTTTCAAGGAAAACTTGACGTCACATACCGATATGGTCCGG
GACTGATAAATAATCAGAAACTTAGAGTAACTGTGCACGCTAAAAATGAGGAACGAAAAATTCAAAACGTTCTTGGATATATAAAG
GGAAGCCAAGAGCCGGATAAGTTTGTGCTAGTGGGAAATCATTATGATGCTTGGACGTACGGAGCAGTAGATCCAAACAGTGTCAC
ATCGACCCTCTTGGAAGTAACCAGAGCATTAAAAGCATATCAAAATCTTACAGGATGGAGACCAGTTACTTTCACTCTTGTCCTGA
AAATGGGTTTTTTAACGAGATCAATTCTGTTCGCTCATTGGGATGCTGAGGAATATGGTCTGATTGGGTCCACAGAGTTTGCAGAG
GAGCATCGTACTCAGTTAATGAGAAGAGCTGTTGCATATATAAATACGGATATGATTGGAGGAAACCAGTCATTACTTGCTATGGC
TAATCCTACAGTTGTTAATGTTCTTCGTGCAGCTGCAGCAAAAATTTCACATCCAAATCCGAAAACATTTCTCCCTCACAAAACAA
TAATTCCTCACATCCATTTTACCAGCTTCCAGCAGGTGGCAGTGATCATTTGTCTTTCTTTAATTATTTGGGTATTCCGATGGTTT
TCTTTGTCACATCATCATTGGACAGCCCGCCTGTTTATCCCCTCATATCATACAATTTACGAAACACCCTATTTGATAGACAATAT
TCTTGATCCAGAGTACAAGATGCATAAAGCTATGGGCGAGATGTTAATTGAGTGCATTTTAAACTTTTCGGAAAGCAGAATTCTTC
CTTATGACTTAAAAGAGTTAATGGACAGAGTTCTTGATGAGTATTTCCCGAGAATACAACAACACATTAATAAGGCTCAGACTTTT
GAAAACATTTCTGAGTACTTGACTGAGCCCCAGAAACAGTTTGAACTATTTGAAAAATGTTTCATAAACCCGCATGGTATCCTTGG
AGATCCGCAGAGTCGTCATGTGCTCTTCCGCCCGAGTGCGGACAACTGGTATCGTGGAAACGCAATCTCTCAAGTACACAGCTTGA
TATCAAAAATGGAAACTTCAGTAGACGACGAAGAACTCTTAAAATATTCTAAGCAATTATCCAAGGAGATTGCTTTTGTAAATGTT
GCATTCATTTGCGCGAAACATTCCTTAAACGAATTTTTTACTTTGTGA

Appendix 6: C. elegans RNAi Protocol (293, 303):
Preparing Feeding Plates
Day 1: For feeding plates, use standard NGM agar plus the following ingredients:
Carbenicillin to 25 µg/ml final concentration
IPTG to 1 mM final concentration
Pour plates 4–7 days before seeding, to allow them to dry. If plates are too wet, the bacteria
won't dry after seeding and RNAi phenotypes will be weaker.
Day 4: Spot individual desired bacterial strain(s) from glycerol stock to an LB plate containing
30μg/ml carbenicillin. Streak in a new LB agar plate. Grow overnight at 37°C.
Day 5 (morning): Take a single colony from streak plate and inoculate in to LB broth containing
30μg/ml carbenicillin. (Do not add IPTG to the liquid culture, as this will reduce the RNAi
effect). Grow cultures with shaking at 300rpm for 6 hours- overnight. Bacterial cultures grown
shorter times (6 hours) sometimes give better results. The lawn quality is improved if the culture
is dried quickly by leaving the lids off for about 20 minutes after seeding, but whether this
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affects the RNAi effect is not known. There is anecdotal evidence that plates poured at least 1
week before use work better than freshly poured plates.
Day 5 (evening): Seed NGM agar feeding plates the bacterial culture. Let dry and induce
overnight at room temperature.
Preparing the Worms
Day 5: Grow desired worm strain on standard NGM plates seeded with OP50 bacteria. Carry out
standard bleaching/washing protocol to obtain embryos and leave to hatch into L1s overnight in
M9 buffer. These starved L1s will be synchronized at the beginning of the L1 stage. If feeding
will be done with larvae older than L1, then put hatched L1s onto standard NGM plates
containing OP50 and grow to the desired stage (L4).
Day 6-7 (evening): Transfer an L4-stage hermaphrodite onto first plate; minimizing the amount
of OP50 bacteria transferred (wash 3X with M9 buffer to remove bacteria. It is critical to remove
OP50 as residual non-RNAi bacteria will interfere with the feeding results). Leave 72 hours at
15°C (or 36-40 hours at 22°C) for RNAi to take effect, then replica plate adult onto another plate
seeded with the same bacteria. (Resuspend final worm pellet in M9 buffer containing 0.1%
Tween-20 to prevent them from sticking to plastic. Adjust the volume of buffer so that the
number of worms you want to aliquot per plate is in 10–15 µl)
Day 7-8: After 24 hours, remove the adult from the replica and score the progeny for
phenotypes. Alternatively, aliquot embryos or larvae onto the feeding plates and score them later.
Standard L3/L4 Feeding Protocol: Scoring of Synchronized Progeny
In this protocol, semi-synchronized populations of progeny laid in a 24-hour window are scored.
Day 9-10: Leave 36–40 hours at 22°C for RNAi to take effect, then replica plate single adults
onto other plates or wells seeded with the same bacteria.
Day 12: After 24 hours, remove the adults from the replica and score the progeny for phenotypes
at appropriate time points.
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Phenotypes of Interest for GCPII:
Folate hydrolase- related to progeny production (# of eggs, egg characterization, ect.)
Neuronal impacts- (touch worms’ record reaction)
General phenotypic changes
Be sure to have controls.
Appendix 7: RNAi Vector Sequences
GCP-2.1
GNACGGTCCCTNAGGCNACGACTCTTTCAGCGTGANTGATGCNCATNTTANGCACNCNCGACACAGCNTCTTANACGCGAGCACNC
CNGCACTTGNAGCATGGNAGANNNGGTGNNGAATNNNTCCCNCCGGNCNANATCGCGNGGANNNAANACGCNCCAGGACACNCTGG
AATGAAAGTGTTCCNTGACATGAANGCGGGTGTATCCACNAACCGNAGTCCGCGNCCNCGNNNCNTNANNACNCNCNGTNTNNGAC
TTANGCTGGTGACTNCGGNGANCNACATGCACTATTCTGANNCAACGCGCCNTGNNACNCNNCGNCGCTGGACNANNCANCGTTCC
AGNCGNCGNNCNCCANGATTCNTCTANNGNATNCNGACGANNNANNCCTNCNCAANCCCACTGNGNCNGNNTGCGCNGGGTTNGNG
ACGTNNGTTTTNTNCGAGCAGCAGTGTTGTGTTCATGTTTTGGCAACTTGGANTGAAAAAGGCCCCCCTNTACTGTCTTGAACNCG
ACNTGGNGAGNNGTGCTTANAGACTTGCACTATCTCGACTGAAATCGNTGANTCGAGCTATTAACTCNGNTATAANGCTCNATATA
CAGGGNACGGACAGATANGANAACACGCNGNGACNGNACNCNTGAAGAGGNTGCTCGTCANGNGTNNGANGCCCTNCAACNGGCAG
ACNTCCGGTAAAAAAGNNNAGTTCGATTCNANCNNTAATTNNAAACCCGANNCGGAANNNNACCATTTNGCCACCGGGAATCAATG
TCACATGCGNGTTCTTNNTTGNAAAAAGNNAAAACNTCGAGATCCCCTGGGNNACATCTNNANAAAATCCAAGGGNGGTCGCNCAA
CNTTTAAAAACTTAAACGGTGCCCGCCCCCCTGGGANTTTTTTTGAATTACCCAGGGNAACCNGGTGNTTTTNTTTTTTTCAAAAC
NAGAACCCCCCGGTGAAAAAAATTCCNGGGGNNAAAAGGCCCNATTTCCANCCGGGGTTCCCAAATTTNNGGTTNAAACCGAACNC
TNTTTTTTTNCGGAATNTNTCCCNGTTGAAGGNATTCNCCCCTTNNNNAACCANCCCCCTTTTGGGNCCNNNCCCGNGGNNANAAN
AAATTCCCCCCCCCNGAAAAAANCTNTCCCCNGGAATAAAGNTTNCNCNCANCCNATTTCCCNAAAANNNNNNCCNCAAAAAACCC
CCCCCCCNGNGGGNCAAAAANTTTNTGGGGGGCCTTTTANATNCANANGGCCCNNNTTTTNTAAAAAAAATTTTCNCCAAAAAANT
NNNCCCCCAAACCCCCAAAAGGGNCNAAANNTTTTNNGGGGTNCCCCNTTTTTTNCNAAAAAAANTNTTTTNNCCCCCCAAANTTT
TTTNNCCCGGGGGGGTNTCCCNGNNNCCCCNTNAANAGG

GCP-2.2
GNACGGANCNCCCCGGGCGNAAGNAATTNCGAGTGNNGTGTNACTGATTCGGAGNNTCCGGNGCCTCACANNATCCNANTNCNCAN
ATGTGGCATGNTCACTGANGANCCAACGTTGATGCGGATTCCTAGTACCGNCCTTGTGACTATCATCCCAATCTATNATTTGNGAA
TACTGTCAAGGAATATCAGAAGCNNTNGNCTNCTTAGTCACATTCTGNCACNNANNGCCTGNCCGTATCTATCGNANNACACGCAN
GTGACTNNACNGGCGTGAGAATTCNGAGNGCTCNCGCNANTCCGGNAGCCNGGCACGNTCTGANGGCAGATNNACTNTCCGAGATG
NACGCGCNGCCATGNGACANNGANNCTGTNNCGCCNTGANNCCTTGATCANCNGNNNNCTCCGCATNGCCTTTCANANTCGNCNAA
GNNTATGTGTGCNGGNGCATATGTTTCTGGCGAGNATGNGAACGGANTGCNGAGNCANTNCNGCCCACATGTGTGATTNNTATGGC
GCNTNNNCCCGANTGTGTGNACNCGGATCACTACCTCGTGGNCAGTTTGCNCNCTGNNNCGANCGCCNAGTGANGNNANCNCNGGN
GTTCNTNCTACNCCTAGGCCNAGGTGAGACTGATNCCATCNNGNCCGNANTGCNCGGCCANTNNGGCCGNGATGNCATCAGTCTCC
TCTGNCCTAGGTGATCCGNGAACNCCNGCGTTCCCNTCACTCGCTCANTCTGTTCCTGGACCNAACCGGGCTACATGTAGTGTNTN
CGGATCAACACNNGGGNGCATTCTGCACCTTTCATTACNGGCTGTTGGACGANANNACCNTCNGTACNTNTNCCATGCCCNCGANT
GNANNNCCTCNNCCCAAANCTTATTCGNAACANTTTTCNGCGNCCNTTGAATGCACCTTGNCAGGATTCCNANCGACCCGNATATT
CAACACGCNGGCNTTANCGTTGTGNAAAGTTACATTTNCCCNTCGGCNNGGCCCGNNNCTGAAAAACCCANCCACNTTCNTGNACC
NGNGNAGCCGTTAAGCCCNCANGACAACTGNAACCCCCGANCGGTNGGCCAAAANCCTNNCCTTTTTTCCNTTTCNNANTTCAAGG
GGTTTGGNANGGCCCCCCCGGANCGGAAAACTTTTCNTGGGCCCNTCANTGNCNNTTGGAATCCNGGGGGNGNNCCAAACCNGAAC
ANTTTNCCCCCCCGNAAANTTTNGGGGGGCCCAACCANTNNCCGNNNNCGNNGNAAAANCNAAATTNGNCCCNNTTNCCCCCNNGG
NAAACCCGGGNNCCCCTTNNGCCGGGGNGACCCCTCCCCNGGGGAAAAAANCCCC
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GCP-2.3
GNACGGNTNCCCGNAGGGTCGANGCCCCGCATTTGGCTNTGAATACANCGTNAGTNCGGGGCGTAGGCATTCCCATTTNTANTTNC
NGAGNACGCGANTCTTGTCTTTTNCTTGAGAGGANNAAACANAAANGTCCGNGNNCTGCNCAGTACAATNGAGCNNNCANCCGCNN
CTNATGNNNCGNGTGCACAGAGATNTCGAAGNTGCCGACTANGNANCNCCCCCGGACCNCNNNNNTATGTGACCGCTGGNNNTCCA
NCNGAAGGNNCNTGCCANNTCGGNGNAGNTGTAGATCNNCCANNAANCTTGTTANGNCGCAATGGCGCCCGCTCCATNCGTTTCTT
TCGATCCGTGNTNGCGCTGCNCTATGGGCGTNGGAAGGGAGAATAGCTGGNNTCCTCTNNCCANCCCCCANNCGNGNANNTANTCC
GGNNNCCGGACNNAGNGANNTGTTCAACCTCNTGCTCGNATNCTTCTTTCCGGANNTTGTTTATNATAGGNCAATGCCGGCGATCT
GGGGNCTNCCGNCNNATNCNGNCCAGNGNNGCNCATGCCGTGNTNNGTCGGNANNCCCCNGANTGCCGCCATATCCCCTCTCTATT
ACTCNCTNCGGAGNGAAGTCNGNGCGNGAGGTTTTNCAGAACTCTCNTGTATCCGGANCCAGTACTTGNCNCGTGNATGGANGCNG
AGNAGATCCCACNTGCTCACTGCTCCCTTTTCNACNGCNCGCNGCGCTATGTTACCTCGAAAGNANGAACNGAGACGCCGCGCGTT
GCAGATTGTCNGNANGAGTTGNCTGCTNCATTTNCACCGTNATTTACCNGGNACTNTTTCNTNAAATCTNGCCCCCCACGNNNCGA
TATGCTCNGGGACNGNTGGAGACCCNAGNCTGANAGNAACNGTGCCCNCTCAACTGNGCANCGGCNGATTTGCATNNCNGGGCAGT
TCCCNAACTAAATTTTACCCTCNCANAAATCAAAAANTCCTGCGTCCCCGAAGGGTTANCCAANANCCCGCCCATNTTNTTTCNAG
CTTTNCAANACGTCGGACTCNGGNGGGGGCCGGAANCCNAATCCCCCGTCNCCCNNTCGANAAACCCNNNNAAATTNGGCNNCCCT
TTTNNNCNCCCNGGCCGGGAAANCCCNGGGNTTNCCCANTTNANCNCCGGGGGGGNAATCCCCCTTNCCCCNGGGGGGTAAAANGN
NAAACCCCCCCCCGGGNCCCCNCCCCNAAATNCCCCCCCCCNAANGGNCNANGNAANNCCCCNANCNNNAAAAACCNNNGGGGGGG
GGTNTNTTTNNNNCCCCCCCCCCNGAAAANTTAAAANCCNNCCCCCCCCNTNGTTTTTCCCNTTTTTTTN

VC
GNNCNGATCACGANANTTGAGCTNNCCGANGAGCGTTGATATGCNNTTCAAGNAGCNGCGATNNACANCGACTCCNTTCACGTNGC
CANGGTGCACGCGANGCGATCTNNCATCNNCTNNAGTCAATNNCNNATNCAGCTNATCGNTAAGCGTCGAACTTNCTAGGATGANN
NCNGANTNNGCANNTCNCCCTATAGTGAGTCGTATTAATTTCGATCACNGNGNNTGCTTNNNCNNCTCNCTNAATCGNTANANTCN
TGTCNTTNACCCTGNNTTAATCGCCTATGCAGCTCATNCCCNNTTCGTAATACTGGTTATACTACACGAANCAGGNCCATAACCGC
ATCGANNCTATCNTGNGAGTTGAAACAGCCNTGCAAANGGNNANGNAAACGCANNNNGGACNNGNTNNTNANGNTNTTCCATAGNN
TCGGCCACCCTGACGAGTGATCACANACATTTGACCCTCAACTNAGAGGNGGCTAANTTCGATTNNATNANTTNNATNCNNGNCNT
TTNCCCCTGCANTCTCCNTCNNGCNCTNNCNTGTTCNNACCCTNNNGNTTACCGAATANCTGTNNTNCTTTCNCNCTTCCNCAAAN
NNGTTGNTTNCNCAGATNTCNCACTGAATGTATCTNCGTTCNTGTNTAGANTCGTTTTTCTCCNTTTGACGCTGTGAGTCCGAATT
CCTTTAATACAGNCACGACTTGCTGCNCCTTATCAAGGNANACTATNNNNCNTAGAGTCNAACTATTCTANNANANTTANTNATNG
ACTTNTGNCAANATCCNCCTGATNGCNTNAATAAANNAACNGATTTATNTAANCTTTTNCTACNAATTTNATNAAAATGATTGACC
TATNTACANTTTACGTNANAATTNTCGGATAANNTATCCGCGNNCCNCTAANTNCTTTNTTTNNANAAAAAANANTAGNNAGNTNN
GNTTCNGGAAAAAAAACCCCNGNTNAAAGNNTNGTTTTTTTTNTTTNAAANNAAAANANTTANNNTCCAAAAANNACGGTTTCCCC
CAAAAATCCCNTTTTTTTTTNCAATNGGNCTTCAAGTTTTTNGGNANCCAAAAAACCNNTTTANGGATTTTNGGTNNTGGNAATTN
TNNAAANGGGGNCCNCNCCNGGGNTTCCTTTTAAANNGAAAANNAAANNTTTNAAAANNCCNTTAAAANTTTTTNNCCCNAAAANA
NNTTTTNNANNTNAANAANNNTTTTNAAAGNGNGGNNCNNTTNNNNNGGNNTTTNNNTTTTTTTTCNCCCNAAAAANNNANCCCCC
CCCNNAAAAAAANANNNAAAAANNNGGGGNNTTTAANTTNCCCCCCCNNNNNAAAANNNNNNNNNNANNNNNNNNNNNNNNNANNN
TTTTTNNNNNNAAAANNNNGN
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